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 3 
Abstract 
 
 
Psychosocial stressors have frequently been associated with an increased risk for developing 
depression, anxiety or substance abuse in adult life. Animal studies have also suggested that 
stressful experiences may result in altered behavioural responses to drugs of abuse as 
evidenced by enhanced cocaine self-administration and psychostimulant-induced 
hyperlocomotor activity. 
 
The main aim of our study was to establish whether adversity early in life would render 
individuals more vulnerable to later drug usage. We adopted maternal separation as our 
animal model of early life adversity and treated these animals with methamphetamine during 
the adolescent stage of their life. A conditioned place preference (CPP) paradigm was 
subsequently used to determine the rewarding effects of methamphetamine. To obtain an 
understanding of the underlying molecular mechanisms of methamphetamine-induced 
behaviour, we measured neurochemical changes on a neuroendocrine, neurotrophic, 
neurotransmitter and proteome level. 
 
Firstly, we established that methamphetamine-induced place preference behaviour lasted for 
at least 2 weeks after the last methamphetamine administration. Contrary to expectation, this 
behaviour was not affected by prior exposure to maternal separation. However, rats subjected 
to maternal separation caused a decrease in apomorphine-induced locomotor behaviour in 
methamphetamine-treated rats. Maternal separation therefore preferentially affected the 
behavioural repertoire of the dorsal striatum rather than that of the ventral striatum. 
 
A general down regulation of neuroendocrine activity (ACTH and corticosterone levels) was 
observed in animals subjected to maternal separation or methamphetamine treatment, as well 
as those subjected to the combination of the two interventions. Increased concentrations of 
plasma prolactin levels in maternally separated as well as normally reared animals subjected 
to methamphetamine-CPP were found which suggested a reduction in dopamine inhibition. 
 
Maternal separation resulted in increased NGF levels in the ventral hippocampus of 
methamphetamine treated rats. This suggested that the ventral hippocampus may particularly 
be vulnerable to the effects of early life stress. The increased neurotrophin concentrations may 
reflect a compensatory response to stress and drug exposure. 
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The contributions of the cholinergic (Lobeline) and opioid (Naltrexone) systems in place 
preference behaviour were determined by employing a post-methamphetamine 
pharmacological treatment strategy. These two treatments failed to reverse the 
methamphetamine-induced place preference. However, administration of the drugs did lead to 
alterations in striatal dopamine and serotonin levels which may infer beneficial effects against 
the biochemical alterations induced by methamphetamine. 
 
We used both 2-D gel-based proteomics and isobaric tagging for relative and absolute 
quantitation (iTRAQ) to identify proteins in the frontal cortex, and nucleus accumbens shell 
and core of rats that were subjected to maternal separation, methamphetamine or both 
regimes. The proteins were associated with cytoskeletal modifications, altered energy 
metabolism, degenerative processes, interruptions in normal neurotransmission and enhanced 
intracellular signalling. We found that more proteins were quantitatively expressed in rats that 
were exposed to maternal separation followed by methamphetamine treatment than those 
animals subjected to the individual interventions independently. Additional proteins recruited 
by the combination of MS followed by MA which remained unchanged with independent 
treatments included malate dehydrogenase, V-type proton ATPase subunit E1, beta-synuclein, 
brevican core protein, eukaryotic translation initiation factor 4H, histidine triad nucleotide 
binding protein 1 and stress-induced phosphoprotein in the nucleus accumbens shell sub-
region. Additional proteins recruited in the core subregion with the combination treatment 
included thymosin beta-4, calretinin, Arpp-21 protein, alpha-synuclein, ubiquitin carboxyl-
terminal hydrolase isozyme L1, cytochrome c, brain acid soluble protein 1, prosaposin and 
stress-induced phosphoprotein 1. Although, on a behavioural level via the use of CPP we 
found that MS did not exacerbate the rewarding effects of MA, the proteomic data does infer 
a role played by early life stress by the recruitment of additional proteins. We therefore 
propose that the molecular mechanisms by which early adverse events predispose animals to 
the addictive state may involve a complex assembly of cellular processes within the brain. 
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Opsomming 
 
Psigososiale stressors word gereeld geassosieer met ‘n verhoogde risiko vir die ontwikkeling 
van depressie, angs en dwelm misbruik in volwassenheid. Diere studies het ook al bewys dat 
vroeë lewensstres in die vorm van moederlike skeiding lei tot veranderde gedrag teenoor 
dwelm misbruik. Hierdie veranderde gedrag veroorsaak deur moederlike skeiding sluit die 
verhoodge kokaïne toediening en psigostimulant geinduseerde verhoging in lokomotoriese 
aktiwiteit in. 
 
Die hoofdoel van die studie was om vas te stel of vroeë lewensstres mense meer vatbaar laat 
vir latere dwelm misbruik. ‘n Moederlike skeidings diere model was gebruik om vroeë 
lewensstres voor te stel and het verder hierdie diere behandel met metamfetamiene gedurende 
adolesensie. Die gekondisioneerde plek voorkeur model was gebruik om die euforiese / 
verslawende effekte van metamfetamiene te bepaal. Om die onderliggende molekulêre 
meganismes van metamfetamien geinduseerde gedrag te verstaan het ons neurochemiese 
veranderinge op ‘n neuroendokriene, neurotrofiese, neurotransmissie en proteinvlak vasgestel.  
 
Eerstens het ons was gestel dat metamfetamien geinduseerde plek voorkeur vir ten minste 
twee weke na die laaste metafetamien toediening voortduur. In teenoorstelling met 
verwagting, het moederlike skeiding nie metamfetamien geinduseerde plek voorkeur 
beinvloed nie, maar eerder apo-morfien geinduseerde lokomotoriese aktiwiteit geaffekteer. 
Moederlike skeiding stres het by voorkeur die gedrags funksie van die dorsale striatum 
beinvloed eerder as die ventrale gedragsfunksie.  
 
‘n Algemene afregulering van neuroendokriene aktiwiteit was waargeneem 
(adrenokortikotrofiene en kortikosteroon vlakke) in diere wat aan moederlike skeiding of 
metafetamien behandeling sowel as die kombinasie behandeling blootgestel was. Verhoogde 
plasma prolaktien vlakke was gevind in moederlike skeidings rotte sowel as kontrole diere 
wat verder blootgestel is aan metamfetamien behandeling wat ‘n inhibisie van die dopamiene 
sisteem toon.       
 
Moederlike skeiding het ook ‘n verhooging in neurotrofiene (NGF) in die ventrale 
hippokampus van metamfetamien behandelde rotte veroorsaak. Hierdie bevinding stel voor 
dat die ventrale hippokampus veral vatbaar is vir die effekte van vroeë lewensstres. ‘n 
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Verhoging in neurotrofien konsentrasies mag ‘n kompenserende teenslag van die brein wees 
teen stres en dwelm blootstelling. 
 
Die bydrae van die cholinergiese (Lobeline) en opiaat (Naltrexone) sisteme in plek voorkeur 
gedrag was bepaal deur farmaseutiese behandeling te volg na metamftemien toediening. 
Lobeline en naltrexone was egter nie suksesvol om die metamfetamien geinduseerde plek 
voorkeur te wysig nie. Alhoewel die toediening van die twee behandelings het tot 
veranderinge in neurotransmissie (dopamiene en serotoniene) gelei wat moontlik tot 
voordelige effekte teen die biochemiese veranderinge van metamfetamien kan lei. 
 
Om veranderinge op proteinvlak in die frontale korteks en nukleus akkumbens middel en 
buitenste subareas vas te stel het ons gebruik gemaak van twee-dimensie gel elektroforese en 
isobariese merkers vir relatiewe en absolute kwantifisering (iTRAQ) gevolg deur massa 
spektrofotometrie. Geindentifiseerde proteine was geassosieer met sitoskeletale modifikasies, 
veranderde energie metabolisme, afbrekende prosesse, onderbrekings met normale 
neurotransmissie en intrasellulêre seintransduksie. Meer proteine was beduidend in die diere 
wat aan beide moederlike skeiding en metamfetamien behandeling blootgestel was. 
Addisionele proteine wat deur die kombinasie behandeling geaffekteer is in die buitenste 
subarea van die nukleus akkumbens sluit ‘malate dehydrogenase’, ‘V-type proton ATPase 
subunit E1’, ‘beta-synuclein’, ‘brevican core protein’, ‘eukaryotic translation initiation factor 
4H’, ‘histidine triad nucleotide binding protein 1’ en ‘stress-induced phosphoprotein’ in. 
Additionele proteine geaffekteer in die middelste subarea van die nukleus akkumbens sluit 
‘thymosin beta-4’, ‘calretinin’, ‘Arpp-21 protein’, ‘alpha-synuclein’, ‘ubiquitin carboxyl-
terminal hydrolase isozyme L1’, ‘cytochrome c’, ‘brain acid soluble protein 1’, ‘prosaposin’ 
en ‘stress-induced phosphoprotein 1’ in. Vanuit ‘n gedrags benadering deur die gebruik van 
metamfetamien geinduseerde plek voorkeur het moederlike skeiding nie diere meer vatbaar 
gemaak vir die effekte van metamfetamien nie, maar die protein data wys wel dat vroeë 
lewens stres ‘n rol speel deur dat meer proteine geaffekteer word deur die kombinasie van 
moederlike skeiding gevolg deur later metamfetamien toediening. Ons stel voor dat die 
molekulêre meganismes waardeur vroeë lewensstres diere meer vatbaar maak vir die 
verslawende effekte van stimulante behels ‘n komplekse samestelling van sellulêre prosesse 
in die brein.       
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CHAPTER 1 
 
 
Introduction to the study 
 
 
Methamphetamine (MA), also known on the streets as “speed”, “meth”, “chalk” or in the 
smoke-able form as “crank”, “ice, “crystal”, “glass” or in the Western Cape lingo as ‘tik-tik”. 
MA is a very addictive psycho-stimulant and is easily synthesized in clandestine laboratories 
from relatively inexpensive ingredients, making the drug low in cost and highly available. For 
these reasons, methamphetamine has become the drug of choice for abuse in South Africa, 
and hence methamphetamine dependence is growing at alarming proportions. Reports from 
the local Medical Research Council’s South African Community Epidemiology Network on 
Drug Use (SACENDU) have shown that in the Western Cape the most common abused 
substance amongst the youth, is methamphetamine (Plüddemann et al., 2009). These alarming 
statistics have kindled our interest in studying environmental factors that may predispose 
individuals to methamphetamine abuse, as well as investigating the underlying molecular 
mechanisms that may be involved in the drug’s addictive action.  
 
Stress has been shown to lead to increased susceptibility towards substance abuse and 
contributes to relapse in addicted individuals (Sinha, 2001; Gordon, 2002). This has been 
evidenced for instance by association studies linking psychosocial stressors with an increased 
risk for developing depression, anxiety or substance abuse in adult life (Kendler et al., 2000). 
This phenomenon has been clearly demonstrated in animal studies where stressful 
experiences early in life such as maternal separation (MS), resulted in altered behavioural 
responses to drugs of abuse that included enhanced cocaine self-administration and 
psychostimulant induced locomotor activity (Brake et al., 2004; Matthews et al., 2003; 
Meaney et al., 2002; Kikusui et al., 2005). 
 
We have previously shown that animals subjected to trauma and stress early in life display 
behavioural abnormalities at a later stage in life. These changes in adult behaviour were 
associated with a dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and 
alterations in the expression of neurotrophic factors (Daniels et al., 2004; Uys et al., 2006; 
Faure et al., 2006; 2007; Marais et al., 2008). These findings confirmed the concept that 
adverse events early in life may affect the development and maturation of the brain 
negatively. Complementary reports were obtained from clinical studies showing significant 
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correlations between patients with early trauma and the subsequent development of 
depression and anxiety disorders (Heit et al., 1997; Ladd et al., 2000). In these cases the 
behavioural abnormalities were also coupled to endocrine dysfunction.  
 
The rewarding effects of MA are mainly mediated by the mesolimbic dopaminergic system 
(Kalivas and Stewart, 1991). MA’s primary mechanism of action is to increase the release of 
dopamine into the synapse via its action on vesicular monoamine transporters (VMAT2) 
(Sulzer and Rayport, 1990; Pifl et al., 1995; Wilhelm et al., 2004; Sulzer et al., 2005). Other 
neurotransmitter systems may also modulate dopaminergic activity in the brain by interacting 
with its circuitry. For instance, serotonin (5-HT) modulates dopaminergic neurotransmission 
by inhibiting the activity of dopaminergic neurons in the ventral tegmental area (VTA) 
(Brodie and Bunney, 1996). Furthermore, it has been suggested that MS alters neurochemical 
role players such as decreased dopamine transporter levels in the nucleus accumbens and 
caudate putamen and an enhanced mesolimbic dopamine response to amphetamines (Hall et 
al., 1999; Meaney et al., 2002; Brake et al., 2004) that are critical in the development of 
addictive processes.  
 
In the current study, we combined maternal separation with methamphetamine-induced 
conditioned place preference, in order to determine whether animals subjected to adverse 
conditions early in life would demonstrate enhanced place preference for methamphetamine 
associated environmental stimuli. In addition, we characterized this model of addictive 
behaviour by determining the duration of place preference behaviour, as well as assessing 
associated neuroendocrine abnormalities in these animals. As such, we evaluated the activity 
of the HPA axis activity and measured neurotrophin concentrations in the hippocampus. Two 
pharmacological interventions (Lobeline and Naltrexone) were used to probe the 
contributions of the cholinergic and opioid systems in place preference behaviour. We also 
wanted to determine whether these agents were able to reverse methamphetamine-induced 
place preference behaviour and whether their effects resulted from altering striatal dopamine 
and serotonin levels. Finally, we employed proteomic techniques to generate a global 
overview of protein changes in the frontal cortex and nucleus accumbens shell and core of 
maternally separated and methamphetamine-treated animals. 
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Methamphetamine (MA / “tik-tik”) addiction – a review of the literature 
 
 
Introduction  
 
Methamphetamine is a very addictive psycho-stimulant and is easily synthesized in 
clandestine laboratories from relatively inexpensive ingredients. Thus, methamphetamine is 
low in cost and highly available. When methamphetamine is consumed it produces a high that 
lasts 4 to 24 hours (Cook et al., 1993) and the additional methyl group makes it more potent 
than its counterparts, amphetamine and dextro-amphetamine (Fasciano et al., 1997). In 
addition, tolerance for the drug is achieved quite rapidly, resulting in ‘binging’ of the drug to 
achieve the same euphoric effects, hence an escalation in consumption (Angrist et al., 1987; 
Brauer et al., 1996). 
 
Recent reports indicate that methamphetamine abuse and addiction has grown to a major 
illicit drug problem in the USA (http://www.usdoj.gov/ndic/pubs11/13846/meth.htm). Similar 
concerns exist in countries such as UK, Finland and Australia. In South Africa reports from 
the local Medical Research Council’s South African Community Epidemiology Network on 
Drug Use (SACENDU) have shown that in the Western Cape the most common abused 
substance is methamphetamine and treated 2807 patients across 24 treatment centres in the 
last 6 months of 2008 with 35% reporting methamphetamine as their primary substance of 
abuse (Plüddemann et al., 2009). In light of these alarming statistics, more research is needed 
that focusses on this topic.  
 
Defining methamphetamine addiction 
 
No clear cut definition of addiction has been formulated and various fields of expertise focus 
on different aspects for the terminology of addiction. The Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV TR) does not include the word ‘addiction.’ Rather they term 
the phenomenon as ‘substance dependence’ and this together with substance abuse is 
classified as Substance Use Disorders (SUD). Substance dependence is defined as an 
individual continuing using a substance despite negative consequences relating to the 
substance. Furthermore, the compulsive and repetitive usage of the substance may lead to 
tolerance to the effects of the drug and the development of withdrawal symptoms after 
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discontinuation of the substance (American Psychiatric Association, 2000). Addiction, from a 
psychiatric point of view, is referred to as psychological dependence, and from a 
physiological standpoint, is referred to as physical dependence. For the purpose of this review 
we will side with the physiological point of view and focus particularly on brain 
neurochemistry and structures involved in addiction.    
 
Methamphetamine dependence or addiction is a brain disorder which is caused by the 
repeated usage of methamphetamine despite negative consequences and resultant loss of 
control. Long-term brain alterations that interfere with the individual’s ability to exercise 
cognitive control, is thought to underlie drug seeking behaviour and hence addiction (Kalivas 
and Volkow, 2005). Goldstein and Volkow (2002) have also proposed that drug addiction can 
be viewed as a syndrome that is characterised by impaired response inhibition and 
abnormalities in reward processing. Natural reinforcers are no longer seen as rewarding and 
are over powered by affects of abused drugs and drug related cues by altering the threshold of 
the reward circuitry. In addition, the addict’s main motivation becomes the “wanting” of the 
drug on which they have become dependent (Robinson and Berridge, 2003). Addiction is also 
referred to as a chronic relapsing disease since more than half of the addicts seeking treatment 
relapses into drug usage again (Miller, 1996).  One of the hypotheses forwarded for this 
phenomenon states that brain functions responsible for self-control and normal cognitive 
functioning are impaired following chronic methamphetamine abuse.  
 
Epidemiology 
 
According to the United Nations Office on Drug and Crime, more than 34 million individuals 
use amphetamines world wide (United Nations Office on Drug and Crime, 2003). The present 
statistics in South Africa show that methamphetamine as the drug of choice for abuse and 
addiction is growing at alarming proportions. The Medical Research Council’s South African 
Community Epidemiology Network on Drug Use found the abuse of MA is especially evident 
in the Western Cape and have shown that the number of patients that use MA as their primary 
substance of abuse have increased dramatically at specialist treatment centres (Plüddemann et 
al., 2009). Other studies have found the age of onset of female MA users to be much younger 
than that of their male counterparts. Females had an average age of onset of 19.2 years for 
MA use and males first encounter with using MA on average were 20.6 years (Hser et al., 
2005).  
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Pharmaco-chemistry 
 
MA is also known on the streets as “speed”, “meth”, “chalk” or in the smoke-able form as 
“crank”, “ice, “crystal”, “glass” or as in the Western Cape lingo as ‘tik-tik” 
(www.whitehousedrugpolicy.gov/streetterms; Plüddemann et al., 2009). MA, an N-methyl 
homologue of amphetamine, is a synthetic drug which is synthesized from the ephedra plant 
Ephedra vulgaris, the active ingredient being ephedrine (Barker and Antia, 2007). It is a 
white, crystalline, bitter-tasting, odourless powder that easily dissolves in water or alcohol 
(Gulaboski et al., 2007). Methods of MA consumption include the injection, smoking, 
snorting or oral ingestion of the drug (Anglin et al., 2000).             
 
MA has a plasma half-life of 12 hours generating effects that may last up to 24 hours (Cook et 
al., 1993). MA is classified as a psychostimulant agent causing psychosis similar to certain 
psychiatric disorders, such as paranoid psychosis and sometimes even schizophrenia-like or 
manic bipolar disorder-like symptoms (Snyder, 1972; Schmidt et al., 1985; Iwanami et al., 
1994; Brauer and de Wit, 1996, 1997; Bufferstein et al., 1999; Lee et al., 2000; Shoptaw et 
al., 2003; Nejtek et al., 2008). These behavioural symptoms can occur acutely after MA use 
and persists long after drug cessation (Sato, 1992; Iwanami et al., 1994; Zweben et al., 2004).  
 
The “high” induced by psychostimulant drugs have been correlated with increases in brain 
dopamine levels as well as a relationship has been established between the intensity of the 
“high” and the occupancy of dopamine D2 receptors (Volkow et al., 1999a). MA also affects 
other neurotransmitters system, which include the serotonergic (5-HT) system and 
abnormalities in this particular system has been linked to the behavioural deficits experienced 
by MA abusers (Schmidt et al., 1985; Ezaki et al., 2008). 
 
 
Brain areas and circuitry involved in MA addiction 
 
Ventral tegmental area and prefrontal cortex: Dopaminergic projection 
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During various stages of drug addiction, drugs of abuse induce differential neuroplastic 
changes. The development of these alterations at the synaptic level over time is suggested to 
underlie the establishment of addictive behaviour.  
 
Initially, a few brain areas and neurotransmitter systems are involved in eliciting the 
rewarding effects of drugs of abuse. The early rewarding experiences are caused by 
dopaminergic projections of the mesocorticolimbic system, particularly those that originate in 
the ventral tegmental area (VTA) and innervate the nucleus accumbens (NAc), specifically 
the shell subregion (Wise, 1981; Carboni et al., 1989; Koob, 1992; Bassareo and Di Chiara, 
1997; Drevets et al., 1999; Bradberry et al., 2000). Another brain area that plays an important 
role during the acute stages of drug taking is the prefrontal cortex (PFC) (Kalivas et al., 
2005). The VTA is the area of the brain that detects motivationally relevant stimuli, i.e. drug 
of choice, and responds to the stimulus by releasing dopamine (Robinson and Berridge, 1993; 
McClure et al., 2003) to the PFC and NAc shell (Bassareo and Di Chiara, 1999a; Berns et al., 
2001; Volkow et al., 2003; Sellings and Clarke, 2003). The anterior cingulate (ACC) and the 
oribitofrontal cortex (OFC), both PFC regions, are of importance during motivational salient 
events. These brain regions are active especially if the reward is predictable (Berns et al., 
2001; Volkow et al., 2003). They appear to determine the intensity of responding to drug 
stimuli (Jentsch and Taylor, 1999; Bush et al., 2002).  
 
The shell of the NAc has a strong reciprocal dopamine innervation to the VTA and thus aids 
in modulating motivational salient stimuli. This projection participates in the learning of 
associations between motivational relevant stimuli and environmental perceptions (Bassareo 
and Di Chiara, 1999; Sellings and Clarke, 2003) and hence plays a role in Pavlovian incentive 
learning by using dopamine as a substrate (Bassareo and Di Chiara, 1997; Bassareo and Di 
Chiara, 1999a, 1999b, Bassareo et al., 2002). Dopamine release is the trigger to direct 
behavioural responses toward motivational salient stimuli and leads to cellular adaptations 
that facilitate learning of associations between stimuli and the event (Jay, 2003). Interestingly, 
as the anticipated reward becomes familiar, dopamine is not released upon exposure to the 
reward (Schultz, 1998). Drug-induced dopamine release is 3-5 times more when compared to 
dopamine release upon a natural reward (Wise, 2002). This demonstrates the powerful effects 
elicited by drugs of abuse and highlights the difficulty of drug cessation.  
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Figure 1: Rat brain illustrating some of the main brain areas involved in methamphetamine 
addiction (www.cellscience.com/CCA.htm).  
 
The nucleus accumbens 
 
The NAc core is primarily involved with the expression of motivation or learned behavioural 
responses (Kelley, 2004; Di Ciano and Everitt, 2001) or habit learning (Ito et al., 2002). This 
brain area is also connected to the ACC and OFC and expresses adaptive learned behaviour 
by glutamatergic innervation from the PFC (Di Ciano et al., 2001). Thus, behavioural 
expression occurs via glutamatergic afferents from the PFC and directing this input towards 
the accumbens-thalamocortical circuitry (Jog et al., 1999; Haber, 2003). The NAc is therefore 
proposed to act as an interface between motivation and action (Mogenson and Yang, 1991).    
 
During the early stages of drug taking, dopamine from the VTA and glutamate from the PFC 
are released in the NAc (Wise and Rompre, 1989; Koob and Le Moal, 2001). It has been 
proposed that these two events are responsible for the synaptic changes at the level of the 
NAc that drives drug seeking behaviour (Cornish et al., 1999; Cornish and Kalivas, 2000; 
Kalivas and Volkow, 2005; Kalivas et al., 2005). Since glutamate plays such an important 
role in learning and neuronal plasticity it is plausible to propose that glutamate transmission is 
pivotal to the conditioning process and is suggested that addiction might involve glutamate-
dependent neuroplasticity in limbic cortico-striatal circuits (Everitt and Wolf, 2002).  
 
The amygdala 
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Some studies suggest that reinstatement of drug seeking also require the release of dopamine 
into the amygdala (See et al., 2001; McFarland and Kalivas, 2001; Capriles et al., 2003; 
McFarland et al., 2004). The amygdala functions in recognising cues that are associated with 
the drug or with using the drug and plays a primary role in conditioned associations and the 
learning of these associations (Everitt et al., 2003). Interestingly, the basolateral nucleus and 
the central nucleus of the amygdala have differential roles in addiction. In order for learned 
associations to influence future more complex behavioural responses towards conditioned 
association, glutamatergic neurotransmission from the basolateral amygdala back to the PFC 
and NAc is necessary (Cardinal et al., 2002). This reciprocal projection is involved in cue-
primed drug seeking (Meil and See, 1997; Erb and Stewart, 1999), since rats with lesioned 
basolateral amygdala were unsuccessful in establishing cue-induced cocaine seeking 
(Whitelaw et al., 1996).  
 
Frontal cortical areas 
 
The frontal and prefrontal brain areas are primarily involved in executive functioning which 
includes higher-order cognition, motivational functions, memory, impulse control, problem 
solving and decision making (Royall et al., 2002). The frontal cortex suppresses inappropriate 
fast behavioural responses in order to allow slower decision making processes to influence 
behaviour (Friedman and Miyake, 2004). Psychostimulant abusers display distorted patterns 
of expectancy, compulsion and decision making (Paulus et al., 2002; London et al., 1999) as 
evidenced by drug-induced functional changes in forebrain structures. Ventromedial 
prefrontal cortical lesions have resulted in patients lacking inhibitory control in decision 
making when measuring immediate reward against long-term negative consequences 
(Bechara et al., 2000). On a microscopic level, increases in dendritic branching and dendritic 
spine density in the PFC (Robinson et al., 2001) reflects altered synaptic connectivity that 
influence decision making and cognitive control over drug taking (Volkow et al., 2003). Some 
of the most prominent frontal brain areas are compromised in addiction and include the 
dorsolateral prefrontal cortex, the OFC, the ACC and the ventromedial cortex. The OFC and 
the ACC are anatomically connected to the limbic structures and show activation during 
periods of drug using, craving and binging and deactivated during drug withdrawal (Goldstein 
and Volkow, 2002). This has been demonstrated by studies using blood-oxygenation-level-
dependent responses during cocaine intoxication (Breiter et al., 1997), decreased relative 
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cerebral blood flow and lower brain glucose metabolism during periods of drug withdrawal 
(Volkow et al., 1988; Volkow et al., 1992).  
 
The OFC is specifically associated with assessing reward value and reinforcing properties 
which include the processing of short- and long-term gains or losses (Bechara, 2001; 
O’Doherty et al., 2000; Rolls, 2000). Damage to the OFC has been shown to lead to 
compulsive behavioural responses to engage in drug seeking in the face of negative 
consequences or unpleasurable drug effects (Rolls, 2000). Similarly, this effect is also seen in 
other compulsive disorders as in the case of obsessive-compulsive disorder (OCD) (Insel, 
1992).  
 
The ACC has also been implicated in processes of cognitive control (Vogt et al., 1992) of 
which the dysfunction has been associated with relapse in MA abusers.  Positron emission 
tomography (PET) studies have shown that the ACC plays a role in emotional processing 
(George et al., 1993; Lane et al., 1997) and the orchestration of appropriate behavioural 
responses (Paus et al., 1993). Dysfunctionality of the ACC has serious implications in 
addiction pathology, since psychostimulant abusers show impaired cognitive control over 
appropriate behavioural responses. In fact, their behaviour is dominated by a sensitization 
toward responses directed by drug-related cues (Aron and Paulus, 2007).  
 
The posterior cingulate cortex is involved in evaluative processes (Vogt et al., 1992) and has 
been implicated in the making of risky choices (McCoy and Platt, 2005). This region 
evaluates the degree to which actions lead to predictable versus unpredictable behavioural 
consequences (Blakemore et al., 1998) as well as controlled versus uncontrolled movements 
(Schubert et al., 1998). Increased neuronal activity in the posterior cingulate cortex has been 
connected to relapse in cocaine addicts and this correlated with poorer treatment outcomes 
(Kosten et al., 2006). Observations such as these have led to the posterior cingulated cortex 
being associated with cocaine-induced craving (Garavan et al., 2000; Kilts et al., 2004). 
 
The parietal cortex 
 
The parietal cortex is important for higher brain functions such as attentional processes, 
memory, skills learning and spatial perception and imagery (Cabeza and Nyberg, 2000). The 
parietal cortex has therefore been linked to addictive behaviour due to these behavioural 
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functions conducted by the parietal cortex. For instance, the right inferior parietal cortex 
directs attention towards selected actions or stimuli and plays a critical role during assessment 
processes and decision making (Aron and Paulus, 2007), sustained and selective attention 
(Coull et al., 1996), control of voluntary attention (Hopfinger et al., 2000) and inhibitory 
control (Garavan et al., 1999). The precuneus or the posteromedial parietal cortex is involved 
in imagery, episodic memory retrieval and consciousness of self (Kjaer et al., 2002). 
Decreased activation of the precuneus has been observed in MA subjects when engaged in a 
decision making task (Paulus et al., 2003).  
 
Pallidal structures 
 
The ventral pallidum forms part of the limbic cortical-ventral striatopallidal circuitry that is 
implicated in drug seeking and reinstatement. The ventral striatopallidal system plays a major 
role in translating a motivational state into a behavioural output (Kalivas and Nakamura, 
1999; Kelley and Berridge, 2002; Kelley, 2004). In general, behavioural output is orchestrated 
by the shell of the NAc via the ventral pallidum and mediodorsal thalamus to motor areas. 
This circuit usually drives the execution of behaviour in response to rewarding stimuli 
(Waraczynski, 2006). The NAc shell also connects to the hypothalamus via the ventral 
pallidum and this projection serves to modulate responding to natural rewards (Kelley, 2004). 
The ventral pallidum may therefore be seen as a relay center for the execution of behavioural 
responses to rewarding or reinforcing stimuli. In addition, this brain area performs other 
complex actions by modulating neurotransmitter input from the NAc and midbrain regions, 
especially via  µ opioid receptors, while also modulating the effectiveness of glutamatergic 
inputs from the PFC and amygdala (Napier and Mitrovic, 1999).   
 
The limbic region 
 
The limbic and paralimbic brain regions play a critical role in the development of addiction 
because of its role in the processing of emotions. The insula is a structure deeply nestled into 
the frontal, temporal and parietal lobes within the lateral fissure and is highly connected to the 
PFC and amygdala (Augustine, 1996). Interestingly, the activation of the left insula was 
inversely correlated with outcome predictability in MA users (Paulus et al., 2003). The 
reduced activation of the insula is proposed to affect response inhibition of behaviour and 
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decision making, since stimulant abusers are less concerned with processing success or failure 
of behavioural responses (Paulus et al., 2005).   
 
The hippocampus is involved in memory consolidation and is instrumental in learned 
associations necessary for addiction development. The hippocampus is involved in 
conditioning to contextual or spatial stimuli, unlike the amygdala that is more involved in 
conditioning to discrete stimuli (Selden et al., 1991; McDonald and White, 1993). Theta burst 
stimulation of the hippocampus has been demonstrated to reinstate extinguished cocaine 
seeking behaviour which occurred only during glutamate neurotransmission in the VTA. This 
increase in neuronal activity has been correlated with context-dependent reinstatement of drug 
taking (Vorel et al., 2001). Reinstatement or relapse has been closely linked to craving 
(Anton, 1999; Hyman and Malenka, 2001) and memory consolidation needed for craving is 
thought to be mediated by the hippocampus in conjunction with the amygdala. The experience 
of craving is however thought to be mediated by the ACC and the thalamo-orbitofrontal 
circuitry (Goldstein and Volkow, 2002).  
 
 
Methamphetamine-induced neurotoxicity 
 
Role of dopamine 
 
Despite the fact that a non-toxic dose was administered to rats in the present study, 
neurotoxicity induced by repeated MA abuse is very prevalent and clinically revelant for 
discussion in this review. One of the major contributing factors of MA toxicity is that MA has 
a very similar chemical structure to that of the body’s natural occuring dopamine and this 
allows MA to enter axons (Iversen, 2006). Toxicity occurs as a result of both endogenous 
dopamine accumulation as well as high extracellular dopamine levels released from nerve 
terminals (Krasnova and Cadet, 2009). Accumulated dopamine rapidly auto-oxidizes and 
results in the formation of oxygen free radical species, which include superoxide radicals, 
hydroxyl radicals, hydrogen peroxide and dopamine quinones (Cubells et al., 1994; Acikgoz 
et al., 1998; LaVoie and Hastings, 1999; Larsen et al., 2002; Miyazaki et al., 2006; Lazzeri et 
al., 2007). Increased dopamine oxidation has been suggested to be one of the leading 
contributing factors to MA-induced dopaminergic terminal damage (LaVoie and Hastings, 
1999). MA has also been found to tip the balance in favour of reactive oxygen species (ROS) 
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production than that of antioxidant potential to scavenge ROS. This has been demonstrated by 
MA reducing copper/zinc-superoxide dismutase (CuZnSOD), glutathione and peroxiredoxins 
which were accompanied by high levels of lipid peroxidation and protein carbonyls (Jayanthi 
et al., 1998; Harold et al., 2000; Gluck et al., 2001; Iwazaki et al., 2006; Chen et al., 2007; 
Kobeissy et al., 2008; Li et al., 2008). When ROS overrides the anti-oxidant capacity of the 
cells it gives rise to MA-induced terminal degeneration and neuronal apoptosis (Potashkin and 
Meredith, 2006). The inhibition of tyrosine hydroxylase via α-methyl-ρ-tyrosine has been 
demonstrated to guard against MA-induced toxicity in the striatum (Wagner et al., 1980; Axt 
et al., 1990; Thomas et al., 2008). In addition, the administration of clorgyline, a monoamine 
oxidase inhibitor (Wagner and Walsh, 1991; Kita et al., 1995; Thomas et al., 2008) and 
reserpine, an irreversible inhibitor of vesicular transport (Wagner et al., 1983; Albers and 
Sonsalla, 1995; Thomas et al., 2008; Kuhn et al., 2008), which results in increased 
cytoplasmic dopamine concentrations, worsens MA toxicity. This is evidence in favour of 
endogenous dopamine levels contributing to MA-induced dopamine terminal degeneration. 
Dopamine released from the terminals has also been shown to contribute to striatal MA 
toxicity, since the DAT inhibitor, amphonelic acid, also protects against damage induced to 
dopamine axons. Similarly, the activation of post-synaptic dopamine D1 receptors has been 
shown to result in degeneration of dopamine terminals, since dopamine receptor antagonists 
prevent terminal damage (Sonsalla et al., 1986; O’Dell et al., 1993; Jayanthi et al., 2005; Xu 
et al., 2005), however, partially depend on changes in dopamine release (Krasnova and Cadet, 
2009). Activation of post-synaptic dopamine receptors also results in the activation of 
transcription factors and Fas/FasL death pathway leading to increased expression of FasL and 
caspase-3 in rat striatal cells, which was inhibited by the pre-treatment of SCH23390, a 
dopamine D1 receptor antagonist (Jayanthi et al., 2005).  
 
Role of glutamate 
     
Dopamine and glutamate are thought to interact to cause neurotoxicity in striatal dopamine 
terminals, since glutamate receptor antagonists decrease MA-induced degeneration of both 
dopamine and serotonin terminals in various brain areas (Sonsalla et al., 1991; Fuller et al., 
1992; Battaglia et al., 2002; Chipana et al., 2008). Also, the involvement of glutamate was 
supported by the fact that MA results in the release of glutamate in the brain, including that of 
the striatum and nucleus accumbens (Baldwin et al., 1993; Abekawa et al., 1994; Mark et al., 
2004; 2007). Glutamate toxicity has been found to result from MA-induced release of large 
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amounts of glutamate activating N-methyl-d-aspartate (NMDA) receptors and resulting in 
formation of reactive oxygen species including nitric oxide (Lafon-Cazal et al., 1993; 
Gunasekar et al., 1995). Not only is nitric oxide a contributing factor towards glutamate 
neurotoxicity, nitric oxide also reacts with superoxide radicals forming peroxynitrite (Pacher 
et al., 2007). Increases in 3-nitrotyrosine induced by MA administration, which is a marker 
for peroxinitrite production, is inhibited by antioxidants and blocks MA-induced dopamine 
depletion (Imam et al., 2001).        
 
 
Morphological alterations in the brain induced by MA 
 
Magnetic resonance imaging (MRI) and PET studies have been used extensively to evaluate 
structural brain changes induced by MA. The basal ganglia have been shown to be 
particularly vulnerable to the effects of MA, due to its enriched innervations of dopamine. 
The neurotoxic effects of MA have been found to be evident even after long periods of 
abstinence (McCann et al., 1998; Ernst et al., 2000; Volkow et al., 2001a; Chang et al., 2005; 
Sekine et al., 2006). Some of the early brain structural changes observed in abstinent adult 
MA users included greater basal ganglia volumes of all its subdivisions, i.e. the caudate, 
globus pallidus and putamen, as well as the parietal cortex (Chang et al., 2005; Jernigan et al., 
2005). Interestingly, after longer periods of abstinence these volume differences seem to 
normalise. The enlarged striatum in abstinent MA abusers has been attributed to increased 
water content, MA-induced inflammation and/or reactive gliosis (Chang et al., 2005). A 
possible mechanism for MA inflammation proposes that MA stimulates matrix degrading 
proteinases (Conant et al., 2004) that compromise the blood-brain-barrier (BBB) resulting in 
the access of pro-inflammatory cytokines, chemokines and macrophages into the brain 
(Chang et al., 2007). An alternative  mechanism suggested that the  enlarged striatum resulted 
from  the influence of glial-mediated neurotrophic factors, since brain-derived neurotrophic 
factor (BDNF) has been shown to be elevated in MA users (Kim et al., 2005). This view was 
supported by animal studies that indicated that BDNF and glial cell-derived neurotrophic 
factor (GDNF) secreted by microglia and macrophages, stimulated sprouting of dopaminergic 
neurons (Batchelor et al., 1999). In addition, dopamine too possesses neurotrophic properties 
as evidenced by increased striatal dopamine neuron spine density after cocaine administration 
(Lee et al., 2006). Since treatment of schizophrenic patients with a typical antipsychotic also 
yielded increased striatal volumes (Corson et al., 1999; Lieberman et al., 2005), the 
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occupancy of D1 or D2 dopaminergic receptors has been suggested to mediate the change in 
striatal size. Therefore, it seems that after the initial increase in basal ganglia during early 
abstinence from MA use, normalization of the volumes of the basal ganglia occurs which 
compares with control volumes during longer periods of abstinence. Therefore, abusing MA 
for longer periods, eventually lead to greater basal ganglia neuronal damage and decreases in 
volume (Chang et al., 2005), which are usually accompanied by cognitive deficits.   
 
Volume decreases in abstinent MA users were not confined to the striatum, but also observed 
in other brain areas. Using MRI and new computational brain-mapping techniques, Thompson 
and colleagues (2004), found chronic MA consumption to result in severe gray matter deficits 
in the cingulate, limbic and paralimbic cortices, and expanded ventricles. In particular, the 
hippocampus was 7.8 % smaller in volume with a 7 % increase in white matter in the 
temporal regions surrounding the hippocampus. Decreased hippocampal volumes were 
correlated to impaired memory performance on a word-recall test. MA users also performed 
poorly on test of verbal memory, perceptual motor speed and executive functioning (Simon et 
al., 2002), as well as on tasks requiring response inhibition and decision making (Salo et al., 
2002; Kalechstein et al., 2003; Paulus et al., 2002). The finding of atrophy of the right 
cingulate in chronic MA abusers resulted in the cancellation of normal asymmetry of the right 
> left gray matter in normal healthy subjects (Thompson et al., 2004). White matter 
hypertrophy was suggested to result from altered myelination or gliosis in response to 
repeated drug exposures. Overall, chronic MA abuse resulted in specific cerebral deterioration 
with main effects found in the medial temporal lobe and limbic cortices (Thompson et al., 
2004). 
 
Structural abnormalities of the corpus callosum have also been observed in abstinent MA 
abusers (Oh et al., 2005). A few studies have demonstrated that white matter tracts within the 
corpus callosum are influenced by substance abuse (Pfefferbaum et al., 2006a, 2006b). 
Automated shape analysis experiments and diffusion tensor imaging studies revealed greater 
curvature of the genu and smaller width of the posterior midbody and isthmus. The 
abnormalities of the genu and the posterior midbody were well correlated with lifetime usage 
of MA. These shape abnormalities of the corpus callosum complimented observed structural 
and functional abnormalities in both the frontal and parietal cortices of MA abusers (Oh et al., 
2005) and correlated with poorer cognitive control (Salo et al., 2009). The frontal white 
matter at the anterior commissure-posterior commissure plane was also decreased as 
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measured by fractional anisotropy. The population of MA abusers in which this decrease was 
observed made significantly more errors in a Wisconsin Card Sorting test when compared to 
healthy controls (Chung et al., 2007). Here too, altered myelination (Alberson et al., 2004; 
Melo et al., 2006) and MA-induced degeneration of axons has been forwarded as possible 
reasons for the structural modifications. Interestingly, a separate analysis found that decreased 
frontal white matter and poorer performance on the Wisconsin Card Sorting test were 
confined to the male MA subjects of the study and were not found in the female MA abusers. 
This observation made the authors suggest that estrogen may offer protection against the 
neurotoxic effects of MA (Chung et al., 2007). 
 
MA has consistently been shown to result in reduced gray matter density in all cortical lobes, 
which included the temporal, frontal, occipital and parietal (Bartzokis et al., 2000; Thompson 
et al., 2004; Kim et al., 2006), and increases in white matter (Thompson et al., 2004; Chang et 
al., 2005; Bae et al., 2006), although mixed results for MA effect on white matter have also 
been reported (Oh et al., 2005; Schlaepfer et al., 2006; Chung et al., 2007). Usually gray 
matter reduces and white matter increases during normal aging (Bartzokis et al., 2001). This 
means that it is important to note the time of abuse onset and age of test subjects when 
conducting imaging studies. Abuse potential has been shown to decline with age (Berman et 
al., 2008) and therefore ascribing structural abnormalities to the actions of psychostimulants 
need to be done with caution (Bartzokis et al., 2002).  
 
Regional cerebral blood flow (rCBF) and hence perfusion rates in brain areas, is often used as 
an indicator of the functionality of that particular brain region. For instance, decreased 
regional cerebral blood flow was noted in the ACC when compared to normal healthy 
subjects (Hwang et al., 2004). Similarly male MA abusers tend to have hypoperfused regions 
in the frontal and parietal cortex. In contrast, female MA abusers present more with 
hyperperfusion of the parietal and occipital cortex (Chang et al., 2002). Hyperperfusion in 
females is suggested to be a protective mechanism of the brain that may decrease neuronal 
injury (Chang et al., 2002). However, it has been suggested that increases in regional cerebral 
blood flow may perhaps be attributed to glial activation and astrogliosis in MA addicts 
(Thompson et al., 2004).  
 
Other studies have found that cerebral blood flow abnormalities overlap with deficits in 
glucose metabolism of regions investigated (Iyo et al., 1997; Chang et al., 2002). Cerebral 
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glucose metabolism is considered an index of brain function. Significant increases in glucose 
metabolism were noted over the first month of abstaining from MA use (Berman et al., 2008). 
This increase in global glucose metabolism was 10.9 %. Closer investigation showed that the 
increased was more than 20 % in the parietal cortex suggesting that posterior cortical 
mechanisms are the driving force behind the global glucose metabolism. Increases in the 
cortical, limbic, striatal and thalamic regions were found to be modest (Berman et al., 2008). 
Volkow et al. (2001a) emphasized that elevations in cerebral glucose metabolism may merely 
result from gliosis. Glial responses have been associated with hypermetabolism (Roh et al., 
1998).  
 
Metabolic markers 
 
Magnetic resonance spectroscopy (MRS) is a technique that assesses the level of specific 
brain metabolites to detect neuronal damage (Sager et al., 2001). Brain metabolite levels are 
therefore indicators of the structural integrity and function of neurons. N-acetyl compounds, 
e.g. N-acetylaspartate (NAA), high energy metabolic compounds like creatine (Cr) and 
phosphocreatine (PCr), cell membrane synthesis or degradation markers e.g. choline-
containing compounds (Cho), and myoinositol have been measured in MA studies. The 
proton spectrum NAA peak is a measure of neuronal loss or neuronal damage since NAA is 
present almost exclusively in neurons and their dendritic and axonal processes (Simmons et 
al., 1991; Tsai and Coyle, 1995; Gonen et al., 2000). Disorders that have been associated with 
neuronal loss or damage include Alzheimer’s disease, brain tumors and head trauma have all 
showed good correlation with NAA peaks (Ernst et al., 1997; Pfefferbaum et al., 1999; Ott et 
al., 1993; Friedman et al., 1999). The creatine and phosphocreatine (Cr + PCr) peak of the 
proton spectrum reflects high-energy phosphate metabolism (Chang et al., 1996; Tedeschi et 
al., 1995). It is often assumed that the creatine peak is constant and used as a reference for 
other peaks, however, gray matter has been found to have higher Cr values than white matter 
(Narayana et al., 1989; Doyle et al., 1995; Chang et al., 1996; Lim et al., 1998). Because of 
this discrepancy the creatine peak has become useful in the study of disorders such as MA 
addiction, where there are discrepant gray and white matter alterations. Membrane synthesis 
and turnover results in increased intensity of choline signal (Miller et al., 1999; Tedeschi et 
al., 1996). It is suggested that Cho can act as a marker to determine the extent of neuronal 
recovery after drug cessation. Myoinositol (MI) is only present in glial cells and can be 
considered a glial marker (Brand et al., 1993).   
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Metabolic abnormalities in abstinent MA users were investigated in the frontal cortex, frontal 
white and gray matter and the basal ganglia (Ernst et al., 2000). Researchers found NAA 
concentrations reduced in the basal ganglia, frontal lobe and frontal white matter of MA users. 
Decreased NAA levels are indicative of neuronal loss or persistent neuronal damage inflicted 
by MA. Total Cr was reported to be decreased in the basal ganglia, while Cho and MI 
concentrations were increased in the frontal gray matter. According to Ernst et al. (2000) the 
combination of decreased NAA levels and elevated Cho and MI reflected glial proliferation in 
response to neuronal damage resulting from MA exposure.  
 
Nordahl et al. (2005) measured the metabolite concentrations in the ACC of recently abstinent 
(1 – 6 months), sustained abstinent (1-5 years) MA users and healthy control subjects. These 
authors assessed the metabolite levels in the primary visual cortex (PVC) which served as a 
control, since this brain area receives minimal dopamine innervation (Hall et al., 1994; 
Eberling et al., 2002). Proton MRS showed decreased NAA levels in the ACC with no change 
in the PVC. The Cho/NAA concentrations in recently abstinent users were higher in the ACC, 
but were normal in long-term abstinent MA users. It was suggested that after drug cessation 
this normalization of metabolite levels may relate to adaptive structural and functional 
changes taking place in the ACC (Nordahl et al., 2005). Animal and human studies have 
shown that neuronal changes accompanying MA exposure are not always permanent and that 
partial recovery may occur with prolonged abstinence (Melega et al., 1996; Wilson et al., 
1996; Harvey et al., 2000; Volkow et al., 2001b; Wang et al., 2004). Similarly to the 
suggestion of Ernst et al. (2000), this study concluded that increased Cho concentrations in 
early abstinence resulted from either acute damage to membranes, gliosis and membrane 
biosynthesis or axonal sprouting. The normalization of the Cho metabolite after a longer 
period of drug cessation probably occurs as a reflection of a subsequent period of axonal 
pruning of misguided axons (Gao et al., 1999).  
 
In another study, the relationship between metabolite concentrations in the frontal gray and 
white matter of abstinent MA users and their clinical characteristics (abstinence duration and 
total cumulative dose of greater or less than 100g lifetime) were tested. Decreased NAA 
concentrations in the frontal white matter that were exposed to more than 100g MA in their 
lifetime were found in abstinent male MA users and hence this finding was correlated with a 
cumulative MA dose. MI concentrations were also significantly reduced in the frontal white 
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matter of MA abusers (Sung et al., 2007). Reduced NAA levels were ascribed to frontal 
dopaminergic nerve fibre degeneration induced by MA as was documented in a T2 white 
matter hyperintensity study (Bae et al., 2006). Increased MI levels were once again ascribed 
to glial cell proliferation in response to toxic damage inflicted by MA (Sheng et al., 1994). 
These findings were not present in the frontal gray matter and it has been suggested that gray 
matter may recover from neurotoxic effects of MA over longer periods of abstinence.  
 
The role of glutamate 
 
A number of animal studies have focused on the modulation of MA-induced dopamine 
release by glutamate. In vivo PET experiments conducted on primates and rodents, have 
demonstrated a suppression of MA-mediated dopamine secretion by blocking the group I 
metabotrophic glutamate receptor with the antagonist 2-methyl-6-(phenylethynyl) pyridine 
(MPEP) (Tokunaga et al., 2009). In line with this evidence, pre-treatment with the NMDA 
glutamate receptor antagonist, MK-801, has been shown to attenuate the toxic effects of 
repeated MA doses which included the  activation of microglial and the depletion of both 
dopamine and the dopamine transporters (DAT) in the terminal striatal neurons (Thomas and 
Kuhn, 2005a). These results suggested that glutamate antagonism may possibly hold 
beneficial effects for MA addicts (Chang et al., 2007; Blandini et al., 1996; Izumi et al., 
2009). Furthermore, this is in line with the need for glutamatergic neurotransmission during 
cue-associated learning and memory processes in the development of addictive behaviour.  
 
The role of inflammatory processes 
 
Microglial cells form part of the body’s immune response and their activation has been 
associated with neurodegenerative disorders such as (Kreutzberg, 1996) Alzheimer’s disease 
and Parkinson’s disease (Banati et al., 2000; Cagnin et al., 2001; Ouchi et al., 2005). Chronic 
self administration of MA in abusers has also been shown to result in increased activation of 
microglia in the midbrain, striatum, thalamus, orbitofrontal cortex and insular cortex. All 
these brain areas are areas innervated by dopaminergic and serotonergic projections from the 
hindbrain. Activation of microglia during MA exposure appears to dissipate over long periods 
of drug abstinence (Sekine et al., 2008; Thomas and Kuhn, 2005b). Administration of anti-
inflammatory agents, ketoprofen and minocycline, attenuate the neurotoxic effects of MA 
(Asanuma et al., 2003; Thomas and Kuhn, 2005a; Hashimoto et al., 2007) and therefore this 
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approach has also been suggested as a therapeutic intervention for MA-abusers (Sekine et al., 
2008). 
 
The role of misfolded proteins 
 
Ubiquitin (Ub) is involved in the ubiquitin proteosome pathway and plays a key role in the 
proteolytic degradation of misfolded or damaged proteins via the 26S proteosomal pathway 
(Dickson et al., 1990; Alves-Rodrigues et al., 1998; Coleman and Ribchester, 2004). 
Ubiquitin plays a major pathological role in neurodegenerative diseases such as Parkinson’s 
disease (PD). This neurodegenerative disorder is characterized by substantial decreases in 
dopamine concentrations in the striatum due to the loss of dopaminergic neurons in the 
substantia nigra pars compacta (Lotharius and Brundin, 2002). Interestingly, PD is also 
identified by the accumulation of Lewy bodies, which are cytoplasmic inclusions containing 
the proteins α-synuclein and ubiquitin (Lowe et al., 1990; Spillantini et al., 1997; Chung et 
al., 2001; Fornai et al., 2004a). MA has neurotoxic effects on particularly dopaminergic 
neurons (Sonsalla et al., 1992; Frost and Cadet, 2000; Iman et al., 2001; Guilarte, 2001). MA 
disrupts the metabolic integrity of the cell, leading to increased oxidative stress, and 
ultimately apoptotisis and/or necrotisis (Davidson et al., 2001; Fornai et al., 2003; Fornai et 
al., 2004b). Oxidative damage to neurons leads to misfolded proteins and degradation via the 
UP pathway (Iwai et al., 2003). Neurons therefore degenerate when the ubiquitin proteosome 
pathway is unable to cope with the onslaught of misfolded proteins. Similar to PD, MA 
neurotoxicity also leads to the formation of inclusion bodies in nigral and striatal neurons 
(Lotharius and Brundin, 2002). PC12 cells treated with MA show that the formed inclusions 
or membranous whorls contain α-synuclein which co-localizes with ubiquitin within the 
whorl (Fornai et al., 2004b). Others have shown that ubiquitination occurs in nigral 
dopaminergic neurons and periaqueductal gray matter in the midbrain of MA abusers and in 
MA fatality victims. Subsequently it has been postulated that dysfunction of these neurons 
may be primarily responsible for clinical symptoms displayed by MA users (Quan et al., 
2005).  
 
 
Genes and proteins affected by MA: possible therapeutic targets 
 
Dopaminergic system 
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MA affects various neurotransmitter systems involved in reward and addiction. Initially, MA 
affects dopaminergic pathways in order to illicit rewarding or reinforcing effects, however 
this subsequently also alters the transmission of various other neurotransmitter pathways 
(Everitt and Wolf, 2002; Di Chiara et al., 2004; Pierce and Kumaresan, 2006). MA acts by 
entering the neuron at the dopaminergic amine transporter (DAT) which is located on the 
surface membrane of the neuron. In doing so, it reverses the function of the transporter 
(Zahniser and Sorkin, 2004; Wilhelm et al., 2006) and acts as an ion channel leading to non-
exocytotic amine release into the synapse. This increases extracellular synaptic cleft 
dopamine availability. In addition, MA affects dopamine concentrations by interacting with 
the vesicular monoamine transporter 2 (VMAT2) and reverses the VMAT2 transporter 
function (Sulzer and Rayport, 1990; Pifl et al., 1995; Wilhelm et al., 2004; Sulzer et al., 
2005). The VMAT2 transporter is responsible for the intracellular vesicle storage of 
dopamine, serotonin, norepinephrine and histamine (Erickson et al., 1992; Weihe and Eiden, 
2000). The enzymes responsible for the intracellular and extracellular break down of 
monoamines, monoamine oxidase (MAO) and catechol-o- methyltranferase (COMT), are 
inhibited by MA (Robinson, 1985; Kita et al., 1995). This effect of MA on these enzymes 
ensures greater dopamine levels in response to MA.     
 
The intensity of the “high” experienced by the MA user was found to be directly related to 
greater dopamine concentration levels and the occupancy of dopamine receptor type 2 (D2) 
(Laruelle et al., 1995; Volkow et al., 1999a; Drevets et al., 2001). D2 receptors are highly 
expressed in the shell subregion of the NAc (Larson and Ariano, 1995). Down regulation of 
D2 was observed in the striatum of MA users (Chang and Haning, 2006) and such reductions 
of striatal D2 receptors correlated well with increased metabolic activity of the OFC (Volkow 
et al., 2001c). Interestingly, decreased D2 brain levels has been associated with feelings of 
pleasure after methylphenidate administration in non-drug users, while increased D2 levels 
produced feelings of aversion (Volkow et al., 1999b). D2 receptor gene polymorphisms have 
been studied in substance abusers (Young et al., 2004). Here, it was suggested that the low 
functionality D2- TaqI A1 allele may serve as a risk factor in addictive behavioural disorders 
(Blum et al., 1996; Harano et al., 2001; Volkow et al., 2001c). Other studies have shown a 
greater prevalence of the D2- TaqI A1 allele polymorphism in MA abusers. These individuals 
also presented with greater novelty seeking behaviour and a trend towards decreased frontal 
executive functioning (Han et al., 2008). Similarly, greater TaqI A1 allele and the TaqI B1 
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allele of the D2 receptor gene were documented in Caucasian poly-drug users, one of the 
drugs being amphetamine (Smith et al., 1992; O’Hara et al., 1993). This was confirmed in a 
separate study of cocaine dependent individuals (Noble et al., 1993).  
 
The dopamine receptor type 4 (D4) gene, which forms part of the D2 receptor family, and the 
COMT gene was also investigated for possible association with MA abuse (Li et al., 2004). 
Here it was noted that the 120-base-pair (bp) variable number tandem repeat (VNTR) 
polymorphism in the promoter of the D4 gene did not result in a significant association with 
MA abuse. However, an interaction between the Val158Met polymorphism in the COMT 
gene and D4 120 bp promoter polymorphism was reported as well as between COMT 158 
Val/Met and the 48 bp VNTR polymorphism of D4 receptor gene. The researchers concluded 
that these genetic variations may constitute important risk factors for MA dependence (Li et 
al., 2004). This view was supported by reports of significant associations between MA abuse 
and the D4 and COMT genes (Bousman et al., 2009).            
 
PET studies have indicated that chronic MA abuse is characterised by decreased DAT in the 
striatum (McCann et al., 1998; Sekine et al., 2001; Volkow et al., 2001d), OFC and 
dorsolateral PFC and the amygdala (Sekine et al., 2003). The SLC6A3 gene (or also referred 
to as the hDAT1 gene) encodes the dopamine transporter and found that MA psychosis was 
associated with a significant excess of the 9- or fewer-repeat alleles of the VNTR in 3' 
untranslated region (UTR) of the SLC6A3 gene (Ujike et al., 2003). A single photon emission 
computed tomography (SPECT) in vivo study demonstrated that a 22% reduction of DAT 
protein in the putamen of individuals possessing the 9-repeat/10-repeat genotype when 
compared to individuals with the 10-repeat homozygosity (Heinz et al., 2000). It has been 
suggested that genotypes with 9- or fewer-repeat alleles of the VNTR have decreased 
transcriptional activity of the SLC6A3 gene and that these individuals might be more 
susceptible to the neurotoxic effects of MA (Ujike et al., 2003). However, the 40-bp VNTR 
polymorphism of the 3'UTR of the DAT gene and allele frequencies for DAT repeats 11, 10 
and 9 were found to have no significant associations with the clinical outcome of MA abusers 
(Liu et al., 2004). Similarly, no association between the DAT 3'-VNTR and MA dependence 
were also found in another study (Hong et al., 2003).  
 
DAT inhibitors have been suggested to have possible therapeutic benefits in MA dependence, 
since chronic MA use results in low dopaminergic tone (Volkow et al., 2001c) and the 
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antidepressant, bupropion, may aid in restoring dopamine homeostasis. Bupropion has been 
shown to decrease subjective effects of MA and reduce craving (Newton et al., 2006). The 
drug also increased abstinence in males with low to moderate MA dependence (Shoptaw et 
al., 2008). In addition, animal studies have indicated that bupropion reduces the neurotoxic 
effects of MA in rats (Montoya and Vocci, 2008), thereby supporting the drug’s potential 
benefit as a therapeutic agent in substance abuse.     
  
The neuronal specific, vesicular monamine transporter 2 (VMAT2), transports monoamines 
from the cytosol into intracellular secretory vesicles for storage (Schuldiner, 1994). This 
transporter is therefore essential in preventing dopaminergic accumulation in the cytosol and 
reducing possible neurotoxic effects of dopamine break down. VMAT2 has been implicated 
in MA dependence because of MA’s reversal of the transporter function, leading to the 
promotion of the increases in cytosolic dopamine concentrations (Sulzer and Rayport, 1990; 
Erickson et al., 1992; Pifl et al., 1995; Weihe and Eiden, 2000; Wilhelm et al., 2004; Sulzer et 
al., 2005). It has been demonstrated that MA neurotoxicity results from decreased VMAT2 
uptake capacity in the striatum and this MA effect was blocked by the prior use of DAT 
inhibitors (Fleckenstein and Hanson, 2003). Heterozygous VMAT2 knockout mice have also 
been shown to lead to enhanced MA-induced neurotoxicity (Fumagalli et al., 1999). 
Enhancement of VMAT2 function has been suggested to lower dopamine concentrations and 
related neurotoxic effects and exert a possible neuroprotective effect (Vergo et al., 2007). 
VMAT2 can therefore be considered therapeutic target for treating MA abuse. Contrastingly, 
the competitive VMAT2 inhibitor, tetrabenazine has been proposed to have possible 
therapeutic effects (Howell et al., 1994; Peter and Edwards, 1996). Evidence from animal 
studies has shown how tetrabenazine opposes the discriminative stimulus properties of MA in 
rats and decreases the locomotor activity stimulated by MA in mice (Vocci and Appel, 2007).         
 
A few other genes and proteins have also been investigated in MA abusers. The SLC22A3 
encodes the organic cation transporter 3 (OCT3) which is a transporter for MA and several 
other neurotransmitters including dopamine and serotonin (Grundemann et al., 1998; Wu et 
al., 1998). Decreased expression of OCT3 mRNA was found in the brains of rats that were 
behaviourally sensitized to the effects of MA (Kitaichi et al., 2003). In a clinical study, 
SLC22A4 polymorphisms were not associated with MA dependence. However, when test 
subjects were divided into poly-drug users and MA-only users, genotype and allele 
frequencies of single nucleotide polymorphism (SNP) 2 and SNP3 and haplotype frequencies 
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of the two SNPs were found to be significantly different between the groups. This observation 
suggested that repeated exposure to one drug results in behavioural and neurochemical cross-
sensitization to the usage of other drugs (Beyer et al., 2001, Akimoto et al., 1990; Kazahaya et 
al., 1989). The authors proposed that SLC22A3 polymorphisms may lead to poly-drug use in 
MA dependent individuals (Aoyama et al., 2006), and this was substantiated by a similar 
finding in a recent study (Bousman et al., 2009).    
 
A functional polymorphism of the promoter region of the human protein interacting with C-
kinase-1 (PICK1) gene has been associated with the susceptibility to spontaneous relapse of 
MA-induced psychosis (Matsuzawa et al., 2007). Single nucleotide polymorphisms (SNPs) 
rs713729 was significantly associated with MA abuse and rs713729 and rs2076369 was 
associated with spontaneous relapse of psychosis (Matsuzawa et al., 2007). PICK-1 is a 
scaffolding protein that plays a role in the targeting and localization of synaptic membrane 
proteins (Deken et al., 2001) and the clustering of the DAT on the cell surface (Torres et al., 
2001) by the modulation of protein kinase C activity (Blakely and Bauman, 2000; Deken et 
al., 2001; Robinson, 2002). The PICK-1 gene that has been associated with schizophrenia 
(Hong et al., 2004; Fujii et al., 2006) was subsequently linked to MA psychosis. A recent 
study confirmed the implication of a role for the PICK-1 gene in MA dependence (Bousman 
et al., 2009). It therefore seems that the genetic polymorphisms of the PICK-1 gene results in 
impaired DAT function and dopamine activity which may give rise to MA-induced psychosis.    
 
Serotonergic system 
 
Various transmitter systems play modulatory roles in dopaminergic circuitry and some of 
these include serotonin (5-HT), glutamate and gamma-aminobutyric acid (GABA). The 5-HT 
system is ideally situated for its modulatory role of dopaminergic activity, since the 5-HT 
neurons from the dorsal and median raphe nuclei innervate dopaminergic neurons of the 
nigro-striatal and mesolimbic systems (Herve et al., 1987; Phelix and Broderick, 1995). 
Serotonin has been shown to increase the inhibitory effect of dopamine on dopaminergic 
VTA neurons (Brodie and Bunney, 1996), resulting in decreased dopaminergic 
neurotransmission. Di Matteo et al. (2001) have specifically shown that 5-HT2C receptors 
inhibit mesolimbic dopamine function.  
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Serotonin plays an important role in drug reinforcement, since mice deficient of 5-HT 
demonstrate increased self-administration of cocaine when compared to normal mice (Parsons 
et al., 1998). PET studies have also indicated that global brain 5-HT transporter (SERT) 
densities were lower in MA abusers (Sekine et al., 2006) and hence lead to the attenuation of 
dopamine concentration modulation. In addition, agonists of the 5-HT2C receptor and 
inhibitors of SERT decreases the firing rates of VTA dopaminergic neurons (Prisco et al., 
1994; Di Mascio et al., 1998), resulting in reduced dopaminergic concentrations in the NAc 
(Di Matteo et al., 2000).  
 
The 5-HT2C receptors are located on GABAergic neurons and affects orchestrated by 
serotonin are proposed to be mediated by increased GABA inhibitory action of VTA 
dopaminergic neurons (Eberle-Wang et al., 1997; Howell and Kimmel, 2008). The 5-HT6 
receptors expressed in the limbic and motor brain areas (Monsma et al., 1993; Ruat et al., 
1993) have also been implicated in amphetamine-induced behaviours. For instance, pre-
treatment with the novel 5-HT6 receptor antagonist, SB 258510A, dose-dependently 
enhanced amphetamine’s reinforcing effects and increased extracellular dopamine 
concentrations in the frontal cortex (Frantz et al., 2002). Behavioural and locomotor activities 
induced by MA that were prevented by DAT inhibitors or the deletion of the DAT gene, 
coincided with the release of 5-HT via SERT (Torres et al., 2003). The serotonin transporter 
gene, 5-HTTLPR, polymorphism particularly the S alleles which have reduced transcriptional 
efficiency and lower 5-HT1A receptor binding have been linked to MA psychosis (Ezaki et 
al., 2008). The 5-HTT VNTR polymorphism has also been correlated with susceptibility to 
affective disorders (Ogilvie et al., 1996). However, an association study between the triallelic 
5-HTTLPR polymorphism (S, LG, LA) and MA psychosis was not significant (Chen et al., 
2007).  
 
Activation of other serotonergic receptor subtypes has mixed effects on the central 
dopaminergic system. For example, stimulation of 5-HT1B receptors reduced GABA 
inhibitory action in the VTA (Cameron and Williams, 1994) thereby, indirectly stimulating 
dopamine release. In contrast, antagonism of the 5-HT2A receptor, via the selective 5-HT2A 
antagonist, SR46349B, decreases amphetamine-induced dopaminergic release in the NAc and 
striatum (Porras et al., 2002).  
 
Glutamatergic system 
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It is suggested that glutamatergic tone plays an important modulatory role for dopamine and 
glutamate concentrations (Howell and Kimmel, 2008). In general, glutamate has an excitatory 
effect on dopaminergic neurons in the VTA, usually leading to enhanced mesocorticolimbic 
dopaminergic activity (Jones and Kauer, 1999). Subsequent animal studies have confirmed a 
role for the glutamatergic system in the rewarding effects of psychostimulants (Pierce et al., 
1996; Cornish and Kalivas, 2000; Carlezon and Nestler, 2002; Harris and Aston-Jones, 2003; 
Kalivas et al., 2003; McFarland et al., 2003). Acute effects of cocaine administration has been 
found to enhance NAc, VTA and PFC glutamate levels (Smith et al., 1995; Kalivas and 
Duffy, 1995; Reid and Berger, 1996; Pierce et al., 1996; Reid et al., 1997), while chronic 
exposure to cocaine results in decreased extracellular NAc glutamate concentrations (Keys et 
al., 1998; Bell et al., 2000). Moreover, chronic cocaine administration reduces metabotropic 
glutamate receptor 2 or 3 (mGluR2/3) autoreceptor function in the NAc (Xi et al., 2002a) and 
this is proposed to be a compensatory mechanism to decrease extracellular glutamate levels 
(Dackis and O’Brien, 2003). In line with this evidence, the administration of a mGluR2/3 
agonist decreases both dopamine and glutamate release in the NAc, striatum and the PFC 
(Moghaddam and Adams, 1998; Hu et al., 1999; Xi et al., 2002b), while antagonists to the 
mGluR5 and N-methyl-d-aspartate (NMDA) receptor have been shown to decrease cocaine 
reward (Pulvirenti et al., 1997; McGeehan and Olive, 2003). Also, mGluR5-deficient mice do 
not acquire intravenous cocaine self-administration (Karler et al., 1998), thereby supporting 
an important function of this receptor in cocaine-induced effects.  
 
Interestingly, the administration of N-acetylcysteine (NAC) normalizes glutamate 
concentrations in cocaine pretreated rats and prevents cocaine-induced drug reinstatement in 
these animals. Apparently, this is achieved by restoring the cysteine/glutamate exchanger (Xi 
et al., 2002a; Baker et al., 2003). However, the therapeutic mechanism of action has been 
questioned, since NAC does not cross the BBB. NAC has a negatively charged carbonyl 
group which is repelled by the negatively charged surface area of the endothelial cells of the 
BBB (de Boer and Gaillard, 2006). MA neurotoxicity has been shown to result from 
dopamine oxidation following MA’s release of massive amounts of dopamine and the 
formation of toxic reactive oxygen species (ROS) (Davidson et al., 2001). As a result, ROS 
overrides the antioxidant defense mechanism of the BBB, which leads to a state of oxidative 
stress (Plateel et al., 1995). Disturbances in protective mechanisms of the BBB allow access 
of toxic subtances into the brain. MA has been shown to cause disturbances of the BBB by 
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regulation the tight junction expression and Rho-A activation (Bowyer and Ali, 2006; 
Mahajan et al., 2008). Zhang et al. (2009) has also demonstrated that MA results in a loss of 
BBB permeability of human brain microvascular endothelial (HBMVEC) cells. Glutathione is 
an intracellular thiol and acts as an antioxidant which scavenges ROS (Akca et al., 2005), 
which reduces oxidative stress (Yamamoto and Zhu, 1998) and is critical for maintaining the 
integrity of the BBB (Agarwal and Shukla, 1999). When glutathione is depleted it leads to a 
reduction in protein sulfhydryls which is important for membrane function (Agarwal and 
Shukla, 1999). MA significantly reduces glutathione levels which lead to compromised cell 
viability (Zhang et al., 2009). NAC has been shown to increase glutathione levels (Chen et al., 
2008). Additionally, ROS increases P-glycoprotein (P-gp) (Ziemann et al., 1999; Hirsch-Ernst 
and Kietzmann, 2000), which is also known as a multidrug resistance protein and located in 
the BBB transmembrane and hence expressed in endothelial cells (Demeule et al., 2000), 
which allows the protein to act as an efflux transporter and subsequently limits the uptake of 
drugs from the blood into the brain. P-gp expression is also increased by glutathione 
depletion-induced oxidative stress in microvessel endothelial cells of rats (Hong et al., 2006). 
Similarly, NAC decreases P-gp upregulation which is induced by diethyl maleate (Wu et al., 
2009). Since, NAC increases glutathione levels which protects against the oxidative stress 
induced by MA and decreases P-gp efflux functionality, NAC might gain access to the brain 
to prevent reinstatement or drug seeking in addicts. Alternatively, the NAC might gain access 
to the brain, as MA induces an oxidative state leading to altered cell viability, loss of BBB 
permeability, cell death or apoptosis and hence would allow passage through the BBB.   
 
In a pharmacological study, the administration of modafinil, a non-amphetamine and weak 
psychostimulant, has been found to enhance striatal glutamate synthesis and striatal glutamate 
brain concentrations (Touret et al., 1994). Modafinil also directly inhibits rat midbrain 
dopamine neurons via D2 dopaminergic receptors (Korotkova et al., 2007). Subsequent 
clinical studies have reported higher prevalence rates for cocaine abstinence with modafinil 
treatment in patients with cocaine withdrawal symptoms (Dackis et al., 2003; 2005).        
 
NMDA receptors can be activated by either the binding of glutamate to the NR2 subunit 
(Laube et al., 1997), or the binding of glycine to the NR1 NMDA subunit (Johnson and 
Ascher, 1987). Glutamatergic transmission from the PFC to the NAc, amygdala and VTA, 
together with the activation of NMDA receptors in these areas, have been proposed to be 
instrumental in the development of CPP and behavioural sensitization induced by MA 
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administration (Wolf, 1998). The glycine transporters (GlyTs) are essential in the regulation 
of glycine levels at the synapses (Smith et al., 1992). Antagonising the GlyT leads to the 
inhibition of glycine uptake (Harsing et al., 2003) which enhanced NMDA receptor function 
(Bergeron et al., 1998; Kinney et al., 2003). It would seem that glycine enhances 
glutamatergic neurotransmission and therefore glycine administration may be therapeutic. 
This suggestion may be feasible since the GlyT-1 gene has been suggested to contribute to the 
vulnerability to MA dependence and psychosis (Morita et al., 2008; Bousman et al., 2009).  
 
Gamma-Aminobutyric acid (GABA) 
 
GABA, an inhibitory amino acid, modulates the release of basal dopamine and glutamate 
(Dewey et al., 1992) and has therefore been implicated in the effects caused by 
psychostimulants (Roberts and Brebner, 2000; Cousins et al., 2002). The GABA-A1 and G2 
(GABRA1, GABRG2) has been associated with MA abuse and abuse/dependence 
respectively (Lin et al., 2003; Nishiyama et al., 2005; Bousman et al., 2009). VTA dopamine 
activity is modulated by GABAergic interneurons (Churchill et al., 1992; White, 1996; 
Steffensen et al., 1998) and a major portion of NAc afferents are GABAergic. These fibres are 
thought to regulate dopaminergic input from the VTA to the NAc (Kita and Kitai, 1988). 
 
On the other hand, cocaine and amphetamine both decrease GABAergic activity in the 
striatum and this effect is mediated by D2 dopamine receptors (Centonze et al., 2002). A 
number of drugs that have their effects on GABA metabolism have been tested in substance 
abuse. The idea is to inhibit GABA-transaminase, an enzyme that metabolises GABA, 
thereby increasing synaptic GABA levels (Dewey et al., 1998; Kushner et al., 1999). 
Vigabatrin (gamma-vinyl-GABA), an irreversible GABA transaminase inhibitor, has been 
shown to prevent stimulant-induced dopaminergic increases in the NAc and 
corticomesolimbic system, leading to an attenuation of their rewarding effects (Ashby et al., 
1999; Gerasimov et al., 1999; 2000). Similarly, topiramate, a drug that potentiates 
GABAergic transmission (Shank et al., 2000), enhanced cocaine abstinence (Kampman et al., 
2004).     
          
Norepinephrine (NE) 
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It is suggested that the reinforcing effects of the central nervous system is not only induced by 
increases in dopaminergic concentrations alone, since dopamine receptor antagonists do not 
inhibit the subjective effects caused by cocaine or amphetamine administration (Ohuoha et al., 
1997; Brauer and de Wit, 1996; 1997). Amphetamines and cocaine has been shown to release 
norepinephrine (NE) more potently than they release dopamine and serotonin (Segal and 
Kuczenski, 1997; Reith et al., 1997; Rothman et al., 2001). These increases in NE have been 
demonstrated to contribute to the subjective effects induced by stimulants. The locus 
coeruleus has projections to the VTA and has the ability to influence activity of dopaminergic 
neurons (Liprando et al., 2004). For example, lesions of the locus coeruleus reduce NAc 
dopamine levels (Lategan et al., 1990; Grenhoff et al., 1993), while NE depletion in the PFC 
results in decreased amphetamine-induced CPP (Ventura et al., 2003). Interestingly, 
dopamine is taken up by both dopaminergic and noradrenergic neurons and hence the 
inhibition of NE transporters (NET) increases extracellular dopamine (Carboni et al., 1990; 
Reith et al., 1997; Yamamoto and Novotney, 1998), an effect that may enhance addictive 
behaviour. It is proposed that cocaine which is an inhibitor of NET (Eshleman et al., 1999) 
would inhibit dopamine uptake into NE neurons, resulting in increased extracellular dopamine 
and concomitant reinforcement of cocaine effects (Rothman et al., 2001). These findings 
therefore caution against the use of drugs that act on NET such as atomoxetine, which is often 
used in the treatment of attention-deficit hyperactivity disorder (ADHD) (Prince, 2006).    
 
 
Conclusions 
 
Methamphetamine is a highly addictive substance and the abuse of this drug is increasing at 
an alarming rate in many countries world wide. MA induces alterations and morphological 
changes in numerous brain areas and neurotransmitter pathways and results in various 
neurochemical and behavioural abnormalities. Studies focusing on MA-induced abnormalities 
can result in a greater understanding of the underlying molecular mechanisms and resultantly 
address MA-induced changes by using effective therapeutic interventions.  
 
Research done in the field of methamphetamine addiction has shown that the dopaminergic 
neural system is mainly affected by MA and hence attention has been focused on employing 
dopaminergic drugs to address and treat abnormalities induced by MA. The most important 
brain areas recruited by MA involved in the dopaminergic system includes the ventral 
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tegmental area, prefrontal cortex and the nucleus accumbens which play a role in the initial 
execution of reward. Additional recruitment of other brain areas is important for the 
establishment of addictive MA behaviour and neurochemistry which is achieved after 
multiple or chronic MA exposures.   
 
Methamphetamine has repeatedly been shown to have neurotoxic effects on neurons as a 
result of accumulation of MA-induced increases in dopamine concentrations. These 
neurotoxic effects lead to various morphological alterations in affected areas in the brain. 
Structural brain changes are studied by using multiple imaging techniques and the 
measurement of brain metabolite levels determine the structural integrity and function of 
neurons which indicates the measure of neuronal damage inflicted by MA exposure.  
 
Multiple genes and proteins have been implicated in the neurochemical and behavioural 
effects induced by MA. After the differential effects of cocaine and methamphetamine have 
been established, pharmacological treatment of MA addiction is still in the initial stages and 
future studies are needed to further elucidate the effects of MA in order to develop effective 
treatment strategies for methamphetamine addiction.   
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Abstract 
 
The maternal separation (MS) paradigm is an animal model that has been successfully used to 
study the long term effects of child abuse and neglect. Experiments showed that animals 
subjected to trauma and stress early in life display behavioural, endocrinological and growth 
factor abnormalities at a later stage in life, results that mirrored clinical conditions. It is 
apparent that adverse events early in life may affect the development and maturation of the 
brain negatively. The purpose of the present study was to investigate whether the abnormal 
brain development occurring in separated animals would also enhance the development of a 
preference for psychostimulant drug usage. Rats were subjected to maternal deprivation and 
further exposed to methamphetamine-induced conditioned place preference (CPP) which 
primarily measures drug reward (ventral striatum), learning and memory. Apomorphine-
induced locomotor activity was also assessed to investigate the effects of methamphetamine 
on the dorsal (primarily locomotor activity) striatal dopaminergic system. We found that 4 
consecutive injections of methamphetamine resulted in CPP behaviour 24 hours after the 4th 
injection. A further 4 injections yielded similar CPP results and this effect lasted for at least 7 
days until the third CPP assessment. These animals also had decreased ACTH and 
corticosterone secretions, but the prolactin levels were increased. Prior exposure to maternal 
separation did not have any effect on the CPP test. The ACTH and corticosterone secretions 
were also similarly reduced. However, maternal separation decreased the release of prolactin 
and this reduction was not evident in the separated group that received methamphetamine. 
There was no significant difference in the apomorphine-induced locomotor activity of 
normally reared animals whether they received methamphetamine or saline. Interestingly 
there was a significant difference in locomotor activity between the two groups of animals 
that were subjected to maternal deprivation. The separated animals that received 
methamphetamine displayed markedly reduced locomotor activity upon apomorphine 
administration when compared to those that were treated with saline. Taken together, we 
conclude that maternal deprivation differentially influences dorsal and ventral striatal regions 
implicating dopaminergic mechanisms. 
 
Keywords 
Maternal separation; Methamphetamine-induced place preference; Apomorphine-induced 
locomotor activity; HPA axis; Dopaminergic function; Striatum 
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Introduction 
 
Early life stress has continually been associated with anxiety-related stress disorders and 
substance abuse later in adult life. Clinical studies have shown that many anxiety-related 
disorders for example post-traumatic stress disorder (PTSD), social phobia and panic disorder 
comorbids greatly with the risk of substance abuse (Penk et al., 1988; Donovan et al., 2001; 
Lopez et al., 2005). This has lead to various hypotheses of the role of causality, in particular 
the self-medication hypothesis (Stanton, 1976; Khantzian, 1997) suggesting that substances 
are taken in order to cope with trauma or stress experienced (Tyssen et al., 1998) or to relieve 
symptoms of anxiety (Volpicelli et al., 1999). During the adolescent period, in particular, 
individuals that is in the process of developing coping mechanisms to combat the deleterious 
consequences of exposure to adverse experiences and social stressors. Failure to develop 
successful coping strategies has been postulated to result in susceptibility for drug taking 
(Goeders, 2003). Epidemiological studies have also indicated that early life experiences 
allows for the identification of populations at risk for abusing drugs in adulthood (Dobkin et 
al., 1997). 
 
Clinical studies of patients with early trauma and subsequent development of depression and 
anxiety disorders (Heit et al., 1997; Ladd et al., 2000) show that behavioural abnormalities are 
frequently coupled to neuroendocrine dysfunction. Similar to humans, animals display 
behavioural abnormalities at a later stage in life after being subjected to trauma and stress 
early in life. These changes in adult behaviour have been associated with a dysregulation of 
the hypothalamic-pituitary-adrenal (HPA) axis and alterations in neurotrophic factors 
(Daniels et al., 2004; Uys et al., 2006; Faure et al., 2006). It is therefore evident that 
alterations in behaviour that appears during adulthood have a strong neurochemical basis. 
 
The mesolimbic pathway is one of major dopaminergic pathways in the brain and is 
fundamental to the reward system. This pathway projects from the ventral tegmental area 
(VTA) to the striatum, which consists of both dorsal and ventral regions. In particular, this 
pathway has been shown to be involved in motivated behaviour and plays a key role in the 
reinforcing effects of psychostimulants (Koob et al., 1998; Wise, 1998). The mesocortical 
dopaminergic pathway plays a critical role in the initiation of the progressive process of 
addiction as it involves certain aspects of learning and memory (Goto and Grace, 2008). It 
also originates in the VTA where dopaminergic neurons project to the medial prefrontal 
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cortex. These two dopaminergic pathways are linked via glutamatergic neurotransmission 
from the medial prefrontal cortex to the nucleus accumbens (McFarland et al., 2003; Kalivas, 
2004; Kalivas and Volkow, 2005). The consequences of the administration of 
psychostimulants may therefore reflect the neurobiological status of these two central 
dopaminergic systems. 
 
The nigrostriatal dopaminergic pathway is involved in the regulation of locomotor activity 
and stereotypical or repetitive motor behaviours (Borlongan and Sanberg, 1995). In this case 
the dopaminergic neurones are located in the substantia nigra and they project to the dorsal 
striatum and specifically to the area called the caudate putamen (Afifi, 2003). This pathway 
mediates some of the behavioural effects induced by stimulant drugs (Koob, 1992); therefore 
the effects of pharmacological manipulation of this pathway can be readily determined by 
locomotor behavioural assessments.    
 
Prolactin (PRL) is one of the hormones that are primarily involved in the process of lactation. 
PRL is synthesized and produced in lactrotrope cells that are located in the anterior pituitary 
gland. The release or inhibition of prolactin is regulated by two major hypothalamic 
dopaminergic systems; the tuberinfundibular (TIDA) and the tuberohypophysial (THDA) 
dopaminergic systems. The THDA neurons originate in the periventricular nucleus of the 
hypothalamus and project to the neurointermediate lobe of the pituitary. TIDA neurons 
originate in the arcuate nucleus of the hypothalamus and project to the primary capillary 
plexus in the median eminence. Its content is released in the portal blood system which carries 
the dopamine to the anterior lobe of the pituitary (Moore and Lookingland, 2000). 
Measurement of plasma prolactin levels may therefore provide a useful insight into the status 
of the dopaminergic systems of the hypothalamus (Ben-Jonathan and Hnasko, 2001). 
 
The HPA axis has been implicated in precipitating the deleterious effects of both early life 
stress as well as substance abuse (Ortiz et al., 1995; Meaney et al., 2002). For example rats 
subjected to maternal separation exhibit elevated baseline corticosterone levels (Marais et al., 
2008), while administration of the corticosterone synthesis inhibitor (ketoconazole) reduced 
the time required to achieve cocaine self-administration in rats (Campbell and Carroll, 2001). 
Slotten et al. (2006) found decreased basal corticosterone levels in maternally separated 
animals when compared to their non-handled counterparts. Discrepancies between these and 
the present findings can be ascribed to gender differences as well as differential maternal 
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separation paradigms employed. The HPA axis is also under dopaminergic control since 
strong immunoreactivity for glucocorticoid receptors were found on hypothalamic 
dopaminergic cell groups indicating direct connectivity between the two modalities 
(Härfstrand et al., 1986). The mesocortical dopamine system has been found to be a 
modulator of stress reactivity including that of the HPA-axis (Sullivan and Dufresne, 2006). 
Corticosterone release upon stress exposure has also been correlated to mesocortical 
dopamine release (Sullivan and Gratton, 1998). In addition, amphetamine-induced dopamine 
release in the ventral striatum was associated with increased cortisol levels and subjects with 
high cortisol levels were also linked to positive effects of the drug (Oswald et al., 2005). 
Besides prolactin, the measurement of corticosterone may therefore provide additional 
information regarding the integrity of the central dopaminergic system.  
 
The present study was done to determine whether animals subjected to maternal deprivation 
(MS) early in life would display exaggerated responses to methamphetamine treatment and in 
addition to assess the effects of methamphetamine on dopaminergic systems in rats. Our 
behavioural measurements included methamphetamine-induced place preference behaviours 
and apomorphine-induced locomotor activity in the open field. Our neurochemical 
assessments included the determination of prolactin, ACTH and corticosterone plasma levels.  
 
 
Materials and Methods 
 
Animals 
Twenty seven male Sprague Dawley rats were used in this experiment. Animals were housed 
at the central research animal facility (AAALAC accredited) of Stellenbosch University. All 
rats were housed in the same colony room separate from where stress procedures, 
methamphetamine exposures or dissections were to take place. Animals were housed 
according to standard laboratory conditions as stipulated by the Ethical Guidelines of the 
University for the Housing of Experimental Animals. Rats were housed (2-4) in 40 x 25 x 20 
cm Plexiglas cages with corncobs bedding. Temperature was kept constant at 22ºC, humidity 
at 55% and food and water was available ad libitum for the duration of the experiment. 
 
Drugs 
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R-(-)-Apomorphine hydrochloride was procured from Sigma-Aldrich Chemicals (St. Louis, 
MO). Methamphetamine hydrochloride was obtained from US Pharmacopeia Convention Inc. 
(Rockville, USA). Apomorphine and methamphetamine were both dissolved in 0.9 % saline 
prior to being administered to the rats at a volume of 0.1ml/100g of body weight.   
 
Experimental design 
All rat pups were weaned at the age of postnatal day (PND) 21 according to gender and male 
rats were divided into 4 groups. The groups included: 
1) Control saline group (C Sal): animals not subjected to MS and receiving saline 
injections during conditioned place preference (CPP) (n = 7). 
2) Control methamphetamine group (C Meth): animals not subjected to MS and 
subjected to methamphetamine-induced CPP (n = 7). 
3) MS saline group (MS Sal): animals subjected to MS and receiving saline injections 
during CPP (n = 6). 
4) MS methamphetamine group (MS Meth): animals subjected to MS and subjected to 
methamphetamine-induced CPP (n = 7). 
 
Each of the above groups was tested on PND 37 (after first 4 methamphetamine 
administrations), PND 43 (after further 4 methamphetamine injections) and 7 days (PND 50) 
after 8 methamphetamine conditioning sessions to characterise the duration of place 
preference behaviour. In addition, all of the rats were exposed to apomorphine-induced 
locomotor activity on PND 38, 44 and 51 after each post conditioning test. Animals were all 
sacrificed by means of decapitation the day after the last apomorphine-induced locomotor 
activity in the open field on PND 52. 
 
Maternal separation (MS) paradigm 
Male and female rats were paired and their offspring were used. The day of birth was 
designated as PND 0, where after maternal separation commenced two days later on PND 2 
until PND 14 for a 3 hour daily period between 09h00 and 13h00. This protocol is in 
accordance with the deprivation procedures as employed by Ladd et al. (2000). During the 
separation period, the pups were removed from the mother and kept in a separate cage and the 
mother kept in the home cage. The cage containing the pups were then moved to an isolated 
dedicated room where the pups were kept warm under infrared lights (30-33ºC) in order to 
control for exposure to hypothermic conditions. Control litters were reared normally without 
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separations. After maternal deprivation was completed, animals were subjected to normal 
housing conditions. All rat pups were weaned at the age of 21 days, according to gender. Rats 
were regularly handled to minimize the effects of handling stress during the behavioural 
assessments. 
 
Conditioned Place Preference (CPP) paradigm 
The CPP test is a Pavlovian classical conditioning test, whereby the drug state is paired with a 
neutral environment (the CPP two compartment box). Colour and floor texture are differential 
cues used in the two compartments of the CPP box in order to differentiate between each 
compartment. These cues aid in the associations made between the drug state and the 
environment of one of the CPP compartments. In our study, the one compartment was black 
with a smooth floor, whilst the opposing compartment was black with white vertical stripes 
and a grid textured floor. The amount of time spent in the drug-paired environment is 
considered as a measure of the positive reinforcing or rewarding effects of the drug. This 
phenomenon has been confirmed in human cocaine addicts, whereby drug paraphernalia that 
is considered as a neutral environmental stimuli, become associated with the effects 
experienced by cocaine use (Gawin, 1991). 
 
Adolescent male rats were handled from PND 25 until PND 30, where after they were 
habituated to the test cage the day before the testing (PND 31) for 15 minutes. On PND 32 
rats in all groups were subjected to the CCP test. The CPP test consists of 3 stages: pre-
conditioning stage, the conditioning stages and the post-conditioning stage. 
  
Pre-conditioning 
During the pre-conditioning stage, animals were given free access to both compartments for a 
period of 15 min of the CPP test box and the amount of time spent in each compartment were 
recorded and measured. The pre-test phase allows for the determination of the natural 
preference of the animal for either one of the two compartments of the CPP box.  
 
 Conditioning 
The conditioning stage involves a pavlovian associative learning method, whereby a neutral 
stimulus (drug-paired compartment) was paired with the drug state induced by 
methamphetamine. The animals designated to the methamphetamine groups were intra-
peritoneally injected with methamphetamine (1mg/kg, i.p.) 20 min before being confined for 
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a further 30 min period to the compartment of the test box opposite to the natural preference 
of the rat. The 50 min period in total was allowed for the drug to take affect and to ensure the 
formation of associations in the CPP box. The conditioning stage was repeated twice on two 
separate 4 consecutive day periods (PND 33-36 and PND 39-42). Control rats received 
equivalent saline injections and were also placed in opposing compartments of the CPP box.  
 
 Post-conditioning  
On PND 37, 43 and 50 post-conditioning occurred to establish the duration of 
methamphetamine-induced place preference. During the post-conditioning stage animals were 
once again given free access to both compartments, and the amount of time spent in each 
compartment was recorded to allow for analyses at a later stage by using an automated 
behavioural tracking system (Noldis Ethovision). The CPP score was calculated as the 
difference between the amount of time spent in the drug-paired compartment before and after 
the conditioning stages.  
 
Apomorphine-induced locomotor activity in the open field  
The non-selective dopamine agonist, apomorphine was used in order to determine whether 
dopaminergic pathways was activated, and in particular, the striatum of which the nucleus 
accumbens comprises the ventral area which would lead to the deduction that the 
dopaminergic pathways to this particular area was activated as well. In addition, try to 
establish to what extent dopamine transmission induced by methamphetamine has influenced 
DA receptor numbers or resulted in the desensitization of post-synaptic dopaminergic 
receptors. Thus, all animals were additionally exposed to 3 separate apomorphine 
administrations as to determine methamphetamine-induced dopaminergic status over time.  
 
The day after each post-conditioning test on PNDs 38, 44 and 51, rats were subjected to 
apomorphine-induced locomotor activity in the open field. All rats were exposed to a 
subcutaneous apomorphine injection (1 mg/kg, s.c.) and placed in the open field after 30 min, 
to allow for the drug to take affect, in order to record locomotor activity for a 10min period. 
After each behavioural recording, the open field was cleaned with 70 % ethanol to prevent 
interference with the next animal’s behaviour in the apparatus. 
 
Behavioural analysis of CPP test and locomotor activity 
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On all days of behavioural testing during the pre-test, post-tests and apomorphine-induced 
locomotor activity in the open field; behaviour was recorded on video tape in order to allow 
for later analysis. Video recordings were analysed using Noldus Ethovision (Wageningen, 
The Netherlands) software where the behaviour of animals were digitally tracked in both the 
CPP box and the open field.  
 
Determination of plasma neuroendocrine hormones 
On PND 52, animals were decapitated and trunk blood collected in pre-cooled EDTA tubes 
for neurohormonal measurement of adrenocorticotropin hormone (ACTH), corticosterone and 
prolactin (PRL) concentrations. The blood samples were centrifuged at 4000 rpm for 10 min 
at 4ºC to separate the plasma, where-after the samples were frozen in liquid nitrogen until 
assayed. Plasma ACTH concentrations were determined using a solid phase 
immunoradiometric (IRMA) assay (EURIA-ACTH c.t., Euro-diagnostica, Medeon, Sweden). 
Plasma corticosterone concentrations were determined using radioimmunoassay (RIA) kits 
(ImmuChemTM Double Antibody Corticosterone 125I RIA kit, MP Biomedicals, Orangeburg, 
NY). Plasma prolactin levels were measured using an enzyme immunoassay (EIA) Kit (Rat 
Prolactin EIA Kit, A05101, SPI-BIO, Bertin Group, Montigny Le Bretonneux, France). 
 
Statistical analysis 
The nonparametric analysis of variance (ANOVA), the Kruskal-Wallis test was used to 
analyse behavioural parameters, ACTH, corticosterone and prolactin data. Statistical 
significance of this test (H-statistic) was followed by the Mann-Whitney U post hoc test 
where applicable.  Statistical tests were all done with the aid of SPSS (version 15.0). The 
level of significance was accepted as p<0.05. Data is reported as mean ± SEM. 
 
 
Results 
 
Conditioned place preference behaviour 24hrs after 4 methamphetamine conditioning 
sessions (CPP score 1) on PND 37 
Animals subjected to saline conditioning resulted in spending less time in the compartment 
allocated for conditioning showing a preference for the opposing side of the place preference 
box when compared to animals exposed to methamphetamine conditioning (p = 0.018) 
(H=12.741, 3 df, P=0.005). Similarly, maternally separated rats exposed to saline 
 101 
conditioning exhibited a preference for the opposing compartment of the CPP box when 
compared to rats subjected to drug conditioning (p = 0.010). Methamphetamine conditioned 
rats showed a preference for the drug-paired compartment of the place preference apparatus, 
while rats also subjected to maternal separation early in life exhibited similar place preference 
for the drug-paired compartment. Non-MS and MS rats exposed to methamphetamine 
conditioning exhibited a very large preference in comparison to saline conditioned animals 
(Figure 1). 
 
Conditioned place preference behaviour after 8 methamphetamine conditioning sessions 
(CPP score 2) 
On PND 43, all animals had been exposed to 8 methamphetamine conditioning sessions, and 
showed similar preference behaviours as in CPP score 1 behaviours (H=17.232, 3 df, 
P=0.001). Control (p = 0.003) and maternally deprived (p = 0.010) animals subjected to saline 
conditioning displayed an opposing preference for the saline-paired compartment. In contrast, 
animals exposed to methamphetamine conditioning in both control (p = 0.003) and maternally 
separated rats (p = 0.010) exhibited place preference for the drug-paired compartment. In 
addition, the maternally separated rats exposed to saline conditioning displayed significantly 
less preference for the opposing conditioned compartment of the CPP box than when 
compared to the animals experiencing control rearing conditions (p = 0.046) (Figure 2). 
 
Conditioned place preference behaviour 7 days after last conditioning session (CPP score 3)  
In order to characterise the duration of place preference behaviour after 8 methamphetamine 
administrations a post-test was conducted 7 days after last conditioning session on PND 50. 
Surprisingly, all animals still displayed similar place preference behaviours as in CPP score 1 
and 2 (H=8.905, 3 df, P=0.031). Both control (p = 0.041) and maternally separated rats (p = 
0.046) subjected to saline-paired conditioning displayed less preference for the conditioning 
compartment of the CPP box. Animals exposed to normal rearing (p = 0.041) and to maternal 
deprivation (p = 0.046) when subjected to methamphetamine conditioning displayed place 
preference for the drug-paired compartment of the CPP box (Figure 3).  
 
Apomorphine-induced locomotor activity in the open field 
Control and maternally separated rats were both exposed to apomorphine-induced locomotor 
activity after each post-conditioning test on PND 38, 44 and 51 in order to assess 
dopaminergic function and receptor status. All experimental groups displayed similar 
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locomotor activity in the open field after apomorphine administration on PNDs 38 (H=4.644, 
3 df, P=0.2) and 44 (H=4.105, 3 df, P=0.25). Maternally deprived animals subjected to 
methamphetamine conditioning displayed a gradual reduction in locomotor activity in the 
open field and this decrease in locomotion only became significantly different after the third 
apomorphine-induced open field activity on PND 51 (H=8.952, 3 df, P=0.030). This group 
differed significantly from the third apomorphine-induced locomotor activity in the animals in 
both control (p = 0.025) and maternally deprived (p = 0.007) groups subjected to saline-
conditioning (Figure 4).  
 
Basal plasma ACTH concentration in rats subjected to CPP 
Various significant differences between groups were found regarding ACTH levels in blood 
plasma (H=14.5, 3 df, P=0.002). All experimental groups showed lower ACTH levels when 
compared to normally reared animals that received saline injections. The normally reared 
control rats subjected to methamphetamine conditioning had lower ACTH concentrations 
when compared to normally reared saline animals (p = 0.007). This group had similar ACTH 
levels when compared to both groups exposed to maternal separation. Maternally deprived 
rats that were subjected to saline conditioning had significantly lower ACTH levels when 
compared to the control saline rats (p = 0.008). Similarly, the maternally separated rats 
exposed to methamphetamine conditioning showed lower levels compared to control saline 
rats (p = 0.003) (Figure 5). 
 
Basal plasma corticosterone levels in animals subjected to CPP 
Corticosterone concentrations followed a similar pattern as that of ACTH levels in all 
experimental groups (H=12.729, 3 df, P=0.005). Both groups of animals exposed to 
methamphetamine and rats subjected to maternal separation and saline conditioning displayed 
stress corticosterone levels that were comparable. Rats not previously subjected to maternal 
deprivation but exposed to saline conditioning resulted in higher corticosterone levels when 
compared to methamphetamine conditioned rats (p = 0.009) and saline conditioned rats 
previously exposed to maternal deprivation (p = 0.017) and lastly higher corticosterone 
concentrations than maternally separated animals subjected to methamphetamine conditioning 
(p = 0.003) (Figure 6).  
 
Basal plasma prolactin concentration in rats subjected to CPP 
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The control animals exposed to methamphetamine conditioning displayed increased prolactin 
levels when compared to rats subjected to saline conditioning (p = 0.018) (H=10.575, 3 df, 
P=0.014). In addition, control rats that received the methamphetamine conditioning also 
exhibited significantly higher prolactin concentrations when compared to maternally 
separated rats subjected to saline conditioning (p = 0.023). Animals exposed to maternal 
separation exhibited lower prolactin levels compared to their drug exposed counterparts (p = 
0.043). Interestingly, the maternally deprived and drug conditioned animals demonstrated 
increased prolactin concentrations when compared to saline controls (p = 0.023) (Figure 7). 
 
 
Discussion 
 
The major findings of the present study were as follows: (1) animals treated with 
methamphetamine display conditioned place preference behaviour when compared to their 
respective controls; (2) the place preference behaviour lasted for at least 7 days; (3) 
significant reductions in apomorphine-induced locomotor activity were observed only in rats 
that were exposed to maternal separation and methamphetamine; (4) basal stress hormone 
levels (ACTH and corticosterone) were similarly reduced in maternally deprived rats and 
animals treated with methamphetamine and (5) prolactin levels were increased in those 
animals that were subjected to methamphetamine conditioning. 
 
Addiction usually arises as a result of repeated drug exposures to ensure long lasting chemical 
and molecular changes induced by repeated drug exposures, hence the increased risk of 
relapse and craving long after drug cessation (Nestler, 2001). In our study, we found that CPP 
behaviour resulted 24hrs after 4 consecutive conditioning sessions, in addition to CPP 
behaviour displayed 7 days after the 8th methamphetamine conditioning session. We 
administered an additional 4 injections of methamphetamine, since pilot studies done in our 
laboratory of 4 methamphetamine injections did not result in CPP behaviour. However, 
Cherng et al. (2007) induced CPP in mice with three, two and even one alternate 
administration of methamphetamine with saline pairings. These discrepancies between 
findings can possibly be accounted for by variations in CPP paradigm used as well as mice 
versus rats used in present study. Similarly, Mizoguchi and colleagues (2004) induced CPP 
with three cycles of alternate methamphetamine and saline conditioned pairings, here too 
differences can be ascribed to variations in CPP protocols, dosages used, route of 
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administration of the drugs, in addition to different animal strains employed. Interestingly, 
when methamphetamine conditioning takes place without alternate saline pairings it did not 
result in eliciting reliable methamphetamine induced place preference (Cherng et al., 2007). 
This latter finding is in contrast to the present findings, since rats exposed to 
methamphetamine conditioning resulted in significant place preference behaviours. It is not 
surprising to find prolonged place preference behaviour in animals exposed to 
methamphetamine conditioning as in the present study. Lin et al. (2007) also demonstrated 
that six methamphetamine injections resulted in behavioural sensitization and induced 
conditioned place preference which lasted for 7 days.  
  
We found that animals exposed to early life stress and normally reared controls developed 
place preference behaviours after repeated methamphetamine exposure. Stress-induced 
reinstatement is one of the major risk factors resulting in relapse or reinstatement, in addition 
to the other modalities of a drug dose itself or any other environmental stimuli previously 
associated with drug taking (Shalev et al., 2002). Numerous studies have shown that early life 
stress induces definite behavioural and endocrinological effects and that these detriments 
persist well into adulthood (Matthews et al., 1996a; Ladd et al., 1996; Matthews et al., 1999). 
A study by Vazquez et al. (2007) indicated that maternal separation resulted in prolonged 
morphine-induced CPP behaviour when compared to control animals and that these 
behaviours were accompanied by a decrease in dopamine D2 receptors in  the nucleus 
accumbens core and an even greater decrease in the shell region. Brake et al. (2004) found 
maternal separation to induce a higher sensitivity to cocaine locomotor activity and display 
greater dopaminergic response in the nucleus accumbens to a mild stressor and show 
hyperactivity in a novel setting. The maternally deprived animals also reacted to 
amphetamine’s locomotor effects more strongly when repeatedly stressed in comparison to 
their handled and non-handled counterparts. These behavioural findings were accompanied by 
a decrease in DAT levels in the deprived rats which provided evidence for early life stress 
implicating dopaminergic mechanisms and resulting in a possible neurological vulnerability 
to abusing drugs (Brake et al., 2004). Contrastingly, we however did not observe a great 
difference in CPP behaviour between control and maternally separated animals, but maternal 
deprivation did alter the stress hormones and dopaminergic function. Possible reasons for this 
discrepancy may reside in differences in animal strain used, as well as variations within the 
respective maternal separation paradigms. These results illustrate that more research must be 
done to ascertain the controversial role that early life stress plays in drug addiction and 
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whether early life stress introduces a vulnerability or resiliency factor for subsequent 
addictive biochemistry. 
 
Exposure to a novel setting and the resultant locomotor response of the animal has been 
shown to be a good indicator of rearing differences (Meaney et al., 2002). Maternally 
separated and non-handled animals initially display either freezing or anxious behaviours in 
the beginning of an open field exposure after which their locomotor activity becomes 
significantly more than the handled animals which are usually very active at the beginning 
after which this activity decreases (Meaney et al., 2002). Higher rates of amphetamine self-
administration have also been found in high locomotor responders (Piazza et al., 1989) and 
they too have increased dopaminergic response to amphetamine in the nucleus accumbens 
(Hooks et al., 1992). In the present study, animals received an apomorphine injection and 
were subjected to the open field to assess locomotor activity. No real difference were noted 
during the first two assessments of apomorphine-induced open field activity between 
maternally separated and control animals on PNDs 38 and 44. However, after the third 
apomorphine administration on PND 51 maternally deprived rats previously exposed to 
methamphetamine conditioning exhibited reduced locomotor activity when compared to the 
maternally separated rats that received saline conditioning and the normally-reared control 
animals. Given the fact that animals only showed a significant decrease in apomorphine-
induced locomotor activity on PND 51 and not earlier may suggests that a more pronounced 
effect on locomotor activity might be seen in true adulthood (PND 60+). This finding 
indicated that early life stress predisposed the animals to subsequent insults such that the 
added exposures to methamphetamine and apomorphine resulted in significant decreases in 
locomotor activity. Increased dopaminergic transmission in response to both maternal 
separation and methamphetamine conditioning may have led to the desensitization of post-
synaptic dopamine D2 receptor signalling or even a decrease in D2 receptor number. Such a 
mechanism may explain the observed decrease in locomotor activity upon apomorphine 
challenge. A similar result was reported by Matthews et al. (1996b) who found that adult 
animals previously exposed to repeated maternal deprivation are less responsive to the 
locomotor effects induced by amphetamine. The reduction in locomotor activity only after the 
third apomorphine administration in the present study could possibly reflect the gradual 
adjustment of the central dopaminergic system to the effects of multiple exposures to 
methamphetamine and apomorphine. Since these drugs are known to induce differential 
aspects of addiction namely conditioned place preference and behavioural sensitization (Kim 
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and Jang, 1997; Dias et al., 2006; Bloise et al., 2007), it can be expected that they influence 
the dopaminergic reward system differently. For instance, it has been shown that 
methamphetamine primarily acts upon the dopamine transporter (Zahniser and Sorkin, 2004), 
whilst apomorphine preferentially binds to postsynaptic D2 receptors to exert their effects 
(Dias et al., 2006). Interestingly, Kaneno et al. (1986) reported that repeated 
methamphetamine administration enhanced apomorphine stereotyped behaviours but 
methamphetamine pre-treatment however did not result in changing striatal dopamine, 
homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) contents. In contrast, 
the sensitivity of striatal dopaminergic metabolism to apomorphine was shown to be reduced 
after methamphetamine pre-treatment (Kashihara et al., 1987) and that apomorphine lowered 
striatal dopaminergic metabolism less in methamphetamine treated rats compared to saline 
treated control rats (Kashihara et al., 1986). As reported in the present study, 
methamphetamine treatment in maternally separated animals resulted in decreased 
apomorphine-induced locomotor activity which may rather implicate the role of early life 
stress in influencing locomotor and hence dorsal striatal dopaminergic mechanisms. It is 
important to mention that stress too has been shown to play a definite role in the enhancement 
of the psychomotor stimulating effects of psychostimulant drugs (Kalivas and Stewart, 1991) 
which is also referred to as stress-induced sensitization. When exposed to stressful situations 
the resultant increase in glucocorticoids is suggested to play a role in the development of 
stress-induced sensitization (Marinelli and Piazza, 2002), suggesting that stress cross-sensitize 
with the effects of psychostimulants. When high levels of glucocorticoids are blocked by 
metyrapone the psychomotor stimulating effects of cocaine or amphetamine is reduced 
(Rouge-Pont et al., 1995; Reid et al., 1998). Contrastingly, when stress corticosteroids levels 
are induced it leads to increased amphetamine psychomotor activity (Deroche et al., 1992). 
Multiple biochemical role players are involved in behavioural outcomes that caution must be 
taken when interpreting above findings. However, it would seem that maternal separation 
plays a significant role in affecting the locomotor response of animals subjected to several 
methamphetamine exposures. 
 
The stress response system of the brain plays an important role in the early stages of 
development in determining vulnerability to drug abuse and relapse (Goeders, 1997; Piazza 
and Le Moal, 1998). Stress activates the HPA-axis which ultimately leads to the secretion of 
glucocorticoids influencing various areas of the brain where glucocorticoid receptors are 
expressed. Interestingly, glucocorticoid receptors are expressed on dopaminergic neurons 
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(Härfstrand et al., 1986) which partially explain the influence of the stress response on drug 
related effects. For example, stress has been shown to lead to increased glucocorticoid levels 
causing higher dopamine concentrations especially in mesolimbic pathways. This apparently 
facilitates enhanced sensitivity to the reinforcing effects of drugs and higher rates of self-
administration (Deroche et al., 1997; Piazza and Le Moal, 1998; Le Moal and Koob, 2007). 
Also, both glucocorticoids and psychostimulants act on the nucleus accumbens shell region 
(Barrot et al., 2000). In addition, it has been found that corticosterone treatment leads to the 
development of cocaine sensitization as assessed by VTA regulated locomotor activity (Ortiz 
et al., 1995). Surprisingly, non-contingent electric footshock or the pre-treatment of 
corticosterone itself did not lead to the acquisition of methamphetamine self-administration 
(Moffett and Goeders, 2005). These examples demonstrate that differential hormonal 
responses are needed to inflict various drug-induced phases of addiction for different 
psychostimulants even though these drugs have similar behavioural outcomes.    
 
As stress and amphetamine are known to cross-sensitize (Cole et al., 1990; Deroche et al., 
1992), it may be possible that stress experienced during the injection of methamphetamine 
might confound the rewarding effects as tested by the CPP paradigm. Corticosterone has been 
found to have reinforcing properties, as the administration of corticosterone increases the 
reinforcing properties of psychostimulants (Deroche et al., 1997), while adrenalectomy 
reduces psychostimulant-induced reinforcing effects (Goeders and Guerin, 1996; Deroche et 
al., 1997). In the present study, animals subjected to methamphetamine resulted in lower 
ACTH and corticosterone levels when compared to rats exposed to saline conditioning. This 
could possible be ascribed to an exhaustive HPA axis as a result of multiple 
methamphetamine exposures during the conditioning phase. In addition, Dietz et al. (2007) 
also found that corticosterone neither resulted in conditioned place preference or aversion 
when compared to cocaine-induced conditioning. We propose that the added release of 
corticosterone upon injection of methamphetamine of a stress response system already taxed 
with large releases of stress hormones, the additional secretion of hormones during injection 
stress would not have had a significant effect and thus not confound the place preference 
behaviour induced by methamphetamine.  
 
In the present study, methamphetamine administration led to reduced levels of both ACTH 
and corticosterone. This finding is in contrast with others that reported methamphetamine to 
transiently increase plasma corticosterone. This apparent stimulation of corticosterone 
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secretion was however observed after only a single injection (Asano and Moroji, 1974; 
Szumlinski et al., 2001). Interestingly, hypoactive HPA response of decreased blood cortisol 
levels were found during the withdrawal period of cocaine addicts after long-term abuse 
(Buydens-Branchey et al., 1997). In our experiments, the maternally separated rats also had 
decreased ACTH and corticosterone concentrations when compared to saline conditioned rats.  
Previous work done in our laboratory yielded similar results where maternal deprivation alone 
resulted in reduced ACTH and corticosterone levels (Faure et al., 2006). These findings are 
therefore in line with clinical observations showing  the comorbidity of  substance abuse and 
hypoactive HPA axis responses that occur in individuals suffering from post-traumatic stress 
disorder (PTSD) (Yehuda et al., 1995) or those that were subjected to childhood abuse (Heim 
et al., 2001). It is thus not surprising, since maternal separation is an animal model for 
childhood abuse and neglect that decreased stress hormonal responses were observed in our 
animals. However, the combination of maternal separation and methamphetamine 
conditioning did not result in an additive effect but rather in similar levels suggesting that the 
two interventions may have independent mechanisms of action with respect to the regulation 
of the HPA axis. 
 
All animals subjected to methamphetamine conditioning had increased prolactin levels when 
compared to saline conditioned rats. Increased prolactin levels are generally an indication of 
low dopamine levels or an exhausted hypothalamic-tuberinfundibular dopaminergic system. 
Alternatively, prolactin release from the anterior pituitary could have been altered (Mantsch et 
al., 2000). Animals subjected to maternal separation alone had similar prolactin levels when 
compared to control animals exposed to saline conditioning. This result suggests that maternal 
separation per se had no effect on hypothalamic dopaminergic neurons.    
 
In summary, our data suggests that maternal separation selectively affects the dorsal striatum 
and hence had a greater influence on locomotor activity. Maternal deprivation in combination 
with methamphetamine conditioning resulted in decreased locomotion. This result is in line 
with work done by others that have shown that adult animals previously exposed to repeated 
maternal separation do not react on the locomotor effects induced by amphetamine (Matthews 
et al., 1996b). On the other hand, methamphetamine induced CPP and decreased 
hypothalamic dopaminergic activity. It was therefore not surprising that prior exposure to 
maternal separation did not exacerbate the CPP effects mediated by methamphetamine. This 
was in contrast to what was expected, since the development of substance abuse has been 
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closely related to stress. Interestingly, exposure to early life stress has been shown to lead to 
increased locomotor activity and increased dopaminergic turnover in mesolimbic brain areas 
whereas striatal dopaminergic inputs from the nigrostriatal pathways were less active when 
exposed to amphetamine challenge (Kehoe et al., 1998). This finding therefore supports our 
current proposal of a preferential effect of maternal separation on the differential 
dopaminergic pathways.  
 
 
Conclusions 
 
Stress during childhood in the form of maternal deprivation did not lead to greater place 
preference behaviour as was expected. However, maternal separation did introduce a 
vulnerability factor on apomorphine-induced locomotor activity in the open field and on stress 
hormone levels and prolactin concentrations. Maternal separation differentially influences 
dorsal and ventral striatal regions implicating dopaminergic mechanisms.  
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 Figure 1: Conditioned place preference (CPP) score 1 (24hrs after first 4 methamphetamine 
conditioning sessions) of groups subjected to control conditions and maternal separation. 
Values given as mean ± SEM. * significantly different from controls. p < 0.05 (N = C Sal: 7, 
C Meth: 7, MS Sal: 6, MS Meth: 7).  
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Figure 2: Conditioned place preference (CPP) score 2 (after 8 methamphetamine 
conditioning sessions) of groups subjected to control conditions and maternal separation. 
Values given as mean ± SEM. * significantly different from controls. p < 0.05 (N = C Sal: 7, 
C Meth: 7, MS Sal: 6, MS Meth: 7). 
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Figure 3: Conditioned place preference (CPP) score 3 (7 days after last conditioning 
sessions) of groups subjected to control conditions and maternal separation. Values given as 
mean ± SEM. * significantly different from controls. p < 0.05 (N = C Sal: 7, C Meth: 7, MS 
Sal: 6, MS Meth: 7).  
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Figure 4: Apomorphine-induced locomotor activity in the open field (Apo 1, Apo 2 and 
Apo3) the day after each post-conditioning test of groups subjected to control conditions and 
maternal separation. Values given as mean ± SEM. * significantly different from controls. p < 
0.05 (N = C Sal: 7, C Meth: 7, MS Sal: 6, MS Meth: 7).  
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Figure 5: Adrenocorticotrophin (ACTH) concentrations in pg/ml of groups subjected to 
control conditions and maternal separation. Values given as mean ± SEM. * significantly 
different from controls. p < 0.05 (N = C Sal: 7, C Meth: 6, MS Sal: 4, MS Meth: 6).  
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Figure 6: Corticosterone concentrations in ng/ml of groups subjected to control conditions 
and maternal separation. Values given as mean ± SEM. * significantly different from controls. 
p < 0.05 (N = C Sal: 7, C Meth: 7, MS Sal: 3, MS Meth: 6). 
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Figure 7: Prolactin (PRL) concentrations in ng/ml of groups subjected to control conditions 
and maternal separation. Values given as mean ± SEM. * significantly different from controls. 
p < 0.05 (N = C Sal: 7, C Meth: 7, MS Sal: 4, MS Meth: 4). 
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CHAPTER 4 
 
 
Maternal separation differentially alters neurotrophic factors in the dorsal and ventral 
hippocampus of methamphetamine-treated rats 
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Abstract 
 
Stress has been shown to lead to increased susceptibility towards abuse of drugs later in life. 
Early life maternal separation (MS) stress has also been shown to alter the response to drugs 
of abuse. A link between methamphetamine use and altered neurotrophic factors has also been 
established. Changes in neurotrophin concentrations may play a role in the underlying 
molecular mechanisms responsible for drug- or stress-induced behaviours. The purpose of the 
present study was to investigate the effect of methamphetamine administration and MS on 
BDNF and NGF levels in both the dorsal and ventral hippocampus and investigate the 
combined effect of MS stress predisposition to methamphetamine-induced neurotrophic factor 
concentrations in the hippocampus. Methamphetamine administration and MS resulted in 
decreased BDNF levels in both the dorsal and ventral hippocampus. Early MS together with 
later methamphetamine administration also resulted in similar decreases in BDNF 
concentrations in the dorsal and ventral hippocampus. Neither MS nor methamphetamine 
altered NGF levels in the dorsal hippocampus. However, MS did decrease NGF levels in the 
ventral hippocampus. The combination of early MS stress and methamphetamine later in life 
resulted in significant elevation of NGF levels in the ventral hippocampus. We propose that 
the ventral hippocampus is specifically vulnerable to the effects of early life stress and that 
increased neurotrophin protein levels in this brain region, might reflect a compensatory 
mechanism. 
 
 
 
 
 
 
 
 
 
 
Keywords: Methamphetamine; Neurotrophins; Dorsal Hippocampus; Ventral Hippocampus; 
Maternal Separation  
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Introduction 
 
Stress has been shown to lead to increased susceptibility towards abuse of drugs and 
contributes to relapse in addicted individuals (Sinha, 2001; Gordon, 2002). This has been 
evidenced for instance by association studies linking psychosocial stressors with an increased 
risk for developing depression, anxiety or substance abuse in adult life (Kendler et al., 2000). 
This phenomenon has been clearly demonstrated in animal studies where stressors early in 
life such as maternal separation (MS) stress have been shown to lead to an altered behavioural 
response to drugs of abuse. Adult animals subjected to MS early in life exhibited enhanced 
cocaine self-administration and psychostimulant induced locomotor activity (Brake et al., 
2004; Matthews et al., 2003; Meaney et al., 2002; Kikusui et al., 2005).  
 
The rewarding effects of methamphetamine are mainly mediated by its effects on the 
mesolimbic dopaminergic system (Kalivas and Stewart, 1991). It has been reported that high 
doses of methamphetamine leads to the excessive release of dopamine, with the eventual 
depletion of synaptic dopamine levels (Zhang et al., 2001; Broom and Yamamoto, 2005; Xi et 
al., 2009). Neurotoxic doses of methamphetamine leads to large release of dopamine and the 
breakdown of the excess synaptic dopamine gives rise to the formation of free radicals and 
this is thought to partially underlie methamphetamine-induced neurotoxicity and 
neurodegeneration observed in various regions of the brain (Cubells et al., 1994; Cadet and 
Brannock, 1998; Fumagalli et al., 1999). Some studies have shown neurotrophic factors to 
protect against the dopamine depleting effects of neurotoxic doses of methamphetamine. For 
instance, brain-derived neurotrophic factor (BDNF) prevented death of primary rat cortical 
neurons subjected to methamphetamine (Matsuzaki et al., 2004), while methamphetamine-
induced neuronal death of cerebellum neural cells are prevented by nerve growth factor 
(NGF) (Zhou et al., 2004). Changes in neurotrophin concentrations may therefore play a part 
in the underlying molecular mechanisms responsible for drug- or stress-induced behaviours. 
Clinical studies have demonstrated a link between methamphetamine users and abnormal 
plasma BDNF concentrations (Kim et al., 2005). In animal studies, methamphetamine 
administration leads to increased BDNF levels in the hippocampus and neostriatum (Grace et 
al., 2008). In addition, glial cell line-derived neurotrophic factor (GDNF) mutant mice display 
enhanced vulnerability towards methamphetamine-seeking behaviour (Yan et al., 2007). 
Contrastingly, an inducer for GDNF protects against methamphetamine-induced reward and 
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sensitization (Niwa et al., 2007). These studies therefore suggest that the exact role of 
neurotrophins in methamphetamine-related effects, remain controversial. 
 
Neurotrophins which play a fundamental role in synaptic plasticity and neuroprotection are 
also affected by stress (Smith et al., 1995; Thoenen, 1995; Duman et al., 1997). Maternal 
separation has been associated with long-term alterations in neurotrophic levels in various 
brain areas such as the hippocampus (Cirulli et al., 1998; Cirulli, 2001; Roceri et al., 2004; 
Sale et al., 2004; Branchi et al., 2006; Faure et al., 2006). Exposure to brief as well as longer 
periods of separation stress has been shown to increase nerve growth factor (NGF) levels in 
the hippocampus, cerebral cortex and hypothalamus (Cirulli et al., 1998; 2000). Similarly, rats 
subjected to repeated maternal separation during the first two weeks of postnatal life resulted 
in increased BDNF mRNA levels in the hippocampus and frontal cortex (Roceri et al., 2004). 
These findings of elevated neurotrophin levels possibly represent an adaptive response to 
maternal separation and may therefore form part of the overall compensatory strategy of the 
brain to combat the onslaughts of stress.   
 
Previously, we too have reported increased neurotrophin levels in the hippocampus of rats 
that were subjected to maternal separation and additional bouts of swim stress (Faure et al., 
2006). However, early life stress in combination with exposure to repeated subsequent stress 
appear to affect the hippocampus differentially with increases in the dorsal hippocampus and 
decreases in the ventral hippocampus in neurotrophin levels being reported (Marais et al., 
2008). Therefore, in view of both maternal separation and methamphetamine causing changes 
in hippocampal neurotrophin levels, the present study determined what the effect of a 
combination of the two interventions would be on BDNF and NGF levels in the dorsal and 
ventral hippocampus.  
 
 
Materials and Methods 
 
Animals 
Male Sprague Dawley rats were used in this experiment. Ethical approval for all experimental 
procedures was provided by the Committee for Experimental Animal Research of the 
University of Stellenbosch. Animals were housed at the Central Research Animal Facility 
(AAALAC accredited) of the University of Stellenbosch. All rats were housed in the same 
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colony room separate from where stress procedures, methamphetamine treatment or where 
dissections of brain tissue occurred. Animals were housed according to standard laboratory 
conditions as stipulated by the Ethical Guidelines of the university for the Housing of 
Experimental Animals. Rats were housed (2-4) in 40 x 25 x 20 cm Plexiglas cages with 
corncobs as bedding. Temperature was kept constant at 22ºC, humidity at 55% and food and 
water was available ad libitum for the duration of the experiment.  
  
Drugs 
Methamphetamine hydrochloride was obtained from US Pharmacopeia Convention Inc. 
(Rockville, USA). Methamphetamine was dissolved in 0.9% saline and administered at a 
concentration of 1mg/kg.  
 
Experimental design 
All rat pups were weaned at the age of postnatal day (PND) 21 according to gender. Male rats 
were subjected to a total of 8 methamphetamine administrations on PND 33 -36 and PND 39 - 
42. The animals were divided into 4 groups: 
 
1) C Sal group: animals not subjected to maternal separation (MS) and receiving saline 
treatment (n = 9). 
2) C Meth group: animals not subjected to MS and receiving methamphetamine 
treatment (n = 7). 
3) MS Sal group: animals subjected to MS and subjected to saline treatment (n = 12). 
4) MS Meth group: animals subjected to MS and subjected to methamphetamine 
treatment (n = 12). 
 
 The rational for subjecting rats to methamphetamine during their adolescent period in life 
(PND 33 – 36 and PND 39 - 42), is that in humans, adolescents typically have an increased 
sensation seeking drive for drugs of abuse and hence presents with an important risk to 
susceptibility for taking drugs (Laviola et al., 1999; Spear, 2000). All animals were 
decapitated on PND 52 for brain tissue collection. 
 
Maternal separation 
Male and female rats were paired and their offspring used for experimental purposes. The day 
of birth was designated as PND 0, where after maternal separation commenced two days later 
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on PND 2 until PND 14 for a 3 hour daily period. The separation always occurred between 
09h00 and 13h00. This protocol is in accordance with the deprivation procedures as employed 
by Ladd et al. (2000). During the separation period, the pups were removed from the mother 
and kept in a separate cage and the mother kept in the home cage. The cage containing the 
pups were then moved to a dedicated room where the pups were kept warm under infrared 
lights (30-33ºC) in order to control for the development of hypothermic conditions. Control 
litters were reared normally without separations. After maternal separation was completed, 
animals were left undisturbed under normal housing conditions.  
 
Measurement of neurotrophic factors (BDNF and NGF) in the hippocampus 
On PND 52, animals were decapitated and the brains were rapidly removed and both the left 
and right hippocampi were dissected into dorsal and ventral parts on an ice cold glass plate. 
The tissue was rapidly frozen and stored in liquid nitrogen for measurement of BDNF and 
NGF concentrations at a later stage.  
 
Dorsal and ventral hippocampus brain tissue samples were weighed and suspended in 300 µl 
lysis buffer ( 137 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1 % Nonidet P-40 (NP 40), 10 % 
glycerol, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml aprotinin, 1 µg/ml leupeptin 
and 0.5 mM sodium vanadate). The samples were then sonicated for 40 s in the lysis buffer, 
vortexed and then centrifuged at 14 000 rpm at 4 ºC for 20 min and the supernatants were 
aliquoted into test tubes. BDNF and NGF concentrations were determined using the Emax 
ImmunoAssay system (Promega, Madison, USA). ELISA kits were completed following the 
manufacturer’s instructions. Determinations were made in duplicate. Results were expressed 
in pg/mg wet weight (ww).        
 
Statistical analysis 
BDNF and NGF results were analyzed using the Kruskal-Wallis test. Statistical significance 
of the H-statistic was followed by the Mann-Whitney U post hoc test. Statistical tests were all 
done with the aid of SPSS (version 17.0). The level of significance was accepted as p<0.05. 
Data is reported as mean ± SEM. 
 
 
Results 
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Brain-derived neurotrophic factor concentrations in the hippocampus 
There were significant differences in the BDNF levels in the dorsal hippocampus of the four 
experimental groups (H = 15.164, 3df, P = 0.002). The BDNF concentration in animals 
subjected to methamphetamine was significantly less than animals treated with saline (p = 
0.001). Animals previously subjected to maternal separation also showed significantly 
reduced BDNF levels compared to non-separated controls (p = 0.006). Separated rats treated 
with methamphetamine had significantly decreased BDNF levels (p = 0.002), but this 
reduction was similar to that observed in animals subjected to the respective treatments alone. 
The combination of maternal separation and methamphetamine exposure did not result in a 
further decrease in BDNF levels.  
 
Similar to the dorsal hippocampus, analysis of the BDNF levels in the ventral hippocampus 
also revealed significant differences between the four groups (H = 13.564, 3df, P = 0.004). 
Methamphetamine treatment alone (p = 0.034), maternal separation (p = 0.001) and maternal 
separation plus methamphetamine (p = 0.004) all caused a significant reduction in BDNF 
levels in the ventral hippocampus when compared to normally reared saline-treated controls.   
 
Nerve growth factor concentrations in the hippocampus 
There were no significant differences in the NGF levels in the dorsal hippocampus of the 
various experimental groups (H = 4.538, 3df, P = 0.209). However, NGF levels in the ventral 
hippocampus were affected by the treatment procedures (H = 8.726, 3df, P = 0.033). While 
methamphetamine treatment per se did not result in significant changes, maternal separation 
alone caused a significant reduction in NGF levels (p = 0.026). Interestingly, maternally 
separated rats subjected to methamphetamine treatment had significantly higher NGF levels 
in the ventral hippocampus when compared to the separation group (p = 0.005).   
 
 
Discussion 
 
Several studies have implicated a role for neurotrophins in both maternal separation and 
methamphetamine treatment. Here we investigated the effects of a combination of these 
modalities on hippocampal neurotrophin levels. The main findings were; (1) 
methamphetamine administration and maternal separation independently resulted in decreased 
BDNF levels in both the dorsal and ventral hippocampus; (2) early separation together with 
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later methamphetamine treatment yielded similar decreases in BDNF concentrations in the 
dorsal and ventral hippocampus; (3) neither maternal separation nor methamphetamine altered 
NGF levels in the dorsal hippocampus; (4) separation per se reduced NGF levels in the 
ventral hippocampus; (5) and finally the combination of early separation stress and 
methamphetamine later in life resulted in NGF levels in the ventral hippocampus comparable 
to controls.  
 
The effect of maternal separation on neurotrophins concentrations in the brain remains 
unclear with both increased and decreased levels being reported. One of the major reasons for 
this inconsistency stems from discrepancies in methodology. For instance a brief 45 min 
session of maternal separation on postnatal day (PND) 2 resulted in increased NGF 
expression levels in the dentate gyrus and hilus of the hippocampus (Cirulli et al., 1998). 
Similarly, a longer separation period of 1 hour or 3 hours respectively also resulted in 
elevated NGF expression levels even when measured at different ages (PND 9 and PND 16). 
Interestingly, this study demonstrated a dose-dependent like effect with longer periods of 
maternal separation generating greater increases in NGF (Cirulli et al., 2000). Not only has 
elevated NGF levels been documented. A daily interval of 180 min of maternal separation 
between PNDs 2 – 14 resulted in increased BDNF levels on PND 17. However, this effect 
was not long lasting as the elevated BDNF levels returned to normal at the end of puberty 
(Roceri et al., 2004). In general, elevations in neurotrophic factor concentrations in the brain 
have been proposed to be part of the compensatory mechanisms in the brain that are triggered 
to protect this vital organ against the negative effects of stress and glucocorticoid exposure 
during the developmental period (Faure et al., 2006; 2007; Marais et al., 2008).      
 
In contrast, a number of studies have demonstrated reductions in neurotrophin levels 
following paradigms of maternal separation. In the present study, we found a decrease in NGF 
levels in the ventral hippocampus, a finding that was in accordance with a reduction in BDNF 
concentration in the hippocampus as reported by Lippmann et al. (2007) and Jaworska et al. 
(2008), but opposite to Cirulli et al. (2000) that found increased NGF levels in the 
hippocampus after maternal separation. An explanation for this discrepancy in the findings 
may be ascribed to the fact that neurotrophin concentrations were measured in young rats in 
the Cirulli study, while our measurements were performed on tissue collected from adult rats. 
Other studies employing separation paradigms supported a decrease in neurotrophic levels in 
the hippocampus. A previous study conducted in our lab, found reduced NGF and 
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neurotropin-3 (NT-3) levels in the ventral hippocampus of adult rats after being subjected to 
180 min of separation between PND 2-14 (Marais et al., 2008). Using a comparable 
separation paradigm, Lippmann et al. (2007), found decreased BDNF levels in both the 
hippocampus and striatum. Similarly, an acute 24 hour separation period on PND 9 produced 
decreased BDNF expression in adulthood (Roceri et al., 2002). Experiments using different 
animal species and models reported analogous data with maternally separated male gerbils 
(PNDs 4-20 for 4 hours daily) reflecting decreased BDNF levels (Jaworska et al., 2008), 
while individually isolated pups (1 hour per day from PND 2-9) yielded decreased expression 
of NGF mRNA in both juvenile (PND 28) and adults (PND 90). The juvenile animals also 
had decreased GDNF mRNA levels in their hippocampi (Kawano et al., 2008).   
 
These studies suggest that the maldevelopment of the brain imposed by maternal separation 
causes the brain to enter a state of prolonged stress. Initially, the brain responds by increasing 
the release of neurotrophins in order to ensure that processes such as neurogenesis, 
synaptogenesis and network development are not significantly compromised. However this 
continuous demand may eventually lead to exhaustion and hence the hyposecretion of 
neurotrophins at a later stage in life. In conjunction with the above-mentioned process is the 
contribution of the hypothalamic-pituitary-adrenal axis to the neuropathology associated with 
maternal separation. Rats subjected to maternal separation during their first two weeks of life 
display increased plasma ACTH and corticosterone responses to stress at adulthood (Plotsky 
and Meaney, 1993). Elevated corticosterone concentrations are toxic to neurons (McEwen, 
2007), and therefore studies showing dysregulated HPA axis activity, further reflect the 
stressful nature under which the brain may have to function. However, the animals subjected 
to maternal separation, resulted in decreased ACTH and corticosterone concentrations. This 
result might be explained by an exhaustive HPA axis system and subsequent reduced stress 
hormone levels as consequence of repeated stress exposures and hence chronic stimulation. 
Alternatively, the HPA axis might be under an enhanced negative feedback inhibition.  
 
In the current study, methamphetamine administration, like maternal separation, resulted in 
changes in neurotrophin levels in the brain. BDNF protein levels were markedly decreased in 
both the dorsal and ventral hippocampus; however methamphetamine treatment did not alter 
NGF levels in either the dorsal and ventral hippocampus substantially. Our BDNF data is in 
agreement with the findings of Angelucci et al. (2007) who observed decreased BDNF levels 
in the occipital cortex and hypothalamus of adult rats chronically treated with 
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methamphetamine. However in their study they also documented reduced NGF levels in these 
brain areas, as well as the hippocampus. A possible reason for the difference in the NGF 
finding may be due to their measurement of neurotrophin concentrations the day after the last 
methamphetamine administration, while our data reflect growth factor levels after a period of 
withdrawal from chronic drug treatment. Our finding of reduced BDNF levels is in line with 
suggestions that amphetamine-induced neurotoxicity leads to a decrease in neurotrophin 
synthesis, thereby compromising the protection of the brain afforded by neurotrophins against 
the damaging effects of amphetamine (Matsuzaki et al., 2004; Angelucci et al., 2007). 
Interestingly these observations of decreased neurotrophin levels after withdrawal is in 
contrast with the results of a clinical study that reported increased plasma BDNF levels after 
more than 30 months amphetamine use followed by a month of abstinence. This increased 
BDNF levels was suggested to compensate for amphetamine-induced neurotoxicity (Kim et 
al., 2005). The discrepancy in findings may possibly be explained by the fact that plasma 
neurotrophin concentrations is considered a global reflection of whole brain extracellular 
neurotrophin concentrations and cannot be compared to specific regional brain tissue 
neurotrophin levels as measured in the hippocampus. In addition, Filip et al. (2006) found 
increased BDNF expression levels in the hippocampus of adult rats after a withdrawal period. 
The increased neurotrophin expression levels (Meredith et al., 2002; Filip et al., 2006) has 
been proposed to be a compensatory mechanism for decreased protein neurotrophin 
concentrations (Angelucci et al., 2007) as was found in the present study.  
 
Interestingly, the present study demonstrated that maternal separation resulted in increased 
NGF levels in the ventral hippocampus of methamphetamine exposed rats. Dorsal and ventral 
regions of the hippocampus have been shown to play different roles in information processing 
and emotional processes. The dorsal hippocampus plays a preferential role in learning and 
memory related processes, while the ventral hippocampus plays a preferential role in anxiety-
related responses (Bannerman et al., 2004). It would seem that maternal separation has a 
definite effect on NGF levels specifically in the ventral hippocampus, which emphasises the 
preferential role of the ventral hippocampus in stress-related processes. Similar findings in 
our laboratory in which repetitive stressors that consisted of a combination of maternal 
separation and two forced swim re-stress session later in life, also resulted in increased 
neurotrophin concentrations in the hippocampus (Faure et al., 2006). Increased neurotrophin 
levels in response to both early life stress and methamphetamine treatment would seem to 
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reflect the brain’s protective response against ventral hippocampal neuronal stress induced by 
both stress and drug exposure. 
 
 
Conclusion 
 
Maternal separation and methamphetamine treatment independently resulted in decreased 
neurotrophin concentrations in the hippocampus. However, combining maternal separation 
and methamphetamine treatment resulted in increased NGF levels in the ventral hippocampus. 
These observations suggest that neurotrophins play an important role in protecting neuron 
structure and function against the detrimental effects of repetitive exposure to stressful events. 
However the nature of this protective role remains elusive and more investigations are 
required to unravel molecular mechanisms and consequences following alterations in 
neurotrophin expression.  
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Figure 1: Brain-derived neurotrophic factor (BDNF) concentration (pg/mg ww) in the dorsal 
hippocampus of groups subjected to maternal separation and control conditions. Values given 
as mean ± SEM. * significantly different from C Sal group (p<0.05). 
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Figure 2: Brain-derived neurotrophic factor (BDNF) concentration (pg/mg ww) in the ventral 
hippocampus of groups subjected to maternal separation and control conditions. Values given 
as mean ± SEM. * significantly different from C Sal group (p<0.05).  
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Figure 3: Nerve growth factor (NGF) concentration (pg/mg ww) in the dorsal hippocampus 
of groups subjected to maternal separation and control conditions. Values given as mean ± 
SEM.  
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Figure 4: Nerve growth factor (NGF) concentration (pg/mg ww) in the ventral hippocampus 
of groups subjected to maternal separation and control conditions. Values given as mean ± 
SEM. * significantly different from MS Sal group (p<0.05). 
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CHAPTER 5 
 
 
The effects of lobeline and naltrexone on methamphetamine-induced place preference 
behaviour and striatal dopamine and serotonin levels of non-stressed and maternally 
separated rats 
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Abstract 
 
Exposure to early stress may increase an individual’s vulnerability to MA dependence. There 
are relatively few data on the optimal treatment of such dependence, but the opioid and 
VMAT2 may be target systems insofar as they play pivotal roles in addictive neurochemistry. 
Here we investigated the effects of naltrexone (opioid antagonist) and lobeline (VMAT2 
inhibitor) on MA-induced place preference behaviour in rodents subjected to early stress 
(maternal separation) and controls, including the effects on dopaminergic and serotonergic 
levels in the striatum. We found; (1) maternal separation attenuated methamphetamine-
induced place preference; (2) two weeks treatment with either lobeline or naltrexone did not 
alter methamphetamine-induced place preference behaviour; (3) lobeline and naltrexone 
treatment had differential effects on serotonin and dopamine concentrations in the striatum. 
Early life stress attenuates MA-induced behavioural effects, however influences 
neurochemical pathways which may underlie a predisposition towards drug dependence.   
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Introduction 
 
Stress has been demonstrated to make an individual more vulnerable to drug abuse (Gordon, 
2002). For example, adults with a history of child adversity have an increased risk for 
substance abuse (Dinwiddie et al., 1992; Gutierres et al., 1994). Stressful life events, like MS 
stress, have been shown to increase the probability of abusing drugs at a later stage in life 
(Sinha, 2001). Early MS led to increased use of cocaine in adult rodents (Matthews and 
Robbins, 2003), as well as to alterations in locomotor response to psychostimulants (Meaney 
et al., 2002). Various animal studies have also shown that the opioid system is affected by 
early life stress, whereby morphine decreases separation-induced distress vocalizations, whilst 
opioid antagonists potentiate separation distress (Herman and Panksepp, 1978; Panksepp et 
al., 1978; Kehoe and Blass, 1986). These findings suggest that MS alters neurochemical role 
players (Meaney et al., 2002) that are critical in the development of addictive processes.  
 
Methamphetamine (MA) is a potent psychostimulant and the abuse of this illicit substance is 
escalating worldwide (United Nations Office on Drug and Crime, 2003). Few research 
outputs exist on the optimal pharmacological treatment of MA abuse and dependence (Vocci 
and Ling, 2005; Vocci et al., 2005). After the differential mechanism of action of both 
cocaine and MA was established, more specific pharmacological clinical trails began for the 
treatment of MA abuse. Currently, only a few treatments have shown some promise in 
successfully treating certain aspects of MA addiction symptomology.  
 
The rewarding effects of MA are mediated by its effects on the mesolimbic dopaminergic 
system (Kalivas and Stewart, 1991). MA’s primary mechanism of action is to increase the 
release of dopamine into the synapse via its action on vesicular monoamine transporters 
(VMAT2) (Sulzer and Rayport, 1990; Pifl et al., 1995; Wilhelm et al., 2004; Sulzer et al., 
2005). Other neurotransmitter systems may also modulate dopaminergic activity in the brain 
by interacting with its circuitry. For instance, serotonin (5-HT) modulates dopaminergic 
neurotransmission by inhibiting dopamine activity in the VTA (Brodie and Bunney, 1996). 
The binding of 5-HT to serotonin type 2C receptors (5-HT2C) (Di Matteo et al., 2001) results 
in decreased firing of these neurons and consequently a reduction in dopaminergic 
neurotransmission.  
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The endogenous opioid system was also found to mediate the neurochemical and behavioural 
effects of amphetamines. The administration of MA has been demonstrated to lead to 
increased endogenous opioid concentrations (Olive et al., 2001) and the combined 
administration of morphine (a µ-opioid receptor agonist) and amphetamine resulted in 
additive rewarding effects (Hubner et al., 1987). In addition, mesolimbic dopamine activity 
has been shown to be indirectly regulated by µ-opioid receptors in the ventral tegmental area 
(VTA) (Johnson and North, 1992; Bergevin et al., 2002) via a mechanism that included 
GABAergic inhibition (Spanagel and Weiss, 1999).  
 
Lobeline, an alkaloidal constituent of Indian tobacco (Lobelia inflata), acts both as an agonist 
and antagonist at nicotinic receptors (Teng et al., 1997; Stolerman et al., 1995; Lecca et al., 
2000; Terry et al., 1998; Miller et al., 2000). However, lobeline can also alter presynaptic 
dopamine storage and release by binding to the dihydrotetrabenazine sites on VMAT2, 
thereby inhibiting dopamine storage (Scherman et al., 1986; Kilbourn et al., 1995; Liu et al., 
1996). Furthermore, lobeline does not reverse dopamine transporter (DAT) function and has 
no inhibitory action on monoamine oxidase (MAO) activity. These effects of lobeline may 
therefore reverse the pharmacological effects of MA (Dwoskin and Crooks, 2002). Taken 
together, lobeline reduces the available vesicular dopaminergic pool and so increases the 
cytosolic pool. Lobeline pretreatment has been shown to inhibit amphetamine-induced 
enhanced locomotor activity and discriminative stimulus properties (Miller et al., 2001) and 
reduces MA self-administration in rats (Harrod et al., 2001).   
 
Naltrexone, a nonselective opioid antagonist, is a promising pharmacotherapy for MA 
addiction, since endogenous opioids have been implicated in the rewarding effects of 
psychostimulants and are disrupted by early adversity. Blockade of opioid receptors have 
been shown to cause a reduction in amphetamine-induced extracellular dopamine levels in the 
nucleus accumbens and striatum (Hooks et al., 1992; Spanagel et al., 1992; Schad et al., 1995; 
Schad et al., 1996) via the increase in GABAergic activity in the VTA (Johnson and North, 
1992; Bergevin et al., 2002). Naltrexone also attenuates the induction and expression of MA-
induced behavioural sensitization (Chiu et al., 2005) and reduces the locomotor activity 
induced by amphetamines (Winslow and Miczek, 1988; Balcells-Olivero and Vezina, 1997). 
In addition, naltrexone diminishes amphetamine- and cocaine-induced reinstatement of drug 
seeking behaviour in rats (Brebner et al., 2005).  
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Although it is clear that early adversity is a vulnerability factor for MA, perhaps via 
disruptions in opioid, nicotinic, DA, and serotonin systems, little work has examined the 
ability of agents acting on these systems (e.g. opioid, nicotoninic) to reverse behavioural and 
neurotransmitter effects of MA (e.g. DA, 5-HT). The purpose of the present study was to 
investigate the effect of both naltrexone (opioid) and lobeline (nicotinic) in maternally 
separated and control rats. We were interested in examining both behavioural effects (i.e. 
effects on MA-induced place preference) and neurotransmitter effects (i.e. effects on 
dopaminergic and serotonergic levels in the striatum). Unlike, various earlier studies that 
administer treatment prior to MA exposure, the present study employed a post-MA treatment 
regime. The rational behind this treatment strategy was that the independent effects of the 
treatment on drug abuse are more evident and that in real life treatment almost always follows 
the abuse of drugs and hence makes the post-abuse treatment approach more relevant. 
 
 
Materials and Methods 
 
Animals 
Male Sprague Dawley rats were used in this experiment. Ethical approval for all experimental 
procedures was provided by the Committee for Experimental Animal Research of the 
University of Stellenbosch. Animals were housed at the Central Research Animal Facility 
(AAALAC accredited) of the University of Stellenbosch. All rats were housed in the same 
colony room separate from where stress procedures, methamphetamine and treatment 
exposures or where dissections occurred. Animals were housed according to standard 
laboratory conditions as stipulated by the Ethical Guidelines of the university for the Housing 
of Experimental Animals. Rats were housed (2-4) in 40 x 25 x 20 cm Plexiglas cages with 
corncobs as bedding. Temperature was kept constant at 22ºC, humidity at 55% and food and 
water was available ad libitum for the duration of the experiment.  
 
Drugs 
Methamphetamine hydrochloride was obtained from US Pharmacopeia Convention Inc. 
(Rockville, USA). α-Lobeline and naltrexone hydrochloride was procured from Sigma-
Aldrich Chemicals (St. Louis, MO). Methamphetamine was dissolved in 0.9% saline and 
administered at a dose of 1mg/kg. Lobeline was dissolved in distilled water and naltrexone 
dissolved in 0.9 % saline and both administered at a dose of 10mg/kg.   
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Maternal separation paradigm 
Male and female rats were paired and their offspring used for experimental purposes. The day 
of birth was designated as PND 0, where after maternal separation commenced two days later 
on PND 2 until PND 14 for a 3 hour daily period between 09h00 and 13h00. This protocol is 
in accordance with the deprivation procedures as employed by Ladd et al. (2000). During the 
separation period, the pups were removed from the mother and kept in a separate cage and the 
mother kept in the home cage. The cage containing the pups were then moved to an isolated 
dedicated room where the pups were kept warm under infrared lights (30-33ºC) in order to 
control for exposure to hypothermic conditions. Control litters were reared normally without 
separations. After maternal deprivation was completed, animals were subjected to normal 
housing conditions.  
 
Experimental design 
All rat pups were weaned at the age of postnatal day (PND) 21 according to gender as only 
male rats were used for the experiments. Rats were regularly handled (PND 25 -30) to 
minimize the effects of handling stress during the behavioural assessments and treatment 
procedures. Two weeks of treatment commenced from PND 37 until PND 50. The rats in the 
lobeline treatment groups were divided into 4 groups. These were: 
 
1) Cont Sal L group: animals not subjected to MS and receiving saline injections during 
CPP and subjected to 2 weeks of lobeline treatment (n = 10). 
2) MS Sal L group: animals subjected to MS and subjected to saline injections during 
CPP and receiving 2 weeks of lobeline treatment (n = 9). 
3) Cont MA L group: animals not subjected to MS and receiving methamphetamine-
induced CPP and subjected to 2 weeks of lobeline treatment (n = 9). 
4) MS MA L group: animals subjected to MS and subjected to methamphetamine-
induced CPP and 2 weeks of lobeline treament (n = 10). 
 
Male rats in the naltrexone treatment groups were divided into 4 similar groups. The groups 
were: 
 
1) Cont Sal N group: animals not subjected to MS and receiving saline injections during 
CPP and subjected to 2 weeks of naltrexone treatment (n = 13). 
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2) MS Sal N group: animals subjected to MS and subjected to saline injections during 
CPP and receiving 2 weeks of naltrexone treatment (n = 14). 
3) Cont MA N group: animals not subjected to MS and receiving methamphetamine-
induced CPP and subjected to 2 weeks of naltrexone treatment (n = 10). 
4) MS MA N group: animals subjected to MS and subjected to methamphetamine-
induced CPP and 2 weeks of naltrexone treatment (n = 14). 
 
Male rats in the saline and no treatment groups were divided into 3 groups. Here only rats 
exposed to methamphetamine CPP were subjected to saline 2 weeks treatment to assess if the 
treatment has any effects on methamphetamine exposure. The groups were: 
 
1) Cont MA group: animals not subjected to MS and receiving methamphetamine-
induced CPP and subjected to no treatment (n = 8). 
2) Cont MA S group: animals not subjected to MS and subjected to methamphetamine-
induced CPP and 2 weeks of saline treatment (n = 9). 
3) MS MA S group: animals subjected to MS and receiving methamphetamine-induced 
CPP and subjected to 2 weeks of saline treatment (n = 8). 
 
Each of the above groups was tested at 24hrs (CPP1) on PND 37 and 2 weeks after treatment 
or no treatment (CPP2) on PND 51 after first 4 methamphetamine conditioning sessions 
(PND 33 - 36) to determine if the treatment had any effect on place preference behaviour. The 
rational for subjecting rats to methamphetamine during their adolescent period in life (PND 
33 – 36), is that in humans, adolescents typically have an increased sensation seeking drive 
for drugs of abuse and hence presents with an important risk to susceptibility for taking drugs 
at this phase (Laviola et al., 1999; Spear, 2000). Animals were all sacrificed by means of 
decapitation the day after the 2 week CPP test (CPP2) on PND 52. 
 
Conditioned Place Preference (CPP) paradigm 
The CPP test is a Pavlovian classical conditioning test, whereby the drug state is paired with a 
neutral environment (the CPP two compartment box). The amount of time spent in the drug-
paired environment is considered as a measure of the positive reinforcing or rewarding effects 
of the drug. This phenomenon has been confirmed in human cocaine addicts, whereby drug 
paraphernalia that is considered as a neutral environmental stimuli, become associated with 
the effects experienced by cocaine use (Gawin, 1991). The two compartment box used had 
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differential cues unique to each compartment in order for the rats to associate the cues in the 
environment with the rewarding effects of the drug. The cues differed in term of wall colour 
and floor texture. The one compartment had black walls and a smooth floor, whilst the 
adjacent compartment had white and black stripped walls and a grid-textured floor.   
 
Adolescent male rats were habituated to the test cage the day before the testing (PND 31). On 
PND 32 rats in all groups were subjected to the CCP test. The CPP test consists of 3 stages: 
pre-conditioning stage, the conditioning stages and the post-conditioning stage. 
 
Pre-conditioning 
During the pre-conditioning stage on PND 32, animals were given free access to both 
compartments for a period of 15 min of the CPP test box and the amount of time spent in each 
compartment was recorded. The pre-test phase allows for the determination of the natural 
preference of the animal for either one of the two compartments of the CPP box.  
 
 Conditioning 
The conditioning stage involves a pavlovian associative learning method, whereby a neutral 
stimulus (drug-paired compartment) was paired with the drug state induced by 
methamphetamine. On PND 33 - 36, the animals designated to the methamphetamine groups 
were intra-peritoneally injected with methamphetamine (1mg/kg, i.p.) 20 min before being 
confined for a further 30 min period to the compartment of the test box opposite to the natural 
preference of the rat. The 50 min period in total was allowed for the drug to take affect and to 
ensure the formation of associations in the CPP box. Control rats received equivalent saline 
injections and were also placed in opposing compartments of the CPP box.  
 
 Post-conditioning  
On PND 37, the first post-conditioning test was done to confirm the presence of place 
preference. On PND 51 a second CPP test was done to determine the effect of the different 
drug treatments on methamphetamine-induced place preference. During the post-conditioning 
stage animals were once again given free access to both compartments, and the amount of 
time spent in each compartment was recorded for analyses at a later stage. The CPP score was 
calculated as the difference between the amount of time spent in the drug-paired compartment 
before and after the conditioning stages.  
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Behavioural analysis of the CPP test  
On all days of behavioural testing during the pre-test (PND 32) and post-tests (PND 37 and 
51); behaviour was recorded on video tape. Video recordings were analyzed using Noldus 
Ethovision software (Wageningen, The Netherlands).  
 
Determination of dopamine and serotonin tissue concentrations 
On PND 52, animals were decapitated and the brains were rapidly removed and both the left 
and right striata were dissected on an ice cold glass plate and rapidly frozen and stored in 
liquid nitrogen for measurement of dopamine and serotonin striatal concentrations at a later 
stage. The striatal tissues were first weighed and placed in ice cooled solution containing 25 
mM Tris-HCl, pH 7.4, 1 mM EDTA and 1 mM EGTA (1 ml/50mg wet weight brain tissue). 
Samples were homogenized and vortexed for 30 seconds followed by centrifugation (15, 000 
g for 15 min at 4 °C) and the supernatant divided into aliquots and stored at -80 °C until 
assayed. Striatal aliquots were again centrifuged at 12, 000 g for 10min at 4 °C before 
commencing with the dopamine and serotonin assays. Striatal tissue dopamine and serotonin 
concentrations were determined using commercial available ELISA kits (IBL, Hamburg, 
Germany). ELISA kits were completed following the manufacturer’s instructions. 
Determinations were made in duplicate. Results were expressed in ng/ml.        
 
Statistical analysis 
CPP behavioural parameters, dopamine and serotonin results were analyzed using non-
parametric ANOVA, the Kruskal-Wallis test. Statistical significance of the H-statistic was 
followed by the Mann-Whitney U post hoc test. Statistical tests were all done with the aid of 
SPSS (version 17.0). The level of significance was accepted as p<0.05. Data is reported as 
mean ± SEM. 
 
 
Results  
 
Effect of lobeline treatment, MA and MS on CPP behaviour 
Two weeks lobeline treatment between first (CPP1) and second (CPP2) post conditioning 
tests did not result in decreased place preference in any of the experimental groups. Animals 
subjected to methamphetamine demonstrated place preference for the drug paired 
compartment of the CPP box (p = 0.004) (H = 13.764, 6df, P = 0.032). As expected, rats 
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exposed to saline conditioning did not result in place preference behaviour. Surprisingly, 
animals exposed to both maternal separation and methamphetamine resulted in attenuated 
CPP behaviour (p = 0.021) (Figure 1).       
 
Effect of lobeline treatment on striatal serotonin and dopamine levels 
Experimental groups exposed to lobeline treatment demonstrated an increased serotonin 
levels when compared to the groups receiving saline for two weeks respectively (p < 0.05) (H 
= 36.583, 6df, P = 0.001) (Figure 2). Similarly those exposed to lobeline exposed groups had 
decreased dopaminergic levels in the striatum when compared to the control 
methamphetamine CPP (Cont MA) group (p < 0.05) (H = 18.634, 6df, P = 0.005) (Figure 3).   
 
Effect of naltrexone treatment, MA and MS on CPP behaviour  
Two weeks naltrexone treatment did not attenuate place preference behaviour between the 
first (CPP1) and second (CPP2) post conditioning tests. Methamphetamine exposed rats 
displayed place preference behaviour when compared to groups subjected to saline 
conditioning (p < 0.05), except the group exposed to both maternal separation and 
methamphetamine conditioning and two weeks saline treatment (MS MA S) (H = 26.843, 6df, 
P = 0.001) (Figure 4).  
 
Effect of naltrexone treatment on striatal serotonin and dopamine levels 
Naltrexone treatment resulted in decreased striatal serotonin levels, although MS rats resulted 
in increased serotonin levels in both saline (p = 0.006) and MA CPP (p = 0.051) (H = 37.034, 
6df, P = 0.001). Saline treatment and no treatment groups also resulted in increased striatal 
serotonin concentrations when compared to the group subjected to maternal separation, saline 
CPP and two weeks of naltrexone treatment and the group subjected to non-stressed 
conditions, methamphetamine CPP and two weeks of naltrexone treatment (MS Sal N and 
Cont MA N) (p < 0.05) (Figure 5). 
Dopamine concentrations in the striatum were increased in the groups exposed to naltrexone 
treatment as well as in the saline and no treatment groups when compared to the group 
exposed to maternal separation, methamphetamine CPP and naltrexone treatment (MS MA N) 
(p < 0.05) (H = 35.468, 6df, P = 0.001) (Figure 6).     
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Discussion 
 
The main findings of the present study are as follows; (1) maternal separation attenuated 
methamphetamine-induced place preference behaviour; (2) two weeks treatment with either 
lobeline or naltrexone did not reduce methamphetamine-induced place preference behaviour; 
(3) lobeline and naltrexone treatment had differential effects on serotonin and dopamine 
concentrations in the striatum.  
 
The CPP paradigm is a widely accepted method of investigating the rewarding or reinforcing 
effects of psychostimulants. A study investigating the effects of methamphetamine CPP in 
both a single- and dual-cue CPP box, found that methamphetamine resulted in CPP behaviour 
and this effect was more pronounced in the dual-cue CPP box (Shimosato and Ohkuma, 
2000). These findings are similar to our data, where the same dose of methamphetamine was 
used (1 mg/kg) and a dual-cue CPP box which also resulted in increased CPP scores. 
However, our study differed in the method of drug administration whereby Shimosato and 
Ohkuma (2000) made use of alternate pairing of methamphetamine and saline during the 
conditioning phase of the CPP test. Our results are also in agreement with the findings of Kim 
and Jang (1997) who also found methamphetamine induced place preference, although in 
mice. Nevertheless, the effects of MA on place preference may differ over development; 
Adriana and Laviola (2002) demonstrated that adolescents display decreased CPP behaviour 
when compared to adults. One of the differences between the present study and that of 
Adriana and Laviola (2002) was that we did not administer MA again in adulthood to assess 
CPP behaviour afterwards, rather assessed the duration of place preference behaviour after 
adolescent MA administration. This allowed us to show that CPP lasted for at least two weeks 
after MA administration in our experimental paradigm.  
 
Environmental stressors may affect behavioural responses to psychostimulants. Socially 
isolated rats display enhanced locomotor activity when exposed to a novel environment and 
this response is even greater after amphetamine administration. Animals also exhibit 
sensitization toward the locomotor effects induced by repeated amphetamine administration 
(Smith et al., 1997). Moreover, socially reared rats have been shown to be more sensitive to 
CPP (Schenk et al., 1986), while isolated rats were found to be more sensitive to the 
locomotor activating effects of cocaine. In addition, this latter group of animals shows 
increased acquisition and maintenance of cocaine self-administration compared to rats reared 
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in groups (Schenck et al., 1987; Boyle et al., 1991; Phillips et al., 1994; Zhang et al., 2005; 
Kosten et al., 2000; 2004).  
 
Similarly, other stressful events such as repeated maternal separation have been shown to 
affect the response to amphetamine administration (Matthews et al., 1996). MS animals were 
found less responsive to amphetamine-induced locomotor effects and displayed enhanced 
acquisition of cocaine self-administration (Matthews et al., 1999). Maternal separation, in the 
present study, resulted in attenuated methamphetamine-induced place preference behaviour 
during adolescence and this effect lasted until adulthood. This finding was in contrast to what 
was expected, i.e. an exaggerated place preference response. Previous studies have shown MS 
animals to have a greater preference for cocaine self-administration and drug-induced 
locomotor activity when compared to handled rats (Meaney et al., 2002; Brake et al., 2004; 
Moffett et al., 2006). Animals subjected to morphine-induced CPP have also shown greater 
place preference behaviour, however the study employed another MS method and measured 
CPP only in adulthood (Michaels and Holtzman, 2008). However, MS in the present study 
could possibly have altered neurochemical pathways involved in addiction in a way that later 
administration of MA failed to induce definite behavioural effects. In the present study, 
dopamine concentrations in the striatum of MS rats did not result in pronounced differences 
between control groups, since the rewarding effects of MA are mediated by increased 
dopamine neurotransmission (Kalivas and Stewart, 1991; Pifl et al., 1995; Wilhelm et al., 
2004; Sulzer et al., 2005) and the finding of decreased MA-induced CPP behaviour could 
possible be explained by the lack of neurochemical changes in the present study. Addictive 
behaviour is complex and hence the present result remains difficult to interpret, since 
contrasting MS findings exist in the current literature.   
 
Early life stress induces long lasting neurochemical changes in the brain. Rats previously 
exposed to MS have decreased DAT levels in the nucleus accumbens and the caudate 
putamen (Meaney et al., 2002; Brake et al., 2004). The decreased transporter levels are 
proposed to render maternally separated rats hypersensitive to the effects of cocaine since a 
lower dose of cocaine is needed to affect extracellular dopamine concentrations. This is 
further supported by the finding that adult rats subjected to MS present with an enhanced 
mesolimbic dopaminergic response to amphetamine (Hall et al., 1999). Also, repeated MS 
during the first two weeks of life has been found to enhance stress-induced sensitization to 
amphetamine and alter the resultant nucleus accumbens dopamine and behavioural responses 
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to stress and cocaine (Brake et al., 2004). Infants and juvenile rats subjected to repeated 
isolation stress also respond to amphetamine with increased striatal dopamine levels (Kehoe 
et al., 1996, 1998; Kosten et al., 2003). Cross-sensitization between stress and drugs is 
suggested to occur with repeated exposures to stress enhancing the behavioural response to 
drugs of abuse (Robinson and Becker, 1986; Sorg and Kalivas, 1991; Stewart and Badiani, 
1993). Furthermore, it is suggested that early life events may alter mesolimbic dopaminergic 
brain pathways in such a way that the response to stress and psychostimulants later in life 
might be permanently changed (Antelman et al., 1980; Sorg and Kalivas, 1991; Kalivas and 
Stewart, 1991; Leyton and Stewart, 1990; Meaney et al., 2002). Similarly, the present study, 
maternally separated rats subjected to methamphetamine-induced CPP later in life resulted in 
slightly higher dopamine levels in adulthood when compared to control animals, although the 
difference did not reach statistical significance. This can possibly be explained by the fact that 
baseline tissue content levels were measured two weeks after MA exposure and thus not in 
response to MA. Another possible explanation might be the lower serotonin levels found 
when compared to dopamine concentrations, which plays a modulatory role in dopamine 
levels. Serotonin has been shown to increase the inhibitory effect of dopamine on 
dopaminergic VTA neurons (Brodie and Bunney, 1996), resulting in decreased dopaminergic 
neurotransmission.  
 
Lobeline has been demonstrated to inhibit the neurochemical and behavioural effects of 
amphetamines in rodents (Miller et al., 2001; Harrod et al., 2001; Harrod et al., 2003) and 
attenuates the stimulant and rewarding properties of MA via its non-competitive interaction 
with VMAT2. Lobeline pre-treatment attenuated MA-induced hyperactivity in mice and also 
decreased the discriminative stimulus properties of MA in rats (Miller et al., 2001). The 
attenuation of discriminative stimulus effects in animals is proposed to lower subjective 
effects of stimulants in humans (Schuster and Johanson, 1988; Holtzman, 1990). Lobeline has 
also been shown to decrease MA self-administration in rats (Harrod et al., 2001) and to 
reduce MA-induced stereotypy in adolescent mice (Tatsuta et al., 2006). Conversely, two 
weeks of lobeline treatment failed to attenuate MA-induced CPP behaviour in the present 
study. This finding may possibly be explained by the fact that although the CPP paradigm is 
used to measure the rewarding effects of psychostimulants, the reward is measured based on 
associative learning between the rewarding effects of the drug and the animals’ surrounding 
environment. It would seem that once learning association has taken place, lobeline was 
unable to eradicate its effects.  
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Only one previous study from the literature could be found that employed post-MA lobeline 
treatment. Lobeline was administered 5 and 7 hours after neurotoxic MA administrations (4 x 
10mg/kg injections over 8 hrs) and examined striatal dopamine and serotonin content. 
Lobeline treatment resulted in attenuating MA neurotoxic effects and led to increased 
dopamine and serotonin striatal concentrations, 7 days after the last MA administration 
(Eyerman and Yamamoto, 2005). Similarly, in the present study two weeks of lobeline 
treatment in a non-neurotoxic MA paradigm (one 1mg/kg administration per day over 4 days) 
resulted in increased striatal serotonin levels, however with no significant change in dopamine 
concentrations. The finding of increase serotonin levels is in line with evidence that lobeline 
interacts with and inhibits the serotonergic transporter (SERT) and observations that lobeline 
increases serotonin release from rat hippocampal slices (Lendvai et al., 1996). Animals 
exposed to lobeline post-treatment failed to significantly differ in dopamine levels when 
compared to animals from the saline treatment groups. Similarly, acute, intermittent and 
continuous systemic lobeline administration (1.0 – 30 mg/kg) did not deplete striatal 
dopamine or DOPAC content, however inhibited amphetamine evoked dopamine release 
from superfused striatal slices (Miller et al., 2001). This finding is in line with in vivo 
microdialysis studies where lobeline treatment did not change extracellular dopamine or 
DOPAC levels in rat striatum (Benwell and Balfour, 1998). This effect of lobeline was also 
demonstrated in experiments using a cell system co-expressing DAT and VMAT2 that 
showed lobeline decreased the dopamine releasing effects of MA (Wilhelm et al., 2008). 
Interestingly, VMAT2 knockout mice had diminished amphetamine-induced CPP when 
compared to wild-type mice (Takahashi et al., 1997). The lack of change in dopamine levels 
in lobeline treated animals may possibly explain why lobeline post treatment had no effect on 
MA-induced CPP behaviour in the present study.  
 
A number of drugs acting on opioid receptors have been suggested as therapeutic agents in 
addiction. Naloxone and naltrexone have been found to induce dysphoria in humans (Hollister 
et al., 1981; Grevert and Golstein, 1977) and resulted in conditioned aversive responses in 
animals and blocks cocaine-induced CPP (Iwamoto, 1985; Parker and Rennie, 1992; Skoubis 
and Maidment, 2003). Naltridole (a non-selective δ-opioid receptor antagonist) and naltriben 
(a selective δ2 – opioid receptor antagonist) were reported to attenuate cocaine- and MA-
induced CPP (Suzuki et al., 1994; Menkens et al., 1992; Van Ree et al., 1999). In contrast to 
these findings, our experiments, two weeks of naltrexone treatment failed to alter CPP 
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behaviour of MA-treated rats. This finding may possibly be ascribed to the fact that 
naltrexone pretreatment before MA administration is needed to block the cue-induced 
reinstatement of drug seeking behaviour. Differences in treatment dosages may also 
contribute to the discrepancy in data as well as differences in species and strain of animals 
used. It may be that a higher dosage of the opioid receptor antagonist is required to decrease 
MA-induced CPP, since the amount of dopamine is released from nerve terminals is greater 
when compared to cocaine’s mechanism of action (Suzuki et al., 1994; Di Chiara and 
Imperato, 1988).  
 
It remains difficult to explain our findings especially in view of the overwhelming evidence 
demonstrating the important role of opioids in the rewarding effects of psychostimulants 
(Miller et al., 2001; Harrod et al., 2001; Pettit et al., 1984; Dworkin et al., 1988). The 
inhibition of the opioid system via the blocking of the opioid receptors is presumed to lead to 
an attenuation of the rewarding effects of drugs of abuse, hence making the finding of no 
difference after two weeks naltrexone post-MA treatment of the present study difficult to 
interpret. However, other studies similarly have found that naltrexone treatment did not have 
a significant effect on cocaine use in rats and MA intake in rhesus monkeys (Harrigan and 
Downs, 1978; Ettenberg et al., 1982; Hemby et al., 1996). In line with this evidence, the non-
selective opioid antagonist, quadazocine, also failed to affect cocaine reinforcing responding 
in rhesus monkeys (Winger et al., 1992). Interestingly, chronic naltrexone treatment (10 
mg/kg/day for 12 days) which was followed by a period of no treatment resulted in the 
facilitation of cocaine self-administration by supposedly enhancing the reinforcing effects of 
cocaine (Ramsey and Van Ree, 1990). In another study, rhesus monkeys trained to self-
administer cocaine were subjected to naltridole treatment for 10 consecutive days. While a 
decrease in cocaine intake was initially observed, in some of the monkeys the response rate 
for cocaine returned to baseline levels during the last days of the treatment (Negus et al., 
1995). Prolonged MA treatment generally results in the desensitization of µ-opioid receptors 
(Chiu et al., 2006). Since, naltrexone preferentially inhibits the µ-opioid receptor (Uwai et al., 
2004), blocking already desensitized receptors may not necessarily cause a decrease in CPP 
behaviour as seen in our study.   
 
Generally it is believed that opioid receptor agonists increase the release of dopamine from 
VTA terminals by suppressing inhibitory GABA neurons (Di Chiara and North, 1992; Leone 
et al., 1991; Rada et al., 1991). The administration of an opioid receptor antagonist would 
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therefore result in increased inhibition of VTA neurons by GABA leading to decreased 
dopamine being released. This mechanism has been proposed for the action of naloxone and 
naltrexone in their attenuation of amphetamine-induced effects (Hooks et al., 1992; Schad et 
al., 1995; Yu et al., 2001). In the present study, naltrexone treatment did not have an expected 
effect on either CPP behaviour or dopaminergic levels in the striatum. This can possibly be 
explained by the overall decrease in serotonin levels in animals subjected to naltrexone 
treatment. The reduction in serotonergic levels has been shown to lead to a decreased 
inhibitory control over dopaminergic concentrations in the VTA (Brodie and Bunney, 1996). 
Such an explanation is plausible as an increase in dopaminergic levels in animals exposed to 
naltrexone treatment was observed. In the group subjected to maternal separation, MA-
induced CPP and two weeks naltrexone treatment (MS MA N) decreased dopamine levels 
were obtained. Despite this decrease, the animals in this group continued to display CPP 
behaviour after naltrexone treatment.  
   
 
Conclusions 
 
Most studies investigating the effects of lobeline or naltrexone on MA consumption employs 
a pre-MA treatment strategy. The clinical relevancy of these studies can be questioned, since 
in real life clinicians are first presented with a drug addict where-after treatment would 
commence. In the present study, post-MA treatment results in no significant behavioural 
changes, however does affect neurochemical role players of drug addiction. Interestingly, 
early life stress attenuated behavioural effects induced by MA. Addictive behaviour and 
neurochemical changes are complex and the treatment used to address these drug induced 
changes is of need of further investigation to find promising pharmacological interventions 
for MA addiction.  
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Figure 1: Conditioned Place Preference (CPP) of groups subjected to control conditions or 
maternal separation. Additionally, groups were either subjected to two weeks of lobeline / 
saline / no treatment conditions. The first CPP test occurred after MA administration (CPP1) 
and the second CPP test occurred after the two weeks of lobeline / saline / no treatment 
(CPP2). Values given as mean ± SEM. * significantly different from the Cont MA group 
(CPP1) (p<0.05) 
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Figure 2: Serotonin concentrations (ng/ml) in the striatum of groups subjected to two weeks 
lobeline / saline / no treatment conditions. Values given as mean ± SEM. * significantly 
different from the Cont MA, Cont MA S and MS MA S groups (p < 0.05)  
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Figure 3: Dopamine concentrations (ng/ml) in the striatum of groups subjected to two weeks 
lobeline / saline / no treatment conditions. Values given as mean ± SEM. * significantly 
different from the Cont MA group (p<0.05); ^ significantly different from the Cont MA S 
group (p<0.05) 
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Figure 4: Conditioned Place Preference (CPP) of groups subjected to control conditions or 
maternal separation. Additionally, groups were either subjected to two weeks of naltrexone / 
saline / no treatment conditions. The first CPP test occurred after MA administration (CPP1) 
and the second CPP test occurred after the two weeks of naltrexone / saline / no treatment 
(CPP2). Values given as mean ± SEM. * significantly different from the Cont Sal N group 
(p<0.05) (CPP1); § significantly different from the MS Sal N group (p<0.05) (CPP1); ^ 
significantly different from the MS MA S group (p<0.05) (CPP1) 
 *  
 § 
 ^ 
 * 
 § 
 *  
 § 
 ^ 
 * 
 § 
* * 
^ 
* 
^ 
 162 
0
1
2
3
4
5
6
Cont Sal N MS Sal N Cont MA N MS MA N Cont MA Cont MA S MS MA S
se
ro
to
n
in
 
(ng
/m
l)
 
 
Figure 5: Serotonin concentrations (ng/ml) in the striatum of groups subjected to two weeks 
naltrexone / saline / no treatment conditions. Values given as mean ± SEM. * significantly 
different from Cont Sal N group (p<0.05); ^ significantly different from MS Sal N and Cont 
MA N groups (p<0.05) 
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Figure 6: Dopamine concentrations (ng/ml) in the striatum of groups subjected to two weeks 
naltrexone / saline / no treatment conditions. Values given as mean ± SEM. * significantly 
different from MS MA N and Cont MA S groups (p<0.05); ^ significantly different from the 
MS MA N group (p<0.05); § significantly different from the Cont MA group (p<0.05) 
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Abstract 
 
Methamphetamine (MA) is an addictive psycho-stimulant and the illicit use of the drug is 
escalating. In the present study, we examined protein expression profiles in the rat frontal 
cortex exposed to a total of 8 MA injections (1 mg/kg, intraperitoneal) using 2-DE based 
proteomics. We investigated protein changes occurring in both the cytosolic fraction and the 
membrane fraction. 2-DE analysis resulted in 62 cytosolic and 44 membrane protein spots 
that were differentially regulated in the frontal cortex of rats exposed to MA when compared 
to control animals. Of these spots, 47 cytosolic and 42 membrane proteins were identified 
respectively, using ESI-Quad-TOF, which included ubiquitin carboxyl-terminal hydrolase 
isozyme L1 (UCH-L1), β-synuclein, 78 kDa glucose-regulated protein (GRP 78), γ-enolase, 
dihydropyrimidase-related protein 2 (DRP 2),  complexin 2 and synapsin II. These proteins 
are associated with protein degradation, redox regulation, energy metabolism, cellular growth, 
cytoskeletal modifications, and synaptic function. Proteomic research may be useful in 
exploring the complex underlying molecular mechanisms of MA dependence.  
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Introduction 
 
Methamphetamine (MA) is a highly addictive psycho-stimulant and the illicit use of this drug 
is continuing to escalate in many countries world wide. MA initially elicits its rewarding 
effects and subsequent detrimental effects by increasing extracellular dopamine 
concentrations in the mesolimbic dopaminergic system and later proceeds to alter the function 
of various other brain pathways (Everitt and Wolf, 2002; Di Chiara et al., 2004; Pierce and 
Kumaresan, 2006). MA achieves this by three unique mechanisms of action. Firstly, MA 
enters neurons via dopaminergic transporters and reverses their transporter function (Zahniser 
and Sorkin, 2004; Wilhelm et al., 2006). Secondly, MA reverses the function of the vesicular 
monoamine transporter 2 (VMAT2), which normally is responsible for intracellular vesicular 
storage of dopamine, serotonin, noradrenaline and histamine in the central nervous system 
(Erickson et al., 1992; Weihe and Eiden, 2000).  
 
Effects of MA are exerted by influencing mainly the mesocorticolimbic dopamine system 
which projects from the ventral tegmental area (VTA) to the nucleus accumbens, olfactory 
tubercle, frontal cortex and amygdala (Kalivas and Stewart, 1991; Volkow et al., 2003). 
Above the ventral striatum (or nucleus accumbens) is the dorsal striatum, and this brain area 
has been implicated in the locomotor response to psychostimulants (Hamamura et al., 1991; 
Nestler, 2001). There is growing interest in the role of frontal cortex in addiction given its 
contribution to decision making and inhibitory control (Royall, 2002). Glutamatergic 
projections from the prefrontal cortex to the nucleus accumbens have been found to be pivotal 
in drug seeking behaviour (Kalivas et al., 2005). Thus, investigation of protein changes in 
frontal cortex, which plays an important role in long term addictive processes, may result in a 
better understanding of the neurobiology of methamphetamine addiction.    
 
Proteomics is a high-throughput technique used to detect global protein changes in complex 
biological systems. It is particularly useful to study multifactorial disease processes, since this 
technique can analyze the final end products of genes (i.e. proteins in their final state), it thus 
provides functional insight. By employing proteomic methodology the differential expression 
of proteins that contribute to a disease state can be identified. This method therefore allows 
for discovery driven rather than hypothesis driven investigations (Lewis et al., 2000; Lee, 
2001). In turn the information gained by these experiments can be used for hypothesis 
formulation and subsequent verification (Liao et al., 2005). The proteomics approach has 
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proven useful in the investigation of the molecular basis of MA dependence (Liao et al., 2005; 
Yang et al., 2008; Li et al., 2008).  
 
The present study was designed to generate a more comprehensive picture of differentially 
expressed cytosolic and membrane proteins in the frontal cortex that are altered by MA 
treatment. To achieve this we used a 2-dimensional gel electrophoresis (2-DE) based 
proteomics approach in combination with image analysis software and mass spectrometry. 
This approach differs from western blotting techniques, allowing identification of changes in 
the expression of multiple proteins rather than researcher-dependent selection of individual 
proteins.  
 
 
Materials and Methods 
 
Animals 
Ethical approval for all experimental procedures was provided by the Committee for 
Experimental Animal Research of the University of Stellenbosch. Animals were housed at the 
Central Research Animal Facility (AAALAC accredited) of the University of Stellenbosch. 
All rats were housed in the same colony room separate from where methamphetamine 
exposures or dissections occurred. Animals were housed according to standard laboratory 
conditions as stipulated by the Ethical Guidelines of the university for the Housing of 
Experimental Animals. Rats were housed (2-4) in 40 x 25 x 20 cm Plexiglas cages with 
corncobs as bedding. Temperature was kept constant at 22ºC, humidity at 55% and food and 
water was available ad libitum for the duration of the experiment. Sprague Dawley, male rats 
(Rattus norvegicus) were used in this experiment. 
 
Drugs 
Methamphetamine hydrochloride was obtained from US Pharmacopeia Convention Inc. 
(Rockville, USA). R-(-)-Apomorphine hydrochloride was procured from Sigma-Aldrich 
Chemicals (St. Louis, MO). Apomorphine and methamphetamine were both dissolved in 0.9 
% saline prior to being administered to the rats at a dose of 1mg/kg.   
 
Experimental design 
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Male rats in the experimental group were subjected to 8 methamphetamine intra-peritoneal 
(i.p.) injections in total, each administered on PND 33-36 and PND 39-42 and 3 apomorphine 
subcutaneous (s.c.) injections in total, each administered on PND 38, 44 and 51. The rational 
for subjecting 33 day old rats to methamphetamine is that this period in a rats’ life 
corresponds to adolescent period in humans. It is known that most addicts start experimenting 
with drugs during their adolescence. Apomorphine was administered as an assessment of 
apomorphine-induced locomotor activity to further evaluate possible hyperactivity induced by 
methamphetamine administration (Faure et al., 2009). An apomorphine control group was not 
included and this could impose a possible limitation when interpreting results, since proteins 
expressed could be due to apomorphine treatment or interaction with methamphetamine. 
However, control rats received volume controlled 0.9% saline injections (1ml/kg) whilst 
experimental animals were subjected to methamphetamine injections which were dissolved in 
0.9% saline and administered at a dose of 1mg/kg. A low dose of MA was specifically used as 
such doses are useful in elucidating protein expression changes that may be related to 
neuroadaptive processes in the brain (Yamada et al., 2005). A non-neurotoxic dose of 1mg/kg 
was repeatedly (8 days) administered to allow for changes to occur in drug-dependent genes 
and resultantly measure protein expression changes (Yamada et al., 2005; Iwazaki et al., 
2006). Animals were all sacrificed by means of decapitation on PND 52. The brains were 
removed and frontal cortex was dissected on a cold glass plate, and rapidly frozen and stored 
in liquid nitrogen for later analysis.  
 
Two-dimensional gel electrophoresis 
The frontal cortex is a large enough brain area that pooling of samples was not deemed 
necessary as they render sufficient protein for the subsequent experiments. The frontal cortex 
of 3 brain samples from each group (experimental and control) were used and run in triplicate 
for both the cytosolic and membrane protein fractions respectively. Tissue samples were first 
subjected to fractionation using a commercially available ProteoExtract Subcellular Proteome 
Extraction Kit (Merck, Calbiochem). The sample was separated into four fractions, which 
included cytosolic, membrane/organelle, nucleic and cytoskeletal matrix protein extracts. 
Most abundant protein changes take place in the cytosolic and membrane regions of neurons 
subjected to methamphetamine and hence the rational to focus and investigate the protein 
expression changes in these two fractions. The cytosolic and membrane protein extracts were 
further used to determine the total protein concentration by using a Bradford method to adhere 
to the specifications of the ReadyPrep 2-D Cleanup Kit (Bio-Rad). These stipulate that 1-500 
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µg of protein in a final volume of not more than 100µl per 1.5ml microcentrifuge tube is 
allowed for efficiency of the cleanup procedure and result in low conductivity samples 
necessary for good iso-electric focusing (IEF) and 2D gel electrophoresis (2-DE). After the 
cleanup samples were dissolved in 2D Sample Buffer (Bio-Rad). A RC DC Protein Assay 
(Bio-Rad) was performed to quantify protein concentrations after the cleanup procedure, 
which contrary to the Bradford, is not affected by interference of reducing agents in the 2D 
Sample Buffer. The first dimension of gel electrophoresis was done using an immobilized pH 
gradient gel (IPG strip, pH 5-8, 11 cm) in a Protean IEF Cell (Bio-Rad). Gels were rehydrated 
with cytosolic and membrane samples respectively from the experimental and control groups 
containing 150 µg of total protein in a total volume of 200 µl per IPG strip for 12 h and 
focused for 7h until the IEF Cell reached 40 000 volt hours (Vh) at 20 ºC. The strips were 
equilibrated twice after IEF for a 15 min period each in equilibration buffer I followed by 
equilibration buffer II and embedded onto Criterion Precast Gels (4-12% Bis-Tris, Bio-Rad). 
The second dimension gel electrophoresis was carried out at 200V for a period of 
approximately 55 min. After electrophoresis, the gels were fixed in a 40% methanol and 7% 
acetic acid solution (v/v) for 1 h and stained overnight at room temperature with Brilliant 
Blue G-Colloidal dye solution (Sigma-Aldrich). The gels were then subjected to a quick 
destain (1 min, 40% methanol and 10% acetic acid) solution followed by destain in which a 
25% methanol solution was used for a 2h period and a further 30 min in newly replaced 
destain. The gels were either scanned immediately or stored in 25% ammonium sulfate at 
room temperature until day of scanning. Prior to scanning gels were first washed in bi-
distilled water to remove ammonium sulfate and then placed in destain to scan.    
   
Gel image analysis and digestion of differentially expressed protein spots 
Gel images were obtained by scanning the 2D gels on a densitometer (GS-800 scanner, Bio-
Rad) using the Quantity One - 4:5.2 (Basic) software program (Bio-Rad). The scanned images 
were analyzed using PD Quest Advanced version 8.0.1 software program, to identify 
differentially expressed (p≤0.05; t-test) protein spots. Protein spots of interest were manually 
excised from the gels and placed into a 96-well microtiter plate for in gel digestion. The spots 
were washed twice with 50% acetonitrile in 100 mM ammonium bicarbonate and rinsed with 
acetonitrile and air dried for a 10min period after which samples were reduced with 10mM 
dithiothreitol in 100mM ammonium bicarbonate for 30 min and alkalyted with 55mM 
iodoacetamide in a 100mM ammonium bicarbonate solution. Spots were then rinsed with 
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acetonitrile and then 100mM ammonium bicarbonate and another further three washes with 
acetonitrile.  A 25µl aliquot of 6 ng/µl trypsin was added to each sample and incubated at 37 
ºC for 4.5 h. The resultant tryptic peptides were extracted twice, first by using 30µl of an 
aqueous solution containing 2% acetonitrile and 1% formic acid and secondly using 15µl of 
an aqueous solution containing 51% acetonitrile and 0.5% formic acid. The two extractions 
were combined and placed in a second cooled 96-well plate. If immediate analysis was not 
possible at this stage, the extractions were stored at -80 ºC before mass spectrometry analysis.  
 
Mass spectrometry identification of cytosolic and membrane extracted peptides 
An in-line NanoAcquity LC and autosampler system was used to resolve extracted tryptic 
peptides. LC solvents were supplied by Mallinckrodt Baker, Inc. A 4.9µl aliquot of each 
sample was injected onto a nanoACQUITY UPLCTM trapping column 10kpsi Symmetry 
C18 180 µm x 20mm 5µm (Waters) equilibrated in 3% aqueous acetonitrile containing 0.1% 
formic acid and the column flushed with 1% aqueous acetonitrile/0.1% formic acid at 
15µLmin-1 for 1 minute. The peptides were then eluted onto a nanoACQUITY UPLC BEH 
C18 Column, 1.7 µm, 100µm x 100mm, 10K psi (Waters) at 1.2µ Lmin-1 using a linear 
gradient of solution A (0.1% formic acid in water) and solution B (0.1% formic acid in 
acetonitrile) and ran over 20min. A Micromass Q-Tof Global Ultima mass spectrometer fitted 
with a nano-LC emitter (New Objective) with an applied capillary voltage of 3-4 kV was used 
to analyze the eluted peptides. The instrument was calibrated against a collisionally induced 
decomposition (CID) spectrum of the doubly charged precursor ion of [glu1]-fibrinopeptide B 
(GFP – Sigma-Aldrich F3261). A calibration was accepted when the average error on a 
subsequent acquisition was <10ppm. Sensitivity was assessed by an injection of 50 fmol of a 
phosphorylase B tryptic digest giving a base peak intensity >1000 counts per sec in MS mode 
on the most intense peptide. Data dependent acquisition (DDA) mode over the mass/charge 
(m/z) range of 50-2000 the instrument was operated in. During the DDA analysis, the three 
most intense peptides eluting from the column both MS and tandem mass spectrometry (CID) 
was performed. The un-interpreted MS/MS data were processed using the Waters 
ProteinLynx Global Server v2.3 software package (smoothed, background subtracted, 
centered and deisotoped) then mass corrected against the doubly charged GFP peptide. Peak 
list file (pkl) was created and subjected t o Mascot (www. Matrixscience.com) using MS/MS 
Ion Search and SwissProt database to identify differentially expressed proteins. Search 
parameters included up to one missed tryptic cleavage, fixed modifications of Carbamido-
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methyl (C) and variable modifications of Oxidation (M), Phospho (ST) and Phospho (Y) and 
mass tolerance 0.5 Da. A positive identification was defined when the MOWSE scores (>37) 
was significant (p<0.05).    
 
 
Results 
 
Proteins from both the cytosolic and membrane protein fractions of the rat frontal cortex were 
separated by 2-DE. Fig. 1 (I) demonstrates a typical composite of triplicate 2D gels of 
cytosolic proteins present in the rat frontal cortex. The gels of both cytosolic and membrane 
fractions from the MA exposed group of animals were compared to those of the control 
group. Analyses by PD Quest software showed 62 cytosolic and 44 membrane protein spots 
to be differentially expressed in the frontal cortex of MA exposed rats (p<0.05; Student’s t-
test). These differentially expressed proteins were then excised from the gel and submitted to 
mass spectrometry for identification purposes. Following mass spectrometric analyses 47 of 
the 62 cytosolic and 42 of the 44 membrane proteins were identified with confidence (p<0.05; 
Student’s t-test). To illustrate Spot 6609 was identified as dihydropyrimidase-related protein 2 
(DRP-2) and its expression was significantly reduced in the MA treatment group (Fig. 1 (II)). 
A summary of the identified proteins is presented in Table I and Table II.  
 
 
Discussion 
 
Using 2-DE based proteomics, the present study revealed that a number of proteins are 
differentially expressed; 47 in the cytosolic fraction and 42 in the membrane fraction 
following MA treatment. As evident from the data, most of these proteins are associated with 
important biological functions such as protein degradation, redox regulation, energy 
metabolism, cellular growth, cytoskeletal modifications, and synaptic signaling. To discuss 
the biological significance of each of these proteins is beyond the scope of this manuscript. 
However the implication of the changes in the expression of some of the cytosolic and 
membrane proteins will be discussed. 
 
In the present study, ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) expression 
was increased in the cytosolic cortical fraction and β-synuclein was increased in the 
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membrane cortical fraction. UCH-L1 is involved in the ubiquitin proteosome pathway and 
this protein in particular has been shown to be altered in various methamphetamine studies 
(Liao et al., 2005; Iwazaki et al., 2006). UCH-L1 is a neuronal protease and plays a key role 
in the proteolytic degradation of misfolded or damaged proteins via the 26S proteosomal 
pathway (Lowe et al., 1990; Castegna et al., 2002; Fornai et al., 2004a; Fornai et al., 2004b; 
Fornai et al., 2006; Carolan et al., 2006). The increased expression of UCH-L1 is in line with 
a previous study where a single non-toxic dose of MA (1mg/kg) also resulted in increased 
UCH-L1 expression. However, the present study administered eight MA injections and this 
might have produced a greater effect on toxic cascades. β-synuclein, which is the non-
amyloidogenic homolog of α-synuclein, has been shown to inhibit aggregation of intracellular 
proteins. The finding of increased β-synuclein levels may therefore reflect a reactive response 
to the neurotoxic effects of MA.  
 
MA produces a massive increase in cytosolic dopamine levels via its action on both VMAT2 
and MAO. Dopamine and its resultant metabolites are known to generate reactive oxygen 
species (ROS), which ultimately result in neurotoxicity and cell death (Slivka and Cohen, 
1985; Gibb et al., 1990). The neurotoxic effects of MA include destruction of dopaminergic 
axons and terminals in the striatum, while the dopaminergic somas in the midbrain areas are 
kept intact (Ricaurte et al., 1982; McCann and Ricaurte, 2004). Increased 78 kDa glucose-
regulated protein (GRP78) mRNA levels after MA administration have been suggested to 
compensate for MA-induced oxidative stress (Cadet et al., 1994; Jayanthi et al., 1998; Cadet 
and Brannock, 1998), since GRP78 protect cells against apoptosis (Morris et al., 1997). In the 
present study, GRP78 was increased in the cytosolic fraction and decreased in the membrane 
fraction. It would seem that in our treated rats GRP78 may also have a compensatory effect 
against MA-induced oxidative stress. This protection might be enhanced by the observed 
increased levels of peroxiredoxin-2 in both cytosolic and membrane fractions in these 
animals. Peroxiredoxins are enzymes that exert their protective antioxidant effects in cells 
through their peroxidase activity, whereby the levels of hydrogen peroxide, peroxynitrite and 
other organic hydroperoxides are reduced and detoxified (Poole and Ellis, 1996; Bryk et al., 
2000; Peshenko and Shichi, 2001; Hofmann et al., 2002).  
 
Differential expression of various proteins involved in energy metabolism was observed in the 
present study. For example enolase, an enzyme that catalyses the formation of 
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phosphoenolpyruvate from 2-phosphoglycerate (Harris et al., 1976), was down regulated in 
the cytosolic fraction. In addition, MA-sensitized animals also had differentially modulated 
amygdala proteins involved in ATP production and some of these included fructose-
biphosphate aldolase C and D-3-phosphoglycerate dehydrogenase (Iwazaki et al., 2008), 
which were also identified in our study. Clinical studies have noted cerebral glucose 
hypometabolism in human MA abusers (Kim et al., 2005). In addition, a significant 
correlation was found between MA-induced decreases in ATP levels and dopamine depletions 
in the striatum (Chan et al., 1994). Our findings indicate that MA treatment may be associated 
with reduced glucose metabolism, possibly leading to neuron malfunction. 
 
In addition to the role of α-enolase in glycolysis, the enolases have also been shown to act as 
neurotrophic factors. Gamma-enolase has been shown to be responsible for increased survival 
of cortical neurons and neuron specific enolase has a functional role in the plasma membrane 
of neuronal cells, where it demonstrates neurotrophic properties (Hattori et al., 1994). In our 
study the increase in gamma-enolase levels in the cytosolic fraction may indicate the presence 
of compensatory mechanisms protecting against the deleterious effects of MA. 
    
The three-dimensional structure of neurons is maintained by microtubules and actin filaments, 
which are primarily scaffolding proteins (Vale et al., 1992; Liao et al. 2005). The cytoskeletal 
network is stabilized by F-actin capping proteins which binds to the fast growing ends of actin 
filaments and hence prevents the loss of actin subunits from these ends (Kilimann and 
Isenberg, 1982). As mentioned earlier, MA results in the loss of dopaminergic terminals while 
the cell bodies are spared (McCann and Ricaurte, 2004), and as expected, Liao et al. (2005) 
found decreased F-actin capping protein beta subunit in striatal tissue after a neurotoxic dose 
of MA. This has been suggested to lead to the disruption of cytoskeletal architecture and 
ultimately to interrupted neuronal transport in the axonal terminals. Similarly, Kobeissy et al. 
(2008) reported decreased concentrations of the F-actin capping protein after an acute MA 
neurotoxic dose supporting previous findings that indicated that the cytoskeletal structure is 
susceptible to MA (Warren et al., 2005; Warren et al., 2007). Decreased expression of actin 
beta was found even after a single dose of MA (Iwazaki et al., 2006). Therefore after repeated 
exposures one would expect structural modifications to be more severe and to lead to chronic 
alterations in specific brain structures and function. In the present study, decreased actin 
(cytoplasmic 1 and 2) was identified in the membrane cortical fraction together with 
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abnormalities in tubulin levels, in both membrane and cytosolic cortical fractions. This 
supports suggestions that MA leads to structural alterations in the frontal cortex. 
 
Dihydropyrimidase-related protein, also referred to as collapsing response mediator protein 2 
(DRP-2 / CRMP-2 / DPYL-2), is an extracellular guidance cue and hence involved in axonal 
outgrowth mediated by extracellular cues (Hamajima et al., 1996). Modifications in this 
protein has been reported in the striatum of animals subjected to chronic use of MA (Iwazaki 
et al., 2007), as well as causing altered neuronal plasticity in the amygdala after acute 
treatment of MA (Iwazaki et al., 2008). In the present study, DRP-2 and DRP-3 levels were 
both decreased in the cytosolic cortical fraction, and DRP-2 and DRP-5 levels were increased 
in the membrane cortical fraction. It is difficult to reconcile these data, but one possibility is 
that the membrane fraction DRP-2 may be more involved in signalling processes after MA 
exposure, while at the cytosolic level DRP-2 may be fulfilling a cytoskeletal role and so is 
down-regulated in response to MA effects on the cytoskeletal structure. DRP-2 has previously 
been associated with postsynaptic densities in the rat brain (Roberts and Sheng, 2000) and 
mitochondrial septin (M-septin) has been found to induce mitochondrial translocation of 
CRAM, which is a CRMP-associated molecule that belongs to the same unc-33 gene family 
(Inatome et al., 2000; Takahashi et al., 2003). This infers that DRP-2 could very well be 
present or associated with the membrane and cytosolic fractions and play a role in 
translocation and could possibly be a different form of the same protein.     
  
Phosphatidylethanolamine-binding protein 1 (PEBP1), also referred to as hippocampal 
cholinergic neurostimulating peptide (HCNP), is a calpain substrate (Chen et al., 2006) and a 
raf-kinase inhibitor, and is functional as a neuronal protein involved in cell signaling 
(Kobeissy et al., 2008). The HCNP has been found work with nerge growth factor or 
independently to enhance choline acetyltransferase production which aids in cholinergic 
development of medial septal nuc1ei (Butterfield et al., 2006). PEPB1 would subsequently be 
involved with neuroplastic changes in brain circuitry involved in addiction. Previously, 
PEBP1 expression levels have been reported to be altered by MA (Iwazaki et al., 2007; 
Iwazaki et al., 2008; Kobeissy et al., 2008). PEBP1 has been proposed to be an inhibitor of 
the proteosome (Hengst et al., 2001; Chen et al., 2006) and PEBP1 up regulation in both the 
cytosolic and membrane cortical protein fraction in the present study may suggest a protective 
role against proteolytic degradation activated by MA. 
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Synapsins are also involved in signaling processes. They regulate neurotransmitter release and 
synaptogenesis (Chin et al., 1995; Ferreira et al., 1995), neuronal development and 
maintenance (Ferreira and Rapoport, 2002), the coating of vesicular surfaces, the anchoring of 
synaptic vesicles to the presynaptic membrane and mediate axonal outgrowth (Ferreira et al., 
1998; Sudhof, 2004; Fdez and Hilfiker, 2006). In addictive brain circuitry, synapsins would 
hence play a huge role in neuoroplasticity induced by repeated psychostimulant use. 
Disruption of synapsin in knockout models or via antibody injections has demonstrated that 
synapsin down regulation leads to the reduction in the number of synaptic vesicles distal to 
the active zone in excitatory neurons (Li et al., 1995; Rosahl et al., 1995; Pieribone et al., 
1995). Glutamate has been shown to be associated with synapsin II (Vawter et al., 2002; 
Villanueva et al., 2006) and may play a key role in the effects of drugs of abuse on cortico-
accumbens glutamatergic projections (Kalivas et al., 2005). Increased synapsin II in the 
membrane cortical fraction in the present study is consistent with previous work emphasizing 
the importance of glutamatergic signaling from the frontal cortex to the ventral striatum in 
response to MA administration (Iwazaki et al., 2007).  
 
Various presynaptic proteins play a role at nerve terminals for synaptic vesicle exocytosis of 
neurotransmitters into the synaptic cleft to occur. In the present study two proteins involved in 
exocytosis, i.e. SNARE (soluble N-ethylmaleimide-sensitive fusion protein attachment 
protein receptors) activities were identified. They are the complexin and septin proteins. 
Complexins binds with high affinity to the SNARE complexes (Chen et al., 2002) and 
function by stabilizing the SNARE complexes in a highly fusogenic state (Reim et al., 2001; 
Xue et al., 2007). Complexins accomplishes this by binding to the groove between syntaxin 
and synaptobrevin in an anti-parallel fashion (Marz and Hanson, 2002) or by acting as a 
prefusion clamp that arrests SNARE complexes to prevent fusion with the presynaptic 
membrane. Altered complexin expression levels leads to deficits in evoked synaptic 
transmitter release (Reim et al., 2001; Huntwork and Littleton, 2007) and hence implicates 
psychostimulant-induced neuroplasticity. After MA exposure, complexin 2 was increased in 
the cytosolic cortical fraction, and complexin 1 and complexin 2 were increased in the 
membrane cortical fraction in the present study. This is in line with enhanced 
neurotransmission of dopamine in various brain areas in response to MA.  
 
 
Conclusion 
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In summary, the present study investigated the effects of methamphetamine using a systems 
biology approach. We have shown methamphetamine to impact neurons at numerous levels. 
For instance MA increased the expression of proteins related to degenerative processes, 
interfered with normal neurotransmission and subsequent intracellular signaling, disrupted 
cyto-architecture, and altered energy metabolism.  Additional work is needed to compare the 
effects of MA on neurobiological systems in different regions of the brain, as these may differ 
(Liao et al, 2005; Yang et al, 2008; Li et al, 2008).  Further research is also needed to 
determine precisely how alterations in the expression of proteins in such systems serve to 
mediate the particular effects of MA on brain and on behavior.   
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Tabel I: Differentially expressed cytosolic proteins of the rat frontal cortex exposed to MA  
(* Proteins identified in more than one experiment – Biological replicates). 
 
Protein name MASCOT  
% 
Sequence 
Swiss 
Prot  Mr (Da) pI Ratio 
  
score Coverage 
Accession 
nr 
    
Exp:Con  
Protein Fate / Redox Regulation 
   
 
  
Ubiquitin carboxyl-terminal hydrolase isozyme L1    155 12 Q00981 25165 5.14 1.43 
Peroxiredoxin-2   138 17 P35704 21941 5.34 1.43 
78 kDa glucose-regulated protein 425 17 P06761 72473 5.07 1.56 
Prohibitin 241 21 P67779 29859 5.57 2.01 
26S protease regulatory subunit 6A 60 2 Q63569 49415 5.13 0.18 
Protein disulfide-isomerase A3 129 6 P11598 57044 5.88 0.63 
Proteasome subunit alpha type-1 396 35 P18420 29784 6.15 0.81 
Proteasome subunit alpha type-2 194 13 P17220 26024 6.92 0.59 
Protein-L-isoaspartate(D-aspartate) O-
methyltransferase 136 9 P22062 24683 7.14 0.59 
       
Energy Metabolism       
Rab GDP dissociation inhibitor alpha  240 14 P50398 51074 5 0.14 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial  137 21 P49432 39299 6.2 1.48 
Alpha-enolase * 521 24 P04764 47440 6.16 0.78 
Fructose-bisphosphate aldolase C  334 21 P09117 39658 6.67 3.16 
Creatine kinase B-type 112 5 P07335 42983 5.39 1.68 
Rab GTPase-binding effector protein 1 168 3 O35550 99766 4.95 2.86 
Lactoylglutathione lyase 107 9 Q6P7Q4 20977 5.12 1.23 
Rho GDP-dissociation inhibitor 1  52 15 Q5XI73 23450 5.12 1.35 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial   159 6 Q99NA5 40044 6.47 0.69 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial 109 4 P08461 67637 8.76 0.45 
D-3-phosphoglycerate dehydrogenase  455 17 O08651 57256 6.28 0.39 
Triosephosphate isomerase  321 32 P48500 27345 6.89 0.39 
Aconitate hydratase, mitochondrial 962 27 Q9ER34 86121 7.87 4.96 
Carbonic anhydrase 1 167 14 B0BNN3 28339 6.86 1.84 
V-type proton ATPase subunit B, brain isoform 188 7 P62815 56857 5.57 0.44 
     
 
 
Protein Synthesis / Neurotrophic 
    
 
 
Elongation factor Tu, mitochondrial 167 5 P85834 49890 7.23 0.72 
Gamma-enolase  743 33 P07323 47510 5.03 1.3 
Adenylate kinase isoenzyme 1 *  234 19 P39069 21570 7.66 0.64 
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Structural / Cytoskeletal       
Tubulin beta-5 chain * 677  41 P69897 50095 4.78 4.01 
Tubulin beta-2A chain  69 4 P85108 50274 4.78 0.61 
Fascin (Fragments) 69 5 P85845 22110 5.86 0.46 
Transgelin-3 64 14 P37805 22657 6.84 1.26 
Microtubule-associated protein 1A 154 1 P34926 300831 4.87 1.84 
 
      
Synaptic Signalling 
      
Phosphatidylethanolamine-binding protein 1 156 14 P31044 20902 5.48 1.43 
Dihydropyrimidinase-related protein 2 *    369 18 P47942 62638 5.95 0.78 
Dihydropyrimidinase-related protein 3  389 14 Q62952 62327 6.04 0.57 
Dual specificity mitogen-activated protein kinase 
kinase 1  113 5 Q01986 43779 6.18 1.68 
Guanine nucleotide exchange factor MSS4 127 22 Q08326 14261 5.19 1.99 
Guanine nucleotide-binding protein subunit beta-1 100 6 P54311 38151 5.6 0.44 
Proto-oncogene C-crk 232 17 Q63768 33881 5.39 0.77 
Voltage-dependent anion-selective channel protein 2  204 17 P81155 32353 7.44 0.59 
Complexin-2 *   101 19 P84087 15499 5.06 1.6 
Protein kinase C and casein kinase substrate in 
neurons protein 1  144 7 Q9Z0W5 50760 5.15 0.14 
Guanine deaminase   365 19 Q9WTT6 51554 5.56 0.5 
       
Other 
  
   
 
Heat shock cognate 71 kDa protein 718 19 P63018 71055 5.37 1.74 
Stress-induced-phosphoprotein 1 573 27 O35814 63158 6.4 0.53 
T-complex protein 1 subunit beta   308 12 Q5XIM9 57764 6.01 0.74 
Protein LZIC  51 4 Q5PQN7 21438 4.89 1.24 
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Tabel II: Differentially expressed membrane proteins of the rat frontal cortex exposed to MA 
(* Proteins identified in more than one experiment – Biological replicates). 
 
Protein name MASCOT  
% 
Sequence Swiss Prot  
Mr 
(Da) pI Ratio 
  
score Coverage 
Accession 
nr 
    
Exp:Con 
Protein Fate / Redox Regulation 
   
 
  
Peroxiredoxin-2 85 24 P35704 21941 5.34 1.39 
78 kDa glucose-regulated protein 784 28 P06761 72473 5.07 0.52 
  
   
  
Energy Metabolism       
Dihydrolipoyllysine-residue acetyltransferase 328 12 P08461 67637 8.76 0.72 
Isocitrate dehydrogenase [NAD] subunit alpha * 372 22 Q99NA5 40044 6.47 0.77 
Triosephosphate isomerase  457 42 P48500 27345 6.89 1.24 
Dihydrolipoyl dehydrogenase 123 12 Q6P6R2 54574 7.96 2.05 
Phosphoglycerate kinase 1 303 22 P16617 44909 8.02 0.56 
NADH dehydrogenase [ubiquinone] flavoprotein 2  295 25 P19234 27703 6.23 1.37 
ATP synthase subunit beta * 158 10 P10719 56318 5.19 0.44 
Pyruvate dehydrogenase E1 component  
subunit alpha * 230 11 P26284 43883 6.2 0.59 
Aconitate hydratase 852 25 Q9ER34 86121 7.87 2.09 
Dihydrolipoyllysine-residue succinyltransferase 167 10 Q01205 49236 8.89 0.63 
Pyruvate kinase isozymes M1/M2 131 10 P11980 58294 6.63 1.82 
       
Protein Synthesis / Neurotrophic 
 
    
 
Beta-synuclein 74 9 Q63754 14495 4.48 1.33 
       
Structural / Cytoskeletal       
Tubulin beta-5 chain 641 47 P69897 50095 4.78 1.78 
Tubulin alpha-1B chain 326 33 Q6P9V9 50804 4.94 0.47 
Tubulin beta-2C chain 185 20 Q6P9T8 50225 4.79 0.44 
Actin, cytoplasmic 1 * 561 38 P60711 42052 5.29 0.27 
Actin, cytoplasmic 2 * 561 38 P63259 42108 5.31 0.27 
Neuronal-specific septin-3 236 17 Q9WU34 40914 6.74 0.59 
Septin-5 151 10 Q9JJM9 43281 6.34 0.59 
Annexin A3 512 30 P14669 36569 5.96 0.77 
T-complex protein 1 subunit epsilon 393 16 Q68FQ0 59955 5.51 0.54 
       
Synaptic Signalling       
Guanine nucleotide-binding protein subunit beta-1 * 453 24 P54311 38151 5.6 0.54 
Guanine nucleotide-binding protein subunit beta-2 * 355 19 P54313 38048 5.6 0.54 
Guanine nucleotide-binding protein subunit beta-3 * 183 13 P52287 38125 5.51 0.54 
Dihydropyrimidinase-related protein 2   353 20 P47942 62638 5.95 1.95 
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Dihydropyrimidinase-related protein 5  533 20 Q9JHU0 62071 6.6 1.78 
Phosphatidylethanolamine-binding protein 1 383 45 P31044 20902 5.48 1.35 
Calmodulin  107 18 P62161 16827 4.09 2.01 
Synapsin-2   125 9 Q63537 63702 8.73 2.81 
Myc box-dependent-interacting protein 1 243 15 O08839 64721 4.95 0.52 
Complexin-2 *  198 35 P84087 15499 5.06 1.21 
Protein kinase C and casein kinase substrate in 
neurons protein 1  255 27 Q9Z0W5 50760 5.15 0.67 
Complexin-1 *   51 8 P63041 15169 4.93 1.6 
Endophilin-A1 350 23 O35179 40045 5.26 0.27 
Endophilin-A2 216 10 O35964 41694 5.45 0.27 
Voltage-dependent anion-selective channel protein 1 250 18 Q9Z2L0 30851 8.62 0.79 
       
Other       
Mu-crystallin homolog * 229 26 Q9QYU4 33704 5.34 2.02 
Isovaleryl-CoA dehydrogenase 267 13 P12007 46862 8.03 0.59 
Heat shock 70 kDa protein 1A/1B 327 11 Q07439 70427 5.61 1.32 
60 kDa heat shock protein 219 13 P63039 61088 5.91 0.54 
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Figure 1. (I) A 2D gel image of expressed proteins in the rat frontal cortex of the cytosolic 
protein fraction. (II) An enhanced image of spot 6609 identified as dihydropyrimidase-related 
protein 2 in both MA exposed and control groups. The expression of spot 6609 was decreased 
in the MA exposed group in the cytosolic cortical protein fraction.  
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CHAPTER 7 
 
 
Methamphetamine differentially affects cytosolic proteins in the nucleus accumbens 
shell and core of maternally separated and non-stressed control rats: a proteomic 
quantification approach.  
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Abstract 
 
The nucleus accumbens core and shell sub-regions are differentially affected by both stressors 
and methamphetamine (MA). Early adversity may predispose individuals to subsequent MA 
use. This study aimed to better characterize and quantify MA-induced protein role players in 
both the shell and core of the nucleus accumbens of animals exposed to maternal separation. 
Proteomics was used to identify proteins involved in the mechanisms and effects induced by 
stress and methamphetamine combined with the isobaric tagging of peptides (iTRAQ) which 
enables simultaneous identification and quantification of peptides by employing tandem mass 
spectrometry (MS/MS). Processes affected by the two interventions were similar in the 
respective subregions. However, significant differences were observed when the individual 
proteins were identified between shell and core sub-regions. Another key finding was the 
involvement of additional proteins when rats were exposed to both early life maternal 
separation and MA treatment. We found 28 cytosolic accumbal shell and 25 accumbal core 
proteins which were quantitatively significantly expressed between experimental groups 
investigated. Some of these proteins included actin cytoplasmic 2, thymosin beta-4, creatine 
kinase B-type, proSAAS, 14-3-3 protein gamma, myristoylated alanine-rich C-kinase 
substrate (MARCKS), Arpp-21, ubiquitin carboxyl-terminal hydrolase isozyme L1, alpha-
synuclein, brain acid soluble protein 1 (BASP1) and myotrophin. These proteins are 
associated with cytoskeletal modifications, energy metabolism, intracellular signaling, protein 
degradation and cellular growth. The quantification of differentially expressed proteins may 
be useful in determining the protein role players involved in the molecular mechanisms of 
early life stress and MA dependence.   
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Maternal separation; Nucleus accumbens shell; Nucleus accumbens core; Methamphetamine; 
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Introduction 
 
Stress has been shown to affect the core and shell subregions of the nucleus accumbens 
differently. Whereby, emotionally stressed rats that witnessed other rats receive electric 
footshocks; have increased extracellular dopamine concentrations in the shell and not the 
accumbens core (Wu et al., 1999). Since maternal separation (MS) has been shown to alter the 
animal’s response to drugs of abuse (e.g. enhanced cocaine self-administration and 
psychostimulant induced locomotor activity (Brake et al., 2004; Matthews et al., 2003; 
Meaney et al., 2002; Kikusui et al., 2005)), we hypothesized that this form of early life stress 
would also differentially affect the shell and core sub-regions of the nucleus accumbens.  
  
Methamphetamine (MA) has also been shown to differentially affect the nucleus accumbens 
core and shell sub-regions. Microdialysis studies in rodents have indicated that drugs of abuse 
increases dopamine neurotransmission preferentially in the nucleus accumbens shell 
(Imperato and Di Chiara, 1986; Imperato et al., 1986; Carboni et al., 1989). This finding was 
confirmed by subsequent brain imaging studies in humans (Drevets et al., 2001; Leyton et al., 
2002; Boileau et al., 2003). Similarly, reinstatement of cocaine seeking behavior in the rat 
involved the activation of dopamine receptors in the accumbal shell rather than the core 
region (Schmidt et al., 2006). The involvement of the shell has been consistently found and is 
involved in emotional and motivational activities while the core region is involved in 
somatomotor functions (Alheid and Heimer, 1988; Heimer et al., 1991). However, not all data 
are consistent - neurotoxic doses of MA selectively caused damage to the dopaminergic input 
to the core, while those to the shell appeared unaffected (Broening et al., 1997). Secondly, we 
hypothesize that MA would also affect the shell and core sub-region of MS rats.       
      
Proteomics is a powerful technique to identify the changes in expression of a multitude of 
proteins following an intervention. This experimental approach has previously been used to 
unravel the mechanisms and effects induced by methamphetamine usage (Liao et al., 2005; 
Iwazaki et al., 2006; 2007; 2008; Li et al., 2008; Yang et al., 2008). Various mass 
spectrometry techniques allow unbiased identification of target proteins and assess the post-
transcriptional modifications of proteins. Isobaric tagging of peptides (iTRAQ) enables 
simultaneous identification and quantification of peptides using tandem mass spectrometry 
(MS/MS) (Thompson et al., 2003). A major advantage of using iTRAQ labeling is the 
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simultaneous proteomic analysis of more than one experimental sample. In the present study 
the parallel proteomic analysis of multiple experimental samples was done.   
 
Since the molecular components mediating stress and MA-induced effects in the shell and 
core sub-regions are not well established, the aim of our study was to characterize and 
quantify protein role players in these conditions by using iTRAQ methodology on both the 
shell and core of the nucleus accumbens of MA-treated animals previously exposed to 
maternal separation and non-stressed rearing conditions. We hypothesize that different 
functional proteins would be involved in MS and MA-mediated effects in the shell and core 
sub-regions.   
 
 
Materials and Methods 
 
Animals 
Male Sprague Dawley rats were used in this experiment. Ethical approval for all experimental 
procedures was provided by the Committee for Experimental Animal Research of the 
University of Stellenbosch. Animals were housed at the Central Research Animal Facility 
(AAALAC accredited) of the University of Stellenbosch. All rats were housed in the same 
colony room separate from where stress procedures, MA injections or where dissections 
occurred. Animals were housed according to standard laboratory conditions as stipulated by 
the Ethical Guidelines of the University for the Housing of Experimental Animals. Rats were 
housed (2-4) in 40 x 25 x 20 cm Plexiglas cages with corncobs as bedding. Temperature was 
kept constant at 22ºC, humidity at 55% and food and water was available ad libitum for the 
duration of the experiment.  
 
Drugs 
Methamphetamine hydrochloride was obtained from US Pharmacopeia Convention Inc. 
(Rockville, USA). Methamphetamine was dissolved in 0.9% saline and administered at a dose 
of 1mg/kg, intraperitoneally (i.p.).  
 
Maternal separation paradigm 
Male and female rats were paired and their offspring used for experimental purposes. The day 
of birth was designated as postnatal day (PND) 0, where after maternal separation 
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commenced two days later on PND 2 until PND 14. Rat pups were separated from their 
mothers for a 3 hour daily period between 09h00 and 13h00. This protocol is in accordance 
with the deprivation procedures as employed by Ladd et al. (2000). The pups were moved to a 
new cage, while the mother remained in the home cage. The cage containing the pups were 
then moved to an isolated dedicated room where the pups were kept warm under infrared 
lights (30-33ºC), thereby preventing exposure to hypothermic conditions. Control litters were 
reared normally without separations. After maternal deprivation was completed, animals were 
subjected to normal housing conditions.  
 
Experimental design 
All rat pups were weaned at the age of PND 21. Only male rats were used for the subsequent 
experiments. The rats were divided into four groups: 
 
1)  Control Saline (CS) group: animals not subjected to MS and receiving 4 saline 
injections. 
2)   MS Saline (MS) group: animals subjected to MS and subjected to 4 saline injections. 
3)  Control MA (CM) group: animals not subjected to MS and receiving 4 
methamphetamine injections. 
4)  MS MA (MM) group: animals subjected to MS and subjected to methamphetamine 
injections. 
 
Methamphetamine administrations occurred on PND 33 – 36. The rational for subjecting rats 
to methamphetamine during their adolescent period in life (PND 33 – 36), is that in humans, 
adolescents typically have an increased sensation seeking drive for drugs of abuse and hence 
presents with an important risk to susceptibility for taking drugs at this stage of life (Laviola 
et al., 1999; Spear, 2000). Animals were all decapitated on PND 52. The brains were removed 
and the shell and core of the nucleus accumbens were dissected according to the rat brain atlas 
(Paxinos and Watson, 1986) and immediately frozen and stored in liquid nitrogen for later 
analysis.  
 
Fractionation of striatal shell and core tissue 
Nine shell and nine core accumbal tissue samples were pooled respectively for each 
experimental group to obtain sufficient protein for the subsequent experiments. Tissue 
samples were subjected to fractionation using a commercially available ProteoExtract 
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Subcellular Proteome Extraction Kit (Merck, Calbiochem). The sample was separated into 
four fractions, which included cytosolic, membrane/organelle, nucleic and cytoskeletal matrix 
protein extracts. The most abundant protein changes often take place in the cytosolic region of 
cells, hence the rationale to focus and investigate the protein expression changes in this 
cellular fraction. The cytosolic protein extracts were subsequently used to determine the total 
protein concentration. This was achieved by using a Bradford method adhering to the 
specifications of the ReadyPrep 2-D Cleanup Kit (Bio-Rad). After the completion of the 
Cleanup kit, samples were re-suspended in ammonium bicarbonate. The samples were further 
subjected to a roto-evaporator (Eppendorf) to reduce the sample volume to form a tight pellet 
for further analysis.   
 
Sample preparation and tryptic digestion  
Each sample was re-suspended in 50µl 1% PPS (pyridinium propyl sulfonate) silent surfactant 
according to the PPS silent detergent protocol and the insoluble matter removed by 
centrifugation. Protein concentration was again determined, this time a nano-drop 
spectrophotomer was used.  The samples were combined using equal amounts of protein from 
each to obtain the final group protein. The combined samples formed groups 1 to 8 
respectively. Equal aliquots (100µg) were taken from each group and digested with trypsin 
according to a slightly modified PPS protocol with trypsin added in a 1:10 ratio. The resultant 
digestion was evaluated using both mass spectrometric and liquid chromatography data. Mass 
spectral analysis showed that digestion occurred and the liquid chromatogram indicated that 
the digest ran to completion. 
 
Isobaric tag for relative and absolute quantitation (iTRAQ) labeling 
Peptides from the 8 groups (50µg) were labeled using 8 – plex iTRAQ labeling. The iTRAQ 
labeling reaction was performed according to the ABI silent protocol substituting isopropanol 
for ethanol. The groups were labeled sequentially with iTRAQ labels 113 to 121, i.e. group 1 
with 113, group 2 with 114 and so forth. An aliquot of each sample was mixed for 
confirmation of labeling with MS and MS/MS. The data indicated that all 8 samples were 
modified with iTRAQ tags. 
 
Peptide clean-up 
The mixture of labeled peptides was separated by re-suspending the sample in strong cation 
exchange (SCX) equilibration buffer (5mM KH2PO4) (Sigma), 25% acetonitrile (ACN) 
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(ROMIL) and applied to a pre-equilibrated SCX SPE device (Supelco SupelClean). The 
peptides were eluted from the device with 300 µL elution buffer (1M HCO2NH4/25% 
acetonitrile (Sigma). Mass spectra indicated some peptide in the flow through and wash as 
expected and peptide was detected in the eluate from the SPE device. The sample volume was 
reduced to 25µL using a roto-evaporator (Eppendorf). The samples for MS analysis were 
desalted using ZipTip C18 SPE devices. 
 
Liquid chromatography 
Peptides were separated on a Dionex Ultimate 3000 nano-LC with a C18 Pepmap column 
(75µm x 15cm, LCPackings). The solvent systems were A: 2% ACN/H2O, 0.1% 
trifluoroacetic acid (TFA); B: 80% ACN/H2O, 0.08% TFA. The sample was loaded onto the 
column using Solvent A. Peptide were eluted 5%B for 5 min, 5-15%B over 5 min, 15%-
45%B over 70 min and 45%-60%B 10 min with a flow rate of 200nL/min. The eluted 
peptides were spotted onto a MALDI source plate using a Probot (LCPackings) with 
continuous matrix addition at 600nL/min. The matrix was 7.5 mg/mL α-cyano-4-
hydroxycinmamic acid (Fluka) with 10 mM NH4H2PO4 (Fluka) in 66% acetonitrile, 0.1% 
TFA. PepMix4 (LaserBiolabs) 5 point calibration mixture was spiked into the sample at an 
average of 10 fmol/µL (final quantity of 6.6 fmol total peptide/spot). Fractions were collected 
every 12s and the collection started 16 min after sample injection. 
 
Mass spectrometry 
The samples collected from the chromatographic separation were mixed with MALDI 
matrix through an inline T connecter and spotted on a MALDI source plate. The α-Cyano-4-
hydroxycinnamic acid (CHCA) matrix was spiked with a 5-point internal calibration mixture. 
Calibration analysis shows that internal calibration was obtained in 99.6% (1014/1018) of the 
spots and that the mass spectrometer was functioning within specifications. 
 
Mass spectrometry was performed using an Applied Biosystems 4800 MALDI ToF/ToF. 
Parent ion spectra were recorded in linear positive ion mode with 400 shots/spectrum and 
laser intensity of 4000 arbitrary units. The grid voltage was set to 16kV. The spectra were 
processed using the PepMix4 internal calibration points. MS/MS spectra were recorded in 
positive mode with 1kV deceleration voltage and a total of 600 laser shots/spectrum with the 
laser set to 5000 arbitrary units. 
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Data Analysis 
Mass spectral data was analyzed using Peak Explorer software and data analysis was 
performed using ProteinPilot. The parameters were set as follows: Analysis type, quantitation 
8-plex iTRAQ with standard correction factors; Enzyme, trypsin; Cys modification, MMTS; 
Database, Ratus ratus; Search effort, thorough; Modifications, biological modifications; 
Quantitation, 113 relative (Shell cytosolic fraction of the control saline (CS) group) and 117 
relative (Core cytosolic fraction of the control saline (CS) group).  
                                                                                                                  
 
Results 
 
Using the Ratus ratus database, 126 proteins (95% confidence) were identified. The average 
mass deviation was calculated as -0.080 Da. The iTRAQ quantitation was performed using 
ProteinPilot with default settings and relative abundance expressed in terms of reporter signal 
113 (Shell fraction) and 117 (Core fraction). Analysis of the peptide report showed that 1129 
ions 48.36% (546/1129) could be auto quantified, 26.48% (299/1129) were auto quantified 
but shared sequence data with other proteins and 24.09% (277/1129) could be auto quantified 
with low confidence. In total 98.93% (1117/1129) of all ions could be quantified. 
Fragmentation data showed that 0.97% of the ions fragmented did not contain an iTRAQ 
label and the experimental groups / samples examined were tagged with isobaric iTRAQ tags 
ranging from 113 to 121 (Table 1). The MS/MS to sequence conversion ratio was 46.4% with 
720 distinct peptides identified. From the 720 peptides 303 proteins were identified with 126 
detected after grouping using the Pro Group algorithm. Of the 126 proteins detected after 
grouping, the cytosolic proteins that were quantitationally significantly different from control 
groups in both shell (Table 2) and nucleus accumbens core (Table 3) fractions, are reported.  
 
We found 28 cytosolic shell and 25 core proteins which we quantitatively significantly 
expressed between the experimental groups investigated. The cytosolic shell proteins of 
animals subjected to MA mostly showed significant changes in proteins involved in 
cytoskeletal or structural functions. Similarly, cytosolic shell proteins of animals exposed to 
MS resulted in cytoskeletal modifications in addition to alterations in energy metabolism, 
protein fate and redox regulatory proteins. The combination of MS and later MA treatment 
resulted in quantitative protein changes in almost all protein functional groups (Table 2).  The 
cytosolic core proteins of MA exposed rats resulted in mainly cytoskeletal and energy 
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metabolism protein changes. Animals subjected to MS early in life resulted in less protein 
changes in the nucleus accumbens core. However, similarly to protein changes in the shell 
sub-region, the major core quantitative protein changes occurred in the group subjected to 
both MS followed by MA treatment (Table 3).   
 
 
Discussion 
 
In the present study we found that processes affected by the two interventions were similar in 
the respective subregions. However, the combination of early life stress exposure and later 
methamphetamine treatment resulted in greater differential expression of proteins in both the 
shell and core sub-region when compared to individual stressors. To our knowledge this is the 
first study to quantify the differential expression of cytosolic nucleus accumbal shell and core 
proteins of animals subjected to MS followed by MA treatment. This study is of relevance 
since the shell and core sub-regions of the nucleus accumbens have been shown to respond to 
drugs of abuse and stress in disparate ways. The proteins which were quantitatively 
significantly expressed between the experimental groups investigated are functionally 
associated with cytoskeletal modifications, energy metabolism, intracellular signaling, protein 
degradation and cellular growth. 
  
Cytoskeletal proteins like actin and microtubules play a key role in the maintenance of 
neuronal structure and function (Vale et al., 1992). Modifications to these proteins may 
therefore have far-reaching effects on neuron function. Cytoskeletal alterations have been 
shown to occur after methamphetamine administration in various brain areas including the 
striatum, hippocampus, prefrontal cortex, cingulated cortex, and the amygdala (Liao et al., 
2005; Iwazaki et al., 2006; 2007; 2008; Yang et al., 2008; Kobeissy et al., 2008). For instance, 
methamphetamine has been shown to disrupt cytoskeletal structure of dopaminergic 
terminals, while sparing neuronal somata (McCann and Ricaurte, 2004). In the present study, 
a number of cytoskeletal proteins were differentially expressed following methamphetamine 
treatment which included actin cytoplasmic 2, tubulin alpha-1B chain and beta-2A chain and 
microtubule-associated protein 2.  In both the shell and core the expression of these proteins 
were mostly decreased. This data shows that maternal separation and methamphetamine 
administration result in changes in cytoskeletal structure that may affect neurotransmission 
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and synapse function. These effects may subsequently contribute to methamphetamine-
induced neuroplasticity in the brain.  
 
In support, thymosin beta-4 concentrations were found to be increased in the accumbens core 
of animals exposed to both early separation and methamphetamine treatment. Thymosin beta-
4 forms a 1:1 complex with actin and inhibits actin polymerization (Safer et al., 1990). Thus, 
the spontaneous assembly of monomeric actin is prevented by thymosin, while profilin 
promotes barbed-end actin filament growth (Goldschmidt-Clermont et al., 1992; Pantaloni 
and Carlier, 1993; Kang et al., 1999). Additionally, thymosin beta-4 also plays a role in 
motility, axonal pathfinding, differentiation, neurite formation and proliferation (Border et al., 
1993; Otero et al., 1993; Molitoris, 1997; Huff et al., 2001; Kobayashi et al., 2002). 
Upregulation of thymosin beta-4 has also been found after brain ischaemia and kainate 
neurotoxicity (Vartiainen et al., 1996; Carpintero et al., 1999; Popoli et al., 2007). Our 
findings are therefore in line with previous evidence advocating adjustments in the expression 
of proteins related to plasticity, under conditions of stress and toxicity.   
  
Clinical studies have reported cerebral glucose hypometabolism in human methamphetamine 
abusers (Kim et al., 2005). Repeated methamphetamine use has also been shown to result in 
decreased energy metabolism in the hippocampus, dorsal raphe nucleus and amygdala in rats 
(Huang et al., 1999; Iwazaki et al., 2008). In accordance with these reports, methamphetamine 
was found to cause striatal ATP reductions which paralleled methamphetamine-induced 
dopamine depletion (Chan et al., 1994). Similarly, the present study demonstrated a general 
decrease in proteins involved in energy metabolism in animals treated with 
methamphetamine. This reduction in protein expression was observed in both the shell and 
core sub-regions. Some of these proteins included glyceraldehyde-3-phosphate 
dehydrogenase, pyruvate kinase isozyme M1/M2 and V-type proton ATPase subunit E1. The 
core was affected more so than the shell region in the methamphetamine treated group, while 
a greater number of proteins involved in metabolism were reduced in the shell following 
maternal separation in combination with later methamphetamine treatment. Overall, 
methamphetamine led to dysregulation of various proteins involved in energy metabolism and 
this effect seemed to be greater in animals with prior exposure to stress, particularly in the 
accumbens shell.   
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Significant differences in the expression of proteins that are members of signal transduction 
or neurotransmission pathways were found in the nucleus accumbens shell and core. For 
example, in the shell sub-region, ProSAAS and 14-3-3 protein gamma respectively showed 
increased and decreased expression after MS and methamphetamine treatment, respectively. 
ProSAAS is a granin-like protein which inhibits the action of prohormone convertase (PC) 1. 
Convertases usually mediate the proteolytic cleavage of many peptide precursors via the 
regulated / constitutive secretory pathway (Fricker et al., 2000; Qian et al., 2000). However, 
in the brain, proSAAS itself is cleaved into a smaller peptide that is unable to inhibit PC1 
(Mzhavia et al., 2001). It has been suggested that cleaved proSAAS may act as a neuropeptide 
in the brain (Mzhavia et al., 2002). The increase in proSAAS expression after maternal 
separation in the shell sub-region could possibly be related to the function neuropeptides play 
in the stress response. For instance, it is known that neuropeptide Y can activate the 
hypothalamic-pituitary-adrenal (HPA) axis in response to maternal separation (Schmidt et al., 
2008).  
 
The 14-3-3 protein gamma was significantly decreased after methamphetamine treatment in 
the present study. This protein is known to regulate signal transduction pathways which is 
involved in proliferation, differentiation and survival (Jin et al., 2004; Bridges and 
Moorehead, 2005; Aitken, 2006; Chen et al., 2006; Ajjappala et al., 2009). With regards to 
methamphetamine-induced proteins that give rise to addictive behavioral pathology, 14-3-3 
protein gamma activates tyrosine and tryptophan hydrolases, protein kinase C (PKC) and Raf-
1 in the mitogen activated protein kinase (MAPK) signal transduction pathway (Aitken et al., 
1995). PKC has also been implicated to play a role in methamphetamine-induced behavioral 
sensitization in the nucleus accumbens (Narita et al., 2004). Similarly, Yang et al. (2008) 
found decreased 14-3-3 protein gamma expression levels in the hippocampus of 
methamphetamine-treated rats. However, in contrast to our findings, increased 14-3-3 protein 
gamma phosphoproteins of the nucleus accumbens was found in cocaine self-administering 
rhesus monkeys (Tannu et al., 2008).      
 
Signal transduction and neurotransmission proteins in the accumbal core, myristoylated 
alanine-rich C-kinase substrate (MARCKS), Arpp-21 and alpha-synuclein were found to be 
quantitatively expressed. MARCKS is phosphorylated by PKC and also targeted by 
calmodulin (CaM) which translocates MARCKS from the plasma membrane, while the return 
of MARCKS back to the plasma membrane is mediated by dephosphorylation by calcineurin 
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or the lowering of intracellular calcium (Thelen et al., 1991; Clarke et al., 1993; Seki et al., 
1996; Arbuzova et al., 1998; Ohmori et al., 2000; Arbuzova et al., 2002). It is proposed that 
MARCKS mediate cross-talk between the PKC and CaM signal transduction pathways 
(Arbuzova et al., 2002). MARCKS has been found to regulate many processes including 
endocytosis, exocytosis and neurosecretion (Aderem, 1992; Blackshear, 1993). The increase 
in MARCKS after methamphetamine treatment in the present study may therefore play an 
important role in methamphetamine mediated signal transduction processes.  
 
Arpp-21 is a neuronal phosphoprotein which occurs in high concentrations in the limbic 
striatum, including the nucleus accumbens (Ouimet et al., 1989). Arpp-21 is a substrate for 
cAMP-dependent protein kinase (Walaas et al., 1983) and is suggested to possibly act as a 
third messenger in the intracellular cascade involving adenylate cyclase (AC). One of the first 
messengers activating AC includes dopamine binding to dopaminergic receptors (Ivkovic et 
al., 1996). The limbic striatum is highly enriched with dopamine D1 and D2 receptors that 
either stimulate or inhibit AC depending on the G-protein linked to the receptor, thereby 
modulating cAMP levels in this brain region (Stoof and Kebabian, 1981; Levey et al., 1993; 
Missale et al., 1998; Zhuang et al., 2000). Furthermore, Caporaso et al. (2000) found Arpp-21 
phosphorylation increased after activation of D1 receptors in the striatum, while D2 activation 
via quinpirole reduced Arpp-21 phosphorylation. Since the rewarding effects of 
psychostimulants are mediated by increased dopamine transmission in the mesolimbic 
dopaminergic pathway (Koob et al., 1998), it was proposed that phosphorylation of Arpp-21 
is likely to participate in the mediation of methamphetamine-induced intracellular signal 
transduction. Also, stimulation of D1 or D2 receptors in the shell and not the core has been 
associated with the reinstatement of cocaine-seeking behavior (Schmidt et al., 2006). The 
increased in Arpp-21 levels in the core as observed in the present study, demonstrated that 
signaling processes in the two sub-divisions of the nucleus accumbens remains unclear and 
that additional studies are needed to determine the exact role of shell and core drug-mediated 
proteins in addiction.    
 
Methamphetamine neurotoxicity has been found to lead to the formation of inclusion bodies 
in nigral and striatal neurons (Lotharius and Brundin, 2002) in both the soma and terminal 
endings (Fornai et al., 2004a; Brenz Verca et al., 2003). Cytoplasmic inclusions have been 
found to contain α-synuclein and ubiquitin (Lowe et al., 1990; Spillantini et al., 1997; Chung 
et al., 2001; Fornai et al., 2004b). Methamphetamine causes an increase in α-synuclein in 
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both the soma and terminal endings of nigral (Fornai et al., 2004a) and striatal neurons (Brenz 
Verca et al., 2003). Alpha-synuclein has been found to possess protective qualities since it 
prevented further oxidative damage by interacting with degradation products of dopamine 
(Sulzer, 2001; Conway et al., 2001; Machida et al., 2005). It has been suggested that 
increased alpha-synuclein might confer a compensatory mechanism to protect neurons against 
oxidative damage induced by methamphetamine (Li et al., 2008). This is in line with findings 
of the present study which found increased alpha-synuclein levels in the accumbens core after 
methamphetamine treatment in conjunction with early maternal separation.  
 
A number of proteins involved in protein synthesis or neurotrophic functions were identified 
to be differentially expressed in the shell and core. Increased expressions of brain acid soluble 
protein 1 (BASP1) were seen after maternal separation in the shell and when exposed to 
further methamphetamine treatment in this rise was evident in both the shell and core. BASP1 
forms part of a family of growth-associated proteins and increased levels are found in neurons 
during nerve regeneration (Mosevitsky et al., 1994; Iino and Maekawa, 1999; Frey et al., 
2000). This effect is apparently dependent on the localization of BASP1 at the plasma 
membrane (Korshunova et al., 2008) and therefore alterations in its expression may have 
implications for the regulation of actin dynamics and membrane structure (Wiederkehr et al., 
1997). A similar increase in myotrophin levels were observed after methamphetamine 
treatment in the core. This protein has been shown to regulate protein synthesis (Taoka et al., 
1992; 1994; Fujigasaki et al., 1996), as well as controlling the expression of 
catecholaminergic enzymes. Overexpression of myotrophin results in increased tyrosine 
hydrolase, aromatic L-amino acid decarboxylase and dopamine β-hydroxylase mRNA levels 
in neuronal cells, with subsequent stimulation of catecholamine synthesis (Yamakuni et al., 
1998). The increase in catecholamines has been postulated to be one of the mechanisms of 
action by which methamphetamine elicits its reinforcing effects (Koob et al., 1998).  In 
agreement with our finding, myotrophin was also identified in a recent proteomic study in the 
hippocampus of methamphetamine-treated rats (Li et al., 2008). Increased levels of BASP1 
and myotrophin in the present study might represent a compensatory mechanism to protect 
neurons against the damaging effects induced by methamphetamine and early life stress. On 
the other hand, decreased gamma-enolase, beta-synuclein and prosaposin which have all been 
shown to possess neurotrophic qualities (Hattori et al., 1994; Misasi et al., 2001; Hashimoto et 
al., 2001; 2004; Sorice et al., 2008), is mostly affected by the combination treatment of early 
maternal separation and later methamphetamine treatment. The reduction in the 
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concentrations of the latter proteins may therefore reflect continued detriment of maternal 
separation combined with methamphetamine treatment on the central nervous system and 
neuronal functionality.  
 
 
Conclusions 
 
In summary, the present study quantitatively identified a variety of cytosolic proteins in the 
shell and core of the nucleus accumbens, in animals subjected to maternal separation and 
methamphetamine treatment, independently or in combination. Collectively, processes 
affected by the two interventions were mostly similar in the respective subregions. However, 
significant differences were observed when the individual functional proteins were identified 
between shell and core sub-regions. Another main finding was the involvement of a certain 
population of proteins in methamphetamine use and additional proteins are recruited when the 
same animals are also exposed to early life maternal separation. It would therefore be 
interesting to ascertain whether these additional proteins in fact render individuals more 
susceptible to later drug abuse. Interpretation of the data as generated in this study, remains 
challenging and further research is required if the intricacies of addictive behavior is to be 
completely understood.  Subsequent studies will aim to confirm quantitative protein results 
obtained by using Western Blotting or ELISA methodology, as only a few samples were 
pooled to represent each experimental group. 
 
 
Acknowledgements 
 
The authors would like to acknowledge the contributions of the Centre for Proteomic and 
Genomic Research (CPGR), Institute of Infectious Diseases and Molecular Medicine, Faculty 
of Health Sciences, University of Cape Town (UCT). This work was supported by a grant 
from the Medical Research Council (MRC).  
 
 
 
 
 
 218 
Table 1. iTRAQ isobaric tags attached to corresponding experimental groups examined.  
 
 
iTRAQ sample      
group number Experimental group 
Nucleus Accumbens 
Cytosolic fraction 
iTRAQ 
isobaric tag 
1 Control Saline (CS) Shell 113 
2 Control MA (CM) Shell 114 
3 MS Saline (MS) Shell 115 
4 MS MA (MM) Shell 116 
5 Control Saline (CS) Core 117 
6 Control MA (CM) Core 118 
7 MS Saline (MS) Core 119 
8 MS MA (MM) Core 121 
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Table 2. iTRAQ Ratios for nucleus accumbens shell cytosolic proteins in methamphetamine 
and maternally separated samples. 
 
Accession 
nr Protein Name MS:CS 
P val 
MS:CS CM:CS 
P val 
CM:CS MM:CS 
P val 
MM:CS 
Cytoskeletal / Structural 
sp|P63259 Actin, cytoplasmic 2  0.409 0.001 0.536 0.001 0.315 0.001 
sp|Q6P9V9 Tubulin alpha-1B chain  0.262 0.001 0.483 0.001 0.213 0.001 
sp|P19332 Microtubule-associated protein tau  1.269 0.052 * 1.000 1.000 1.219 0.343 
sp|P85108 Tubulin beta-2A chain  0.406 0.011 0.544 0.002 0.300 0.002 
sp|Q62658 Peptidyl-prolyl cis-trans isomerase FKBP1A  1.417 0.001 * 0.914 0.496 1.195 0.125 
sp|P15146 Microtubule-associated protein 2 0.565 0.007 0.557 0.001 0.450 0.001 
sp|Q5XIF6 Tubulin alpha-4A chain  0.452 0.034 0.801 0.472 0.338 0.066 
 
  
 
 
 
 
 
Energy Metabolism 
sp|P07335 Creatine kinase B-type  0.690 0.001 0.772 0.001 0.663 0.001 
sp|P04797 Glyceraldehyde-3-phosphate dehydrogenase  0.450 0.001 0.645 0.058 0.395 0.001 
sp|O88989 Malate dehydrogenase, cytoplasmic 0.480 0.066 0.657 0.142 0.362 0.048 
sp|P11980 Pyruvate kinase isozymes M1/M2  0.473 0.006 0.753 0.264 0.417 0.001 
sp|Q6PCU2 V-type proton ATPase subunit E 1  0.942 0.819 1.126 0.835 0.730 0.041 
 
  
 
 
 
 
 
Neurotransmission / Signalling 
sp|Q9QXU9 ProSAAS  1.378 0.047 * 1.215 0.249 1.301 0.357 
sp|P61983 14-3-3 protein gamma  0.799 0.138 0.744 0.011 0.832 0.429 
sp|Q56R16 Importin subunit alpha-6  0.161 0.020 1.178 0.020 * 0.206 0.020 
        
Protein Fate / Redox Regulation 
sp|Q00981 
Ubiquitin carboxyl-terminal hydrolase isozyme 
L1  0.798 0.001 0.829 0.182 0.805 0.003 
sp|P62898 Cytochrome c, somatic  1.516 0.039 * 1.310 0.440 1.673 0.008 * 
sp|P35704 Peroxiredoxin-2  0.733 0.014 0.959 0.857 0.774 0.166 
        
Protein Synthesis / Neurotrophic 
sp|Q05175 Brain acid soluble protein 1  1.602 0.051 * 1.208 0.104 1.698 0.006 * 
sp|P07323 Gamma-enolase  0.500 0.001 0.607 0.007 0.447 0.002 
sp|Q63754 Beta-synuclein  1.183 0.280 1.070 0.657 1.270 0.024 
sp|P55068 Brevican core protein  0.791 0.095 0.722 0.112 0.811 0.028 
        
Other 
tr|Q6PED0 Ribosomal protein S27a  0.714 0.002 1.355 0.031 * 0.829 0.029 
sp|P63055 Purkinje cell protein 4  1.370 0.001 * 1.073 0.574 1.341 0.007 * 
sp|P63018 Heat shock cognate 71 kDa protein  0.377 0.013 0.729 0.004 0.400 0.002 
sp|Q5XI72 Eukaryotic translation initiation factor 4H  1.398 0.118 1.028 0.676 1.194 0.044 * 
sp|P62959 Histidine triad nucleotide-binding protein 1  1.213 0.346 1.286 0.128 1.415 0.037 * 
sp|O35814 Stress-induced-phosphoprotein 1  0.814 0.259 0.906 0.601 0.787 0.045 
            
           
BOLD ratios *, significantly increased compared to CS (p<0.05); BOLD ratios, significantly 
decreased compared to CS (p<0.05) 
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Table 3. iTRAQ Ratios for nucleus accumbens core cytosolic proteins in methamphetamine 
and maternally separated samples. 
 
Accession 
nr Protein Name MS:CS 
P val 
MS:CS CM:CS 
P val 
CM:CS MM:CS 
P val 
MM:CS 
Cytoskeletal / Structural 
sp|P63259 Actin, cytoplasmic 2  0.835 0.001 0.672 0.001 0.803 0.001 
sp|Q6P9V9 Tubulin alpha-1B chain  0.773 0.008 0.623 0.003 0.754 0.016 
sp|P19332 Microtubule-associated protein tau  1.082 0.417 1.171 0.016 * 1.067 0.479 
sp|P85108 Tubulin beta-2A chain  0.800 0.059 0.662 0.001 0.796 0.002 
sp|P62329 Thymosin beta-4  1.107 0.131 1.123 0.285 1.220 0.025 * 
sp|P15146 Microtubule-associated protein 2 0.877 0.219 0.772 0.043 0.785 0.006 
 
  
 
 
 
 
 
Energy Metabolism 
sp|P07335 Creatine kinase B-type  0.980 0.588 0.859 0.001 0.870 0.001 
sp|P04797 Glyceraldehyde-3-phosphate dehydrogenase  0.891 0.318 0.716 0.010 0.832 0.012 
sp|P11980 Pyruvate kinase isozymes M1/M2  0.969 0.494 0.871 0.046 0.973 0.463 
 
  
 
   
 
Neurotransmission / Signalling 
sp|P47728 Calretinin  1.043 0.434 0.933 0.108 0.816 0.033 
sp|P30009 Myristoylated alanine-rich C-kinase substrate  0.914 0.262 1.186 0.002 * 1.106 0.364 
tr|Q5FVI0 Arpp-21 protein  0.802 0.607 0.905 0.634 1.083 0.039 * 
sp|Q56R16 Importin subunit alpha-6  2.137 0.018 * 2.036 0.013 * 1.088 0.026 * 
        
Protein Fate / Redox Regulation  
sp|P37377 Alpha-synuclein  0.972 0.802 1.082 0.187 1.153 0.030 * 
sp|Q00981 
Ubiquitin carboxyl-terminal hydrolase isozyme 
L1  1.035 0.485 0.948 0.395 0.865 0.024 
sp|P11240 
Cytochrome c oxidase subunit 5A, 
mitochondrial  1.220 0.207 1.441 0.012 * 1.128 0.107 
sp|P62898 Cytochrome c, somatic  0.924 0.681 1.092 0.431 1.290 0.034 * 
        
Protein Synthesis / Neurotrophic 
sp|Q05175 Brain acid soluble protein 1  1.089 0.222 1.121 0.119 1.173 0.016 * 
sp|P07323 Gamma-enolase  0.908 0.089 0.758 0.003 0.851 0.050 
tr|Q6P7A4 Prosaposin  0.995 0.987 1.289 0.414 0.813 0.054 
sp|P62775 Myotrophin  1.014 0.799 1.114 0.006 * 1.087 0.352 
        
Other 
sp|P63055 Purkinje cell protein 4  0.987 0.858 1.160 0.019 * 1.113 0.045 * 
sp|P26772 10 kDa heat shock protein, mitochondrial  1.227 0.012 * 1.041 0.368 1.084 0.272 
sp|O35814 Stress-induced-phosphoprotein 1  1.115 0.478 1.138 0.732 1.131 0.037 * 
sp|P02688-4 Isoform 14 kDa of Myelin basic protein S  1.330 0.006 * 0.959 0.638 1.023 0.731 
             
           
BOLD ratios *, significantly increased compared to CS (p<0.05); BOLD ratios, significantly 
decreased compared to CS (p<0.05) 
 
 
 
 
 
 221 
References 
  
Aderem A. The MARCKS brothers: a family of protein kinase C substrates. Cell (1992), 
71:713-716. 
 
Aitken A. 14-3-3 proteins on the MAP. Trends Biochem Sci (1995), 20:95-97.  
 
Aitken A. 14-3-3 proteins: a historic overview. Semin Cancer Biol (2006), 16:162-172. 
 
Ajjappala BS, Kim YS, Kim MS, Lee MY, Lee KY, Ki HY, Cha DH, and Baek KH. 14-3-3γ 
is stimulated by IL-3 and promotes cell proliferation. J Immunology (2009), 182:1050-1060. 
 
Alheid GF, and Heimer L. New perspectives in basal forebrain organization of special 
relevance for neuropsychiatric disorders: the striatopalidal, amygdaloid, and corticopetal 
components of substantia innominata. Neuroscience (1988), 27:1-39.  
 
Arbuzova A, Murray D, and McLaughlin S. MARCKS, membranes, and calmodulin: kinetics 
of their interaction. Biochem Biophys Acta (1998), 1376:369-379. 
 
Arbuzova A, Schmitz AA, and Vergères G. Cross-talk unfolded: MARCKS proteins. 
Biochem J (2002), 362:1-12. 
 
Blackshear PJ. The MARCKS family of cellular protein kinase C substrates. J Biol Chem 
(1993), 268:1501-1504. 
 
Boileau I, Assaad JM, Pihl RO, Benkelfat C, Leyton M, Diksic M, Tremblay RE, and Dagher 
A. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse (2003), 
49:226-231.  
 
Border BG, Lin SC, Griffin WS, Pardue S, and Morrison-Bogorad M. Alterations in actin-
binding beta-thymosin expression accompany neuronal differentiation and migration in rat 
cerebellum. J Neurochem (1993), 61:2104-2114. 
 
 222 
Brake WG, Zhang TY, Diorio J, Meaney MJ, and Gratton A. Influence of early postnatal 
rearing conditions on mesocorticolimbic dopamine and behavioural responses to 
psychostimulants and stressors in adult rats. European Journal of Neuroscience (2004), 
19:1863-1874. 
 
Brenz Verca MS, Bahi A, Boyer F, Wagner GC, and Dreyer JL. Distribution of alpha- and 
gamma-synucleus in the adult rat brain and their modification by high-dose cocaine treatment. 
Eur J Neurosci (2003), 18:1923-1938. 
 
Bridges D, and Moorhead GB. 14-3-3 proteins: a number of functions for a numbered protein. 
Sci STKE (2005), 296: re10. 
 
Broening HW, Pu C, and Vorhees CV. Methamphetamine selectively damages dopaminergic 
innervation to the nucleus accumbens core while sparing the shell. Synapse (1997), 27:153-
160. 
 
Conway KA, Rocket JC, Bieganski RM, and Lansbury J. Kinetic stabilization of the alpha-
synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001), 276:2045-2047. 
 
Caporaso GL, Bibb JA, Snyder GL, Valle C, Rakhilin S, Fienberg AA, Hemmings HC Jr, 
Nairn AC, and Greengard P. Drugs of abuse modulate the phosphorylation of ARPP-21, a 
cyclic AMP-regulated phosphoprotein enriched in the basal ganglia. Neuropharmacol (2000), 
39:1637-1644. 
 
Carboni E, Imperato A, Perezzani L, and Di Chara G. Amphetamine, cocaine, phencyclidine 
and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus 
accumbens of freely moving rats. Neuroscience (1989), 28:653-661.  
 
Carpintero P, Anadon R, az-Regueira S, and Gomez-Marquez J. Expression of thymosin 
beta4 messenger RNA in normal and kainite-treated rat forebrain. Neuroscience (1999), 
90:1433-1444.  
 
 223 
Chan P, Monte DA, Luo JJ, DeLanney LE, Irwin I, and Langston JW. Rapid ATP loss caused 
by methamphetamine in the mouse striatum: relationship between energy impairment and 
dopaminergic neurotoxicity. J Neurochem (1994), 62:2484-2487.  
 
Chen S, Fariss RN, Kutty RK, Nelson R, and Wiggert B. Fenretinide-induced neuronal 
differentiation of ARPE-19 human retinal pigment epithelial cells is associated with the 
differential expression of Hsp70, 14-3-3, pax-6, tubulin β-III, NSE, and bag-1 proteins. Mol 
Vis (2006), 12:1355-1363. 
 
Chung KK, Dawson VL, and Dawson TM. The role of the ubiquitin-proteasome pathway in 
Parkinson’s disease and other neurodegenerative disorders. Trends Neurol Sci (2001), 24:S7-
S14. 
 
Clarke PR, Siddhanti SR, Cohen P, and Blackshear PJ. Okadaic acid-sensitive protein 
phosphatases dephosphorylate MARCKS, a major protein kinase C substrate. FEBS Lett 
(1993), 336:37-42. 
 
Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, and Mathis 
CA. Amphetamine-induced dopamine release in human ventral striatum correlates with 
euphoria. Biol Psychiatry (2001), 49:81-96. 
 
Fornai F, Lenzi P, Gesi M, Soldani P, Ferrucci M, Lazzeri G, Capobianco L, Battaglia G, De 
Blasi A, Nicoletti F, and Paparelli A. Methamphetamine produces neuronal inclusions in the 
nigrostriatal system and in PC12 cells. J Neurochem (2004a), 88:114-123. 
 
Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Capobianco L, De Blasi A, Battaglia G, 
Nicoletti F, Ruggieri S, and Paparelli A. Similarities between methamphetamine toxicity and 
proteasome inhibition. Ann NY Acad Sci (2004b), 1025:162-170. 
 
Frey D, Laux T, Xu L, Schneider C, and Caroni P. Shared and unique roles of CAP23 and 
GAP43 in actin regulation, neurite outgrowth, and anatomical plasticity. J Cell Biol (2000), 
149:1443-1454. 
 
 224 
Fricker LD, McKinzie AA, Sun J, Curran E, Qian Y, Yan L, Patterson SD, Courchesne PL, 
Richards B, Levin N, Mzhavia N, Devi LA, and Douglass J. Identification and 
characterization of proSAAS, a granin-like neuroendocrine peptide precursor that inhibits 
prohormone processing. J Neurosci (2000), 20:639-648.   
 
Fujigasaki H, Song SY, Kobayashi T, and Yamakuni T. Murine central neurons express a 
novel member of the cdc10/SW16 motif-containing protein superfamily. Mol Brain Res 
(1996), 40:203-213. 
 
Goldschmidt-Clermont PJ, Furman MI, Wachsstock D, Safer D, Nachmias VT, and Pollard 
TD. The control of actin nucleotide exchange by thymosin beta4 and profilin. A potential 
regulatory mechanism for actin polymerization in cells. Mol Biol Cell (1992), 3:1015-1024. 
 
Hashimoto M, Bar-on P, Ho G, Takenouchi T, Rockenstein E, Crews L, and Masliah E. β-
synuclein regulates Akt activity in neuronal cells. J Biol Chem (2004), 279:23622-23629. 
 
Hashimoto M, Rockenstein E, Mante M, Mallory M, and Masliah E. β-synuclein inhibits α-
synuclein aggregation: A possible role as an anti-parkinsonian factor. Neuron (2001), 32:213-
223. 
 
Hattori T, Ohsawa K, Mizuno Y, Kato K, and Kohsaka S. Synthetic peptide corresponding to 
30 aminoacids of the C terminal of neuron specific enolase promotes survival of neocortical 
neurons in culture. Biochem Biophys Res Commun (1994), 202:25-30. 
 
Heimer L, Olmos JD, Alheid GF, and Zaborszky L. ´Perestroika´ in the basal forebrain: 
opening the border between neurology and psychiatry. Prog Brain Res (1991), 87:109-169. 
 
Huang YH, Tsai SJ, Su TW, and Sim CB. Effects of repeated high-dose methamphetamine on 
local cerebral glucose utilization in rats. Neuropsychopharmacol (1999), 21:427-434. 
 
Huff T, Muller CS, Otto AM, Netzker R, and Hannappel E. beta-Thymosins, small acidic 
peptides with multiple functions. Int J Biochem Cell Biol (2001), 33:205-220. 
 
 225 
Iino S, and Maekawa S. Immunohistochemical demonstration of a neuronal calmodulin-
binding protein, NAP-22, in the rat spinal cord. Brain Res (1999), 834:66-73. 
 
Imperato A, and Di Chiara G. Preferential stimulation of dopamine release in the nucleus 
accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther (1986), 239:219-228. 
 
Imperato A, Mulas A, and Di Chiara G. Nicotine preferentially stimulates dopamine release in 
the limbic system of freely moving rats. Eur J Pharmacol (1986), 132:337-338.  
 
Ivkovic S, Blau S, Polanskaya O, and Ehrlich ME. ARPP-21: murine gene structure and 
promoter identification of a neuronal phosphoprotein enriched in the limbic striatum. Brain 
Res (1996), 709:10-16. 
 
Iwazaki T, McGregor IS, and Matsumoto I. Protein expression profile in the striatum of acute 
methamphetamine-treated rats. Brain Res (2006), 1097:19-25. 
 
Iwazaki T, McGregor IS, and Matsumoto I. Protein expression profile in the striatum of rats 
with methamphetamine-induced behavioural sensitization. Proteomics (2007), 7:1131-1139. 
 
Iwazaki T, McGregor IS, and Matsumoto I. Protein expression profile in the amygdala of rats 
with methamphetamine-induced behavioural sensitization. Neurosci Lett (2008), 435:113-
119. 
 
Jin J, Smith FD, Starck C, Wells CD, Fawcett JP, Kulkarni S, Metalnikov P, O’Donell P, 
Taylor P, Taylor L, Zougman A, Woodgett JR, Langeberg LK, Scott JD, and Pawson T. 
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved 
in cytoskeletal regulation and cellular organization. Curr Biol (2004), 14:1436-1450. 
 
Kang F, Purich DL, and Southwick FS. Profilin promotes barbed-end actin filament assembly 
without lowering the critical concentration. J Biol Chem (1999), 274:36963-36972. 
 
Kikusui T, Faccidomo S, and Miczek KA. Repeated maternal separation: differences in 
cocaine-induced behavioral sensitization in adult male and female mice. Psychopharmacology 
(2005), 178:202-210.  
 226 
Kim SJ, Lyoo IK, Hwang J, Sung YH, Lee HY, Lee DS, Jeong DU, and Renshaw PF. Frontal 
glucose hypometabolism in abstinent methamphetamine users. Neuropsychopharmacol 
(2005), 30:1383-1391. 
 
Kobayashi T, Okada F, Fujii N, Tomita N, Ito S, Tazawa H, Aoyama T, Choi SK, Shibata T, 
Fujita H, and Hosokawa M. Thymosin-beta4 regulates motility and metastasis of malignant 
mouse fibrosarcoma cells. Am J Pathol (2002), 160:869-882. 
 
Kobeissy FH, Warren MW, Ottens AK, Sadasivan S, Zhang Z, Gold MS, and Wang KKW. 
Psychoproteomic analysis of rat cortex following acute methamphetamine exposure. J 
Proteome Res (2008), 7:1971-1983. 
 
Koob GF, Sanna PP, and Bloom FE. Neuroscience of addiction. Neuron (1998), 21:467-476. 
 
Korshunova I, Caroni P, Kolkova K, Berezin V, Bock E, and Walmod PS. Characterization of 
BASP1-mediated neurite outgrowth. J Neurosci Res (2008), 86:2201-2213. 
 
Ladd CO, Huot RL, Thrivikraman KV, Nemeroff CB, Meaney MJ, and Plotsky PM. Long-
term behavioural and neuroendorine adaptations to adverse early experience. In: Progress in 
brain research: the biological basis for mind body interactions, edited by Mayer EA and Saper 
CB. Amsterdam: Elsevier, 2000, p.81-103. 
 
Laviola G, Adriani W, Terranova ML, and Gerra G. Psychobiological risk factors for 
vulnerability to psychostimulants in human adolescents and animal models. Neurosci 
Biobehav Rev (1999), 23:993-1010. 
 
Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik NB, Kitt CA, Price DL, Maggio R, 
Brann MR, and Ciliax BJ. Localization of D1 and D2 dopamine receptors in brain with 
subtype-specific antibodies. Proc Natl Acad Sci USA (1993), 90:8861-8865. 
 
Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, and Dagher A. Amphetamine-induced 
increases in extracellular dopamine, drug wanting, and novelty seeking: a 
PET/[11C]raclopride study in healthy men. Neuropsychopharmacol (2002), 27:1027-1035.  
 
 227 
Li X, Wang H, Qiu P, and Luo H. Proteomic profiling of proteins associated with 
methamphetamine-induced neurotoxicity in different regions of rat brain. Neurochem Int 
(2008), 52:256-264. 
 
Liao PC, Kuo YM, Hsu HC, Cherng CG, and Lung Y. Local proteins associated with 
methamphetamine-induced nigrostriatal dopaminergic neurotoxicity. J Neurochem (2005), 
95:160-168. 
 
London ED, Berman SM, Voytek B, Simon SL, Mandelkern MA, Monterosso J, Thompson 
PM, Brody AL, Geaga JA, Hong MS, Hayashi KM, Rawson RA, and Ling W. Cerebral 
metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine 
abusers. Biol Psychiatry (2005), 58:770-778. 
 
Lotharius J, and Brundin P. Pathogenesis of Parkinson’s disease: dopamine vesicles and α-
synuclein. Nat Rev Neurosci (2002), 3:932-942. 
 
Lowe J, McDermott H, Landon M, Mayer RJ, and Wilkinson KD. Ubiquitin carboxyl-
terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies 
characteristic of human neurodegenerative diseases. J Pathol (1990), 161:153-160. 
 
Machida Y, Chiba T, Takayanagi A, Tanaka Y, Asanuma M, Ogawa N, Koyama A, Ito S, 
Jansen PH, Tanaka K, and Hattori N. Common anti-apoptotic roles of parkin and alpha-
synuclein in human dopaminergic cells. Biochem Biophys Res Commun (2005), 24:233-240. 
 
Matthews K, and Robbins TW. Early experience as a determinant of adult behavioural 
responses to reward: the effects of repeated maternal separation in the rat. Neurosci Biobehav 
Rev (2003), 27:45-55. 
 
McCann UD, and Ricaurte GA. Amphetamine neurotoxicity: accomplishments and remaining 
challenges. Neurosci Biobehav Rev (2004), 27:821-826. 
 
Meaney MJ, Brake W, and Gratton A. Environmental regulation of the development of 
mesolimbic dopamine systems: a neurobiological mechanism for vulnerability to drug abuse? 
Psychoneuroendocrinology (2002), 27:127-138. 
 228 
Misasi R, Sorice M, Di Marzio L, Campana WM, Molinari S, Cifone MG, Pavan A, Pontieri 
GM, and O’Brien JS. Prosaposin treatment induces PC12 entry in the S phase of the cell cycle 
and prevents apoptosis: activation of ERKs and sphingosine kinase. FASEB J (2001), 15:467-
474. 
 
Missale A, Nash SR, Robinson SW, Jaber M, and Caron MG. Dopamine receptors: from 
structure to function. Physiol Rev (1998), 78:189-225. 
 
Molitoris BA. Putting the actin cytoskeleton into perspective: pathophysiology of ischemic 
alterations. Am J Physiol (1997), 272:430-433. 
 
Mosevitsky MI, Novitskaya VA, Plekhanov AY, and Skladchikova GY. Neuronal protein 
GAP-43 is a member of novel group of brain acid-soluble proteins (BASPs). Neurosci Res 
(1994), 19:223-228. 
 
Mzhavia N, Berman Y, Che F, Fricker LD, and Devi LA. ProSAAS processing in mouse 
brain and pituitary. J Biol Chem (2001), 276:6207-6213. 
 
Mzhavia N, Qian Y, Feng Y, Che FY, Devi LA, and Fricker LD. Processing of proSAAS in 
neuroendocrine cell lines. Biochem J (2002), 361:67-76. 
 
Narita M, Akai H, Nagumo Y, Sunagawa N, Hasebe K, Nagase H, Kita T, Hara C, and 
Suzuki T. Implications of protein kinase C in the nucleus accumbens in the development of 
sensitization to methamphetamine in rats. Neuroscience (2004), 127:941-948. 
 
Ohmori S, Sakai N, Shirai Y, Yamamoto H, Miyamoto E, Shimizu N, and Saito N. 
Importance of protein kinase C targeting for the phosphorylation of its substrate, 
myristoylated alanine-rich C-kinase substrate. J Biol Chem (2000), 275:26449-26457. 
 
Ouimet CC, Hemmings HC Jr, and Greengard P. ARP-21. II. Immunocytochemical 
localization in rat brain. J Neuroscience (1989), 9:865-875. 
 
 229 
Otero A, Bustelo XR, Pichel JG, Freire M, and Gomez-Marquez J. Transcript levels of 
thymosin beta 4, an actin-sequestering peptide, in cell proliferation. Biochem Biophys Acta 
(1993), 1176:59-63. 
 
Pantaloni D, and Cartier MF. How profilin promotes actin filament assembly in the presence 
of thymosin beta4. Cell (1993), 75:1007-1014. 
 
Paxinos G, and Watson C (eds). The rat brain on stereotaxic co-ordinates, 2nd ed. Academic 
Press, Harcourt Brace Jovanovich Publishers, San Diego, USA, 1986.  
 
Popoli P, Pepponi R, Martire A, Armida M, Pezzola A, Galluzzo M, Domenici MR, Potenza 
RL, Tebano MT, Mollinari C, Merlo D, and Garaci E. Neuroprotective effects of thymosin 
beta4 in experimental models of excitotoxicity. Ann NY Acad Sci (2007), 1112:219-224. 
 
Qian Y, Devi LA, Mzhavia N, Munzer S, Seidah NG, and Fricker LD. The C-terminal region 
of proSAAS is a potent inhibitor of prohormone convertase 1. J Biol Chem (2000), 
275:23596-23601. 
 
Safer D, Elzinga M, and Nachmias VT. Thymosin beta4 and Fx, an actin-sequestering peptide, 
are indistinguishable. J Biol Chem (1991), 266:4029-4032. 
 
Schmidt HD, Anderson SM, and Pierce RC. Stimulation of D1-like or D2 dopamine receptors 
in the shell, but not the core, of the nucleus accumbens reinstates cocaine-seeking behaviour 
in the rat. Eur J Neuroscience (2006), 23:219-228. 
 
Schmidt MV, Liebl C, Sterlemann V, Ganea K, Hartmann J, Harbich D, Alam S, and Müller 
MB. Neuropeptide Y mediates the initial hypothalamic-pituitary-adrenal response to maternal 
separation in the neonatal mouse. J Endocrinol (2008), 197:421-427. 
 
Seki K, Chen HC, and Huang KP. Dephosphorylation of protein kinase C substrates, 
neurogranin, neuromodulin, and MARCKS, by calcineurin and protein phosphatases 1 and 
2A. Arch Biochem Biophys (1995), 316:673-679. 
 
 230 
Sorice M, Molinari S, Di Marzio L, Mattei V, Tasciotti V, Ciarlo L, Hiraiwa M, Garofalo T, 
and Misasi R. Neurotrophic signaling pathway triggered by prosaposin in PC 12 cells occurs 
through lipid rafts. FEBS J (2008), 275:4903-4912.  
 
Spear LP. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav 
Rev (2000), 24:417-463.   
 
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, and Goedert M. Alpha-
synuclein in Lewy bodies. Nature (1997), 388:839-840. 
 
Stoof J, and Kebabian J. Opposing roles for D-1 and D-2 dopamine receptors in efflux of 
cyclic AMP from rat neostriatum. Nature (1981), 294:366-368.  
 
Sulzer D. Alpha-synculein and cytosolic dopamine: stabilizing a bad situation. Nat Med 
(2001), 7:1280-1282. 
 
Tannu NS, Howell L, and Hemby SE. Integrative proteomic analysis of the nucleus 
accumbens in rhesus monkeys following cocaine self-administration. Mol Psychiatry (2008), 
Abstract. 
 
Taoka M, Yamakuni T, Song SY, Yamakawa Y, Seta K, Okuyama T, and Isobe T. A rat 
cerebellar protein containing the cdc10/SW16 motif. Eur J Biochem (1992), 207:615-620. 
 
Taoka M, Isobes T, Okuyama T, Watanabe M, Kondo H, Yamakawa Y, Ozawa F, Hishinuma 
F, Kubota M, Minegishi A, Song SY, and Yamakuni T. Murine cerebellar neurons express a 
novel gene encoding a protein related to cell cycle control and cell fate determination 
proteins. J Biol Chem (1994), 269:9946-9951. 
 
Thelen M, Rosen A, Nairn AC, and Aderem A. Regulation by phosphorylation of reversible 
association of a myristoylated protein kinase C substrate with the plasma membrane. Nature 
(London) (1991), 351:320-322.  
 
Thompson A, Schafer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, Neumann T, Johnstone R, 
Mohammed AK, and Hamon C. Tandem mass tags: A novel quantification strategy for 
 231 
comparative analysis of complex protein mixtures by MS/MS. Anal Chem (2003), 75:1895-
1904. 
 
Vale RD, Banker G, and Hall ZW. The neuronal cytoskeleton. In: An Introduction to 
Molecular Neurobiology, edited by Hall ZW. Sunderland, MA, USA: Sinuaer Associates, 
1992, p.247-280.  
 
Vartiainen N, Pyykonen I, Hokfelt T, and Koistinaho J. Induction of thymosin beta(4) mRNA 
following focal brain ischemia. Neuroreport (1996), 7:1613-1616. 
 
Walaas SI, Nairn AC, and Greengard P. Regional distribution of calcium- and cyclic AMP-
regulated protein phosphorylation systems in mammalian brain. I. Soluble system. J Neurosci 
(1983), 3:302-311.  
 
Wiederkehr A, Staple J, and Caroni P. The motility-associated proteins GAP-43, MARCKS, 
and CAP-23 share unique targeting and surface activity-inducing properties. Exp Cell Res 
(1997), 236:103-116. 
 
Wu YL, Yoshida M, Emoto H, and Tanaka M. Psychological stress selectively increases 
extracellular dopamine in the ´shell´, but not in the ´core´ of the rat nucleus accumbens; a 
novel dual-needle probe simultaneous microdialysis study. Neurosci Lett (1999), 275:69-72. 
 
Yamakuni T, Yamamoto T, Hoshino M, Song SY, Yamamoto H, Kunikata-Sumitomo M, 
Minegishi A, Kubota M, Ito M, and Konishi S. A novel protein containing cdc10/SW16 
motifs regulates expression of mRNA endocing catecholamine biosynthesizing enzymes. J 
Biol Chem (1998), 273:27051-27054. 
 
Yang MH, Kim S, Jung MS, Shim JH, Ryu NK, Yook YJ, Jang CG, Bahk YY, Kim KW, and 
Park JH. Proteomic analysis of methamphetamine-induced reinforcement processes within the 
mesolimbic dopamine system. Addict Biol (2008), 13:287-294. 
 
Zhuang X, Belluscio L, and Hen R. Golfalpha mediates dopamine D1 receptor signaling. J 
Neurosci (2000), 20:1-5. 
 
 232 
CHAPTER 8 
 
 
General Conclusions 
 
 
The main aim of the study was to establish whether early life adversity would render 
individuals more vulnerable to later drug usage. We adopted maternal separation as our 
animal model of early life adversity and treated these animals with methamphetamine during 
adolescence. A conditioned place preference (CPP) paradigm was subsequently used to 
determine the rewarding effects of methamphetamine. To obtain an understanding of the 
underlying molecular mechanisms of methamphetamine-induced behaviour, we also 
measured neurochemical changes on a neuroendocrine, neurotrophic, neurotransmitter and 
proteome level. 
 
Statistical tests performed on CPP behaviour, locomotor activity and the neurochemical 
measures were all analysed by non-parametric statistical tests, since the number of animals 
per group (n) in each study investigated were small and a small  biological sample size 
usually does not conform to a symmetrical / normal distribution of the date points. The 
median and quartiles are usually reported when making use of non-parametrical tests, since 
data is not normally distributed. However, for comparative purposes with previous studies in 
the literature, the mean and SEM were reported throughout the present study.  
 
On a behavioural level, we found contrary to expectation, that maternal separation did not 
affect rewarding behaviour as measured by the CPP test, but instead decreased apomorphine-
induced locomotor behaviour in methamphetamine-treated rats. This result suggested that 
maternal separation preferentially affected the behavioural repertoire of the dorsal striatum 
rather than that of the ventral striatum. Maternal separation therefore exhibited a differential 
impact on the central dopaminergic system. This conclusion was further substantiated by 
increased concentrations of plasma prolactin levels in maternally separated animals subjected 
to methamphetamine treatment, suggesting a reduction in dopamine inhibition.   
 
Further characterization of the methamphetamine-induced CPP model indicated that place 
preference behaviour lasted for at least 2 weeks after the last methamphetamine 
administration. Neuroendocrine abnormalities of the HPA axis were evaluated by measuring 
plasma ACTH and corticosterone levels. A general down regulation of neuroendocrine 
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activity was observed in animals subjected to maternal separation or methamphetamine 
treatment, as well as those subjected to the combination of the two interventions. This result 
was in line with previous findings of hypoactivity of the HPA axis (Yehuda et al., 1995; 
Buydens-Branchey et al., 1997; Faure et al., 2006; Heim et al., 2001). However the 
combination group did not display an exaggerated effect, suggesting that the interventions 
may have independent mechanisms of action with respect to the regulation of the HPA axis.   
 
 Altered neurotrophin concentrations in the dorsal and ventral hippocampus were found in 
maternally separated and methamphetamine treated animals independently.  Maternal 
separation resulted in increased NGF levels in the ventral hippocampus of methamphetamine 
treated rats. This observation suggested that the ventral hippocampus may specifically be 
vulnerable to the effects of early life stress, which is in agreement with the preferential role 
the ventral hippocampus plays in anxiety-related responses (Bannerman et al., 2004). The 
increased neurotrophin protein concentrations may further reflect a compensatory response of 
the brain to stress and drug exposure.  
  
Two pharmacological interventions (Lobeline and Naltrexone) were used to probe the 
contributions of the cholinergic and opioid systems in place preference behaviour. We 
employed a post-methamphetamine treatment strategy which was unlike many previous 
studies that rather investigated the effects of drug treatment on methamphetamine 
consumption using a pre-drug treatment strategy. The clinical relevancy of these earlier 
experiments can therefore be questioned. Lobeline and naltrexone post-methamphetamine 
treatment failed to reverse the methamphetamine-induced place preference on a behavioural 
level. However, on a biochemical level administration of the drugs did lead to alterations in 
striatal dopamine and serotonin levels. Surprisingly, in this particularly study, early maternal 
separation resulted in a reduction in methamphetamine-induced place preference behaviour. 
In chapter 3, this particular finding of decreased CPP behaviour was not significantly different 
from animals exposed to MA without previous maternal separation. This could possibly be 
ascribed to differential MA exposure paradigms used. Since maternal separation altered 
neurotransmitter levels, these changes may partially indicate neurochemical mechanisms of 
resiliency that early adversity confer on the brain against the effects of methamphetamine. 
Our findings therefore underline the fact that early life stress in combination with later drug 
usage is a complex interplay between environment and neurochemical changes that is in need 
of further investigation. 
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We employed proteomic techniques to generate a global overview of protein changes in the 
frontal cortex of methamphetamine-treated animals, in an attempt to obtain a better 
understanding of how this brain area may contribute to addictive behaviour. Using 2-DE 
based proteomics we investigated the protein changes in both the cytosolic and membrane 
fractions of methamphetamine-treated rats. We identified 47 cytosolic and 42 membrane 
proteins using ESI-Quad-TOF. Examples of the identified proteins included UCH-L1, β-
synuclein, GRP 78, γ-enolase, DRP 2, complexin 2 and synapsin II. These proteins are 
associated with protein degradation, redox regulation, energy metabolism, cellular growth, 
cytoskeletal modification and synaptic function. In this study we demonstrated how 
methamphetamine affected neurons at numerous levels. However further research is needed to 
determine how these alterations in protein expression translate into the mediation of 
methamphetamine’s effect on the brain and behaviour.  
 
Finally, we conducted a quantitational proteomic study investigating effects of 
methamphetamine on the nucleus accumbens shell and core subregions. To our knowledge, 
this is the first study using proteomics to quantify the differential expression of proteins in the 
shell and core after methamphetamine treatment and determining the effects of maternal 
separation on methamphetamine-induced protein expression. Using isobaric tagging for 
relative and absolute quantitation (iTRAQ) followed by LC MS/MS we found 28 cytosolic 
shell and 25 core proteins to be differentially expressed. Some of these proteins included actin 
cytosolic 2, thymosin beta-4, creatine kinase B-type, proSAAS, 14-3-3 protein gamma, 
MARCKS, Arpp-21, α-synuclein, BASP1 and myotrophin. These proteins are associated with 
cytoskeletal modifications, altered energy metabolism, degenerative processes, interruptions 
with normal neurotransmission and intracellular signaling. Although these processes were 
similarly affected in the shell and core regions of the nucleus accumbens, we were able to 
demonstrate a remarkable difference in the specific proteins in these two brain areas. The 
present study also showed that on a proteome level, more proteins are quantitatively 
expressed in rats that were exposed to maternal separation followed by methamphetamine 
treatment. We therefore proposed that early adverse events may predispose animals to the 
addictive effects of stimulant drugs. However, future studies are needed to establish how 
differentially expressed proteins in the nucleus accumbens shell and core impact on the 
function of other brain areas to mediate the particular effects of early life stress and 
subsequent methamphetamine abuse.  
 235 
References 
 
Bannerman DM, Rawlins JN, McHugh SB, Deacon RM, Yee BK, Bast T, Zhang WN, 
Pothuizen HH, and Feldon J. Regional dissociation within the hippocampus – memory and 
anxiety. Neurosci Biobehav Rev (2004), 28:273-283.  
 
Buydens-Branchey L, Branchey M, Fergeson P, Hudson J, and McKermin C. The meta-
chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological 
responses. Biol Psychiatry (1997), 41:1071-1086. 
 
Faure J, Uys J, Marais L, Stein D, and Daniels W. Early maternal separation followed by later 
stressors leads to dysregulation of the HPA-axis and increases in hippocampal NGF and NT-3 
levels in a rat model. Metab Brain Dis (2006), 21:181-188. 
 
Heim C, Newport DJ, Bonsall R, Miller AH, and Nemeroff CB. Altered pituitary-adrenal axis 
responses to provocative challenge tests in adult survivors of childhood abuse. Am J 
Psychiatry (2001), 158:575-581. 
 
Yehuda R, Kahana B, Binder-Brunes K, Southwick SM, Mason JW, and Giller EL. Low 
urinary cortisol excretion in Holocaust survivors with post-traumatic stress disorder. Am J 
Psychiatry (1995), 152:982-986. 
 
 
 
 
 
